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"Somewhere, something incredible is  wait ing to  be known." 
Dr Carl Sagan 
Steroid hormones, such as oestrogen, mediate their effects via activation of oestrogen 
regulated genes using nuclear receptors. Selective oestrogen receptor modulators 
(SERMs), such as Tamoxifen, are used to treat oestrogen responsive breast cancers, 
hctioning to act as oestrogen antagonists, preventing the oestrogen receptor biding 
DNA and blocking gene expression. However, Tamoxifen has been identified as an 
oestrogen agonist in other tissues which can often lead to secondary tumors in the years 
following the treatment. Identification of the genomic regions where SERMs can act as 
oestrogen agonists can possibly lead to the development of gene targeted therapies or 
other alternatives to prevent this from occurring. 
Investigations of a previously constructed ERE reporter library were directed towards 
the isolation of SERM responsive plasmids. Identified SERM responsive plasmids 
were compared to oestrogen responsive reporter piasmids on the basis of their ability to 
mediate trauscription in conjunction with other nuclear -tors and coactivators to 
establish potential novel interactions. ERa mutation analysis was performed to attempt 
to identify the mechanism by which these sequences have the ability to be activated 
with the addition of SERMs. It was found that SRC-3, a member of the SRC family of 
coactivators, had the ability to corepress SERMs via oestrogen receptors, a response not 
documented previously. 
Further to results obtained from the investigations of the SERM responsive reporter 
plasmids, DamID technology was employed to attempt to construct two libraries of 
sequences that associated, indirectly, with SRC-1A or SRC-3, via ligand bound 
oestrogen or progesterone. Gateway technology was used to transfer cloned sequences 
in to reporter plasmids to enable the luciferase assay to be employed in order to 
determine the functionality of the isolated sequences. 
- ~... . - 
Transactivation assays suggested that the attempt to direct the SRC-1A:Dam fusion 
protein to bind to DNA via either ligand bound oestrogen or progesterone failed, 
however following reporter plasmid sequencing bioinformatical studies were performed 
q d  a number of possible transcription factor binding,motifs were identified in the 
sequences. Further transactivation assays indicated SRC-1A:Dam had, in a subset of 
the reporter plasmids, bound via the orphan nuclear receptors RORa and COUP TFI. 
Results suggest that SRC-1A may mediate this association and coactivate gene 
transcription; the mechanism behind this novel finding remains to be elucidated. 
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1.1. Gene Expression 
The expression of a genome is the mechanism whereby information contained in the 
genome is synthesised into a gene product. 
Steroid hormones mediate their functions by activating the expression of specific 
subsets of genes to elicit a physiological response. The activation and expression of 
genes is a highly regulated series of events which depend on the interaction of RNA 
Polymerase Il with the genome. The interaction of RNA Polymerase I1 with the 
genome in response to steroid hormones is mediated by nuclear receptors. The 
interaction of nuclear receptors with the genome is hindered by the chromatin 
environment which can be altered to either enhance the genomic interaction of inhibit it 
via activators and inhibitors, w-enhancers and co-repressors (Reviewed in McKenna 
and O'Malley, 2002). 
1.2. Steroid Hormones 
Steroid hormones are generally synthesised by cholesterol in the gonads or adrenal 
glands. Being synthesised from cholesterol they are lipophilillic and can readily 
transverse the cell membrane (Olefsky, 2001) and combine with a specific protein 
receptor which, when activated by the steroid hormone, interacts with the cellular 
tmmaiption machinery or specific genomic elements to either activate or inhibit a 
target gene. Steroid hormones are transported through the body via the circulatory 
system bound to specific carrier proteins. 
1.2.1. Oestrogen and Progesterone 
The ovarian steroids, oestrogen and progesterone, are steroid hormones which function 
to regulate a variety of aspects of female reproduction. Oestrogen is produced from 
developing ovarian follicles, the corpus luteum, the placenta during pregnancy and in 
smaller amounts by other tissues (secondary tissues; important source of oestrogen in 
post menopausal females) such as liver, adrenal glands and mammary glands. 
Progesterone, on the other hand, is produced in the ovaries, the brain and also in the 
placenta during pregnancy. Levels of oestrogen and progesterone in menopausal 
females vary depending on the stage of the cycle (Figure 1.1.). 
0 2OW E n ~ l o p d i .  ~rl tmnb.  m*lsrrrmm 
Figure 1.1. Fluchding levels of esiivgen dprogesterone daring the menshual cycle. 
Positive and negative regulation of these steroid hormones are controlled by a series of 
feedback mechanisms incorporating the pituitary hormones: follicle stimulating 
hormone (FSH) and luteinizing hormone (LH) (Biology of Human Reproduction, R 
Pinon). 
1.2.2. Sex Hormone Synthesis 
Oestrogen occurs natural1y in three major forms; oestrone (El), oestrodiol (E2) and 
oestriol (E3) (Figure 1.2.). Estradiol is widely considered to be the principal form 
present in nonpregnant females. 
Oestmne (El) 
Figure 1.2. Molecular structure of Oeshone, Oestradiol and Oestriol 
Estrogens are present in both males and females, usually at a significantly higher level 
in females of reproductive age. All forms promote the development of female 
secondary sex characteristics, such as mammary development and growth of body hair, 
and also in aspects of regulating the menstrual cycle, such as thickening of the 
endometrium. Oestrogen also has functions in males including regulation of sperm 
maturation and release (Hess et al. 1997). 
Progesterone (Figure 1.3.) has a number of physiological roles all of which are 
augmented in the presence of oestrogen. Progesterone converts the endometrium to its 
secretory stage to prepare the uterus for the arrival of a developing embryo in case 
fertilization occurs, it also accelerates the movement of the oocyte or embryo to the 
uterus and causes enlargement of mmmqy glands (in combination with other steroid 
hormones such as estradiol). 
Pqe8temne 
Figure 1.3. Molecular structure of Progesterone 
Follicular theca and granulosa cells in the ovary are the most important site of oestrogen 
synthesis in females of reproductive age where production is stimulated by FSH and LH 
(Figure 1.4.) (Wang et al. 1980; Simpson et al. 1994; Michael et al. 1995; Bulum et 01. 
2000). 
Earfy Folllcular Phase 
Figure 1.4. Synthesis of Oeshogen (Adaptedfiomfigure in Biology of Human Reproduction, 
Pinon) 
Follicular maturation is characterized by the proliferation and functional differentiation 
of ovarian granulosa and theca cells. In the early stage of follicular development 
granulosa cells undergo rapid proliferation with limited capacity for hormonal 
production. As the follicles grow and develop the cells demonstrate an increased ability 
to secrete hormones (Gougeon, 1993). Cross-talk between granulosa and theca cells is 
essential for the maintenance of the physiologic function and structure of follicular cells 
and for the production of the ovarian hormones ( ~ a d a  et al, 1999). 
Synthesis of oestrogen is initiated by increasing levels of the pituitary hormones LH and 
FSH. Oestrogen is synthesized from androstenedione, a substance of moderate 
androgenic activity, which is synthesized from cholesterol (Figure 1.5.). 
Figure 1.5. IIIustration Outlining Oestradiol Synthesis (Ray el al, 2006) 
Cholesterol is the 'building block' of all steroid hormones and undergoes double 
oxidation to produce 20,22-dihydroxycholesterol to initiate the synthesis of both 
oestrogens and progesterone, this is then further oxidized with loss of the side chain 
starting at position C-22 to produce pregnenolone. These conversions occur in ovarian 
mitochondria. 17a-hydroxypregnenolone is then formed by the action of a smooth 
endoplasmic reticulin enzyme, 17a-hydroxylase. Dehydroepiandrosterone is formed by 
another shooth endoplasmic reticulin enzyme, 17,20 lyses, which is converted to 
androstenedione by 3P-hydroxysteroid dehydrogenase which is then converted to 
estrone by aromatase. Alternatively, dehydroepiandrosterone is converted to 
androstenediol by 17P-hydroxysteroid dehydrogenase and then to testosterone by 3P- 
hydroxysteroid dehydrogenase which is then converted to estradiol by aromatase. 
Oestrone and oestradiol can further be converted to estriol in the liver and placenta. 
Theca cells convert cholesterol to androgens under LH stimulation from the pituitary; 
however theca cells lack the enzyme aromatase and so cannot convert the androgens to 
oestrogens. The androgens produced in the theca cells diffuse to the granulosa cells 
which then convert them to oestrogens, primarily oestradiol, under FSH stimulation. 
Therefore, the ability of the ovarian follicle to produce oestrogens is dependant firstly 
on the androgen producing ability of the theca cells, followed by the aromatase activity 
of the granulosa cells. 
Intracellular cyclic adenosine monophosphate (CAMP) regulates aromatase expression 
in the ovary. Upon FSH binding to its G-protein-coupled receptor located in the 
granulosa cell membrane, intracellular cAMP levels increase which functions to 
enhance binding of two critical transcription factors (steroidogenic factor-1 (SF-I) and 
cAMP response element binding protein (CREB)), to the proximal promoter I1 of the 
aromatase gene. This results in aromatase expression and consequently oestrogen 
secretion h m  the preovulatory follicle (Bulum et al, 2000). 
Progesterone is also synthesised h m  cholesterol, production being stimulation by LH 
in vivo (Carlson et al., 1971) and in vitro (Armstrong and Black, 1966) (Figure 1.6.). 
Oestrogen action on both the pituitary and the hypothalamus is required for the LH 
surge that occurs at the end of the follicular phase. FSH and oestrogen action on the 
granulosa cells initiates the synthesis of LH receptors and the combination of LH and 
FSH action on the granulosa calls triggers the initiation of progesterone synthesis. 
Lab Follfcular Phase 
(beginning of luleiniration) 
Fignre 1.6. *thesis of Oestrogen ond progesterone (Adapted from figure in Biology of 
Human Reproduction, Pinon) 
Similarly, progesterone synthesis begins with the conversion of cholesterol to 
pregnenolone by a cholesterol side chain cleavage enzyme present in the mitochondria 
(Figure 1.5.). Pregnenolone is then converted to pmgesterone by 3p-hydroxysteroid 
dehydrogenase. Progesterone can also be converted to oestrogens by 17a-hydroxylase 
convertion to 17a-hydroxy progesterone and subsequent convertion to androstenedione 
and testosterone by 17,20 lyases and 17P-hydroxysteroid dehydrogenase. 
The major sites of oestrogen biosynthesis in postmenopausal women include 
extraglandular tissues such as skin and adipose tissue. Aromatase expression is 
controlled by the cytokines interleukin OL)-6, IL-11, tumor necrosis factor alpha 
(TNFa) and also glucocorticoids in adipose tissue and skin fibroblasts (Simpson et al, 
1994). The major precursor of oestrogen in adipose tissue and skin is androstenedione 
of adrenal origin (Bulum et al, 2000). Androstenedione is then converted to oestradiol 
by 17P hydroxysteroid dehydrogenase (17p-HSD) (reductase) activity in these 
peripheral tissues. 
During pregnancy the placenta becomes the main source of progesterone. 
1.3. Nuclear Receptors 
Oestmgen and progesterone carry out their functions by interacting, via their specific 
receptors, with promoter elements in the genome thereby inducing gene transcription 
and pmtein production. The specific oestrogen and progesterone receptors are just two 
of a major group of protein receptors known as the 'nuclear receptor superfamily'. 
These receptors are responsible for detecting lipophilic hormones and certain other 
molecules in the cell cytosol. Lipophilic hormones, such as oestrogens and 
progesterone, have the ability to transverse the cell membrane (Olefsky, 2001), in 
contrast to hydrophilic hormones which are unable to cross the cell membrane. 
Hydrophillic hormones generally interact with cell surface receptors which cause a 
conformational change inside the cell initiating a cell signalling pathway inducing gene 
transcription of repression. 
Lipophillic hormones however, enter the cell cytosol, b i d  to the appropriate nuclear 
receptor which causes dissociation of receptor bound heat shock proteins and induces 
dimerization, translocation to the nucleus and DNA binding to specific motifs in, or 
close to, the promoter element of the target genes (Beato, 1989) (Fignre 1.7.). 
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F i g m  1.7. The activation of Steroid Receptors. Steroid h o n e s  enter the cell cy toplm 
and bind to nuclear receptors which induce a confonnationnl change in the receptor and 
dissociation of nuelem receptor msociaied herd shock proteins. Ligand b o d  nuclear 
receptors dimerize which enables irmlocation to the nucleus and interaction with specific 
mot13 in the promoter regions of target genes. 
This biding can act to either induce or repress gene transcription. Therefore, the 
nuclear receptor superfamily can act as ligand-dependant transcription factors. 
Members of the nuclear receptor superfamily work with other proteins to coordinate and 
control gene expression, and in effect play an important role in the growth, 
differentiation, metabolism, reproduction and morphogenesis in higher organisms and 
humans (Aranda ei al, 2001). 
The nuclear hormone receptor superfamily includes receptors for thyroid and steroid 
hormones, retinoids and Vitamin D and also a subgroup of transcription factors, orphan 
receptors, for which the ligands have not yet been identified (Aranda et al, 2001). 
1.3.1. Oestrogen Receptors 
Oestrogen receptors (ERs) refer to a group of receptors that are activated by oestrogens. 
These include the well known ER, members of the nuclear hormone family of 
intracellular receptors which has up to 60 members (Lander et al, 2001) as well as a 
trans-membrane intracellular receptor known as GPR30 (G-protein coupled receptor) 
(Revankar, 2005). 
ERs are localized to many sites within the cell including the nucleus and the plasma 
membrane as well as cellular mitochondria (Chen et al, 2004) and endoplasmic 
reticulum (Revankar, 2005). 
There are two known nuclear hormone oestrogen receptors, ERa and ERP. Each are 
encoded by separate gene; ERa by ESRl gene located on chromosome 6 (q24-q27) 
while ERP is encoded by ESR2 gene located on chromosome 14 (q21-q22). There are 8 
isoforms of ERa and P (Figure 1.8.) (Matthews and Gustafsson, 2003). 
ERa and ERB are Class I nuclear receptors that bind to elements in the 5' flanking 
regions of DNA as homodimers. The main function of the oestrogen receptor is as a 
DNA bindiig transcription factor that regulates the expression of genes controlled by 
oestrogen. However, the oestrogen receptor has been found to have additional functions 
which are independent to DNA biding. 
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Figure 1.8. Representation of human ERa and /I and their respective isofom. Both hER$2 
and hER$A.5 can have either the h E ~ 1  long or the short N-termini. In addition, there is no 
evidence offul-length hEw4 or hER$5. The d~ferent fill patterns of the 3' end of hEw2, 4, 
and 5 represent the divergent C-terminal regions of these isofom. (Matthews and Ghtqtison, 
The binding of oestrogen to ERa or EM either activates or represses gene transcription. 
The action carried out is a result of the steroid-receptor complex binding to specific 
regions in the promoters of target genes, known as oestrogen responsive elements 
(EREs). The resulting protein products determine the cell biological actions of the sex 
steroid. 
There is also a second mechanism of action for oestrogen receptors which involves the 
interaction of nuclear estradiol (E2) oestrogen receptor complexes with transcription 
factors, such as activator protein 1 (AP-I), that in turn bind their specific DNA binding 
elements (Kushner et al, 2000). DNA binding via EREs or AP-1 elements leads to 
chromatin remodelling, histone unwinding, recruitment of basal transcription factors 
and co-activators, displacement of co-repressors and f d l y  gene transcription and 
protein expression (discussed in review by Levin, 2005). 
Additionally, a small amount of ERs localize to the plasma membrane whereby a 
response is elucidated via cellular signalling mechanisms such as kinase cascades, 
calcium, and other second messenger signalling pathways which function to regulate 
hmswiption (Qii et al, 2004, Watters et al, 2000). 
GPIUO is uniquely localizedto the endoplasmic reticulum, where it specifically 
bidsoestrogen (Revankar, 2005). Upon oestrogen binding intracellular calcium is 
mobilized and phosphatidylinositol3,4,5-trisphosphate (PIP3: involved in the PIP2 lipid 
signalling second messenger) synthesis is activated in the nucleus where it initiates 
many non-genomic signalling events. 
Human ERa has a molecular weight of 66 to 70 kDa, comprising of 595 amino acids 
(Pam et al, 2001). ERa was isolated in 1962 by Jensen et al, in 1968 it was found to 
be a ligand activated transcription factor (O'Malley et al, 1968) and it was cloned in 
1986 by Greene et al (Greene et al, 1986). ERa is localised in central nervous system, 
cardiovascular system, mgential tract, bone and breast (Gustafsson, 1999). It is also 
the major ER subtype in the liver and the uterus (Gustafsson, 1999; Taylor et al, 2000) 
(Fig- 1.9.). 
ERp was discovered in 1996 by Kuiper et al in rat prostate and ovary and cloned in 
1997 by Enmark et al. Full-length E M  is 530 amino acids in length and has a 
molecular weight of 58 to 62 kDa although it has been shown to be produced in 
multiple isoforms, EM1 and EM2 (Figure 1.8.) (peterson et al, 1998). E M  is seen at 
highest levels in the ovary and prostate with lower expression levels seen in the 
cardiovascular system, bone, breast, uterus and testis (Mosselman et al, 1996; Tremblay 
et al, 1997; Kuiper et el, 1997; Gustafsson, 1999). It is also the major ER subtype in the 
gastrointestinal tract, brain and prostate (Figure 1.9.) (Gustafsson, 1999; Taylor et al, 
2000). 
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Figure 1.9. Overall distribution of ER in d~yerent issues (Gustafson, 1999) 
ERa has 6 main structural and functional domains (named A-F from N to C terminus) 
(Figure 1.10.): a variable or regulatory domain containing a transcriptional activation 
function (AIB), a DNA binding domain (C), a hinge region (D), a ligand binding 
domain (E) and a region that plays a role in distinguishing agonists vs. antagonists (F). 
In vitro site mutagenesis assays, deletion mutation studies and domain swapping 
experiments have confirmed the functional roles of these domains (Green et al, 1987; 
Kumar et al, 1986; Kumar et al, 1987) 
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Figure 1.10. Functional Domains of Human ERa (Pavao et al, 2001) 
The regulatory A/B domain (aa 1-184) of ERa exhibits very little conservation between 
species (Krust et al, 1986) and among other nuclear receptor superfamily members 
(Seagraves, 1991). This domain shows promoter- and cell-specific activity and is likely 
to contribute to the specificity of action among isoforms and that it could interact with 
cell type specific factors (Aranda et al, 2001). A portion of this N-terminal regulatory 
domain AIB (aa 41-150) is known as the Activation Function-l (AF-1) domain, 
associated with the modulation of transcriptional activity (Klinge, 2000). The AF-1 
domain of ERa is phosphorylated at serine or threonine residues via the mitogen- 
activated protein kinase (MAPK) in vitro, and in cells treated with growth factors that 
stimulate the Ras-MAPK cascade, and this phosphorylation has been shown to enhance 
transcriptional activity (Kato et al, 1995; Patrone et al, 1996; Aranda et al, 2001). 
The DNA binding domain, located in region C (aa185-263), is a highly conserved 
region (Kumar et al, 1987) containing two zinc fingers. The zinc fingers (both 1 and 2) 
are responsible for the direct interaction with the DNA double helix (Kumar et al, 
1987). Each zinc finger contains four cysteine residues that coordinate the binding of a 
zinc atom. The 'P Box' is a term given to three amino acids at the base of the first zinc 
finger and is responsible for DNA binding specificity (Nelson et al, 2005), the three 
amino acids at the base of the second zinc finger is known as the 'D Box' and is 
involved in dimerisation (Aranda et al, 2001). The core DBD contains two a-helices: 
the recognition helix located at the third conserved cysteine residue which binds the 
major groove of DNA making contact with specific bases and a second which spans the 
COOH terinus of the second zinc finger forming a right angle with the recognition helix 
(Aranda et al, 2001). 
The hinge region, region D (aa 264-302) serves as a hinge between the DBD and the 
ligand binding domain (Aranda et al, 2001) containing sequences for receptor 
dimerisation and nuclear localization (Klinge, 2000). 
The ligand binding domain (aa 303-553) (region E) is located in the C-terminal section 
of the receptor. This is a multifunctional domain that, in addition to ligand binding, 
mediated homo- and hetero-dimerisation, interaction with heat shock proteins, ligand- 
dependant transcriptional activity and in some cases hormone reversible transcriptional 
repression (Aranda et al, 2001). A portion of this domain (aa 530-553), AF-2 (a second 
activation functional domain), is also associated with transcriptional regulation via 
association with co-regulatory proteins (Henderson et al, 2003). 
Region F (aa 554-595), (Figure I.IO.), is located at the C-termal region. Its function is 
currently unknown but it shows very little sequence conservation similar between 
receptor isoforms (Mosselman et al, 1996). However, it is thought to play a role in 
distinguishing agonist vs. antagonist binding to the receptor (Pavao et al, 2001; 
Henderson et al, 2003). 
Both ERa and ERP share similar domain structure, ERP also containing 6 functional 
domains (A-F). However, the AB domain (aa 1-148) contains a repressor domain 
rather than an AF-I activation domain. The A/B domain is the least conserved of the 
domains between ERa and ERP with only 30% similarity at the amino acid level 
(Pavao et al, 2001). DNA biding domain is 96% and the ligand biding domain (aa 
304-500) (containing a diierisation domain, transactivation domain and a nuclear 
translocation domain) is 58% homologous, with an identical 'P Box', to the ERa 
sequence (Mosselman et al, 1996). There is a nuclear translocation domain located 
between the DNA bindiig domain and Hinge region. The E region (aa 304-500) 
contains a (dimerisation domain, tramactivation domain and a nuclear translocation 
domain). The F region is found between amino acids 500 - 530. 
1.3.1.1. Physiological Roles of Oestrogen Receptors 
Oestrogen Receptors control a wide variety of physiological processes (Figrre I.lI.), 
and therefore, are implicated in many diseases. Below is a brief overview of the major 
roles of the oestrogen receptors. 
Reproduction 
Oestrogens are essential for fertility, ERs being involved in ovulation, implantation, 
pregnancy maintenance and childbirth. It has been proposed the ERa mediates 
proliferative effects while E@ mediates the differentiating effects of oestrogen within 
the follicles. 
Additionally, during puw, the lobular portions of the mammary terminal ducts are 
highly responsive to oestrogen. In breast tissue, oestrogens function to stimulate the 
growth and differentiation of the ductal epithelium, induce mitotic activity of ductal 
cylindric cells, and stimulate the growth of connective tissue (Gruber et al, 2002). ERa 
and ERfl have distinct mles and distributions in the mammary glands. The density of 
oestrogen receptors in breast tissue is highest during the follicular phase of the 
menstrual cycle and gradually decreases following ovulation (Gruber et al, 2002). 
Oestrogen receptors also have a role in male reproduction, ERa being the primary 
receptor responsible being localised in the efferent ductal epithelium. Its roles include 
the regulation of fluid reabsorbtion in the efferent ductules and maintaining a 
diffetenciated epithelial morphology. ERa lmockout mice display dilation of cauda 
epididymal spenn, disruption of sperm morphology, inhibition of sodium transport and 
subsequent water reabsorption and eventual decreased fertility (Hess, 2003). 
F&we 1.11. Physiological Role of Oeshogen Receptors (Gruber et ~1,2002) 
Skeletal System 
Oeshogens have an important role in bone metabolism and homeostasis (reviewed in 
Turner et al, 1994) with effects on skeletal growth and also bone maturation. 
In adolescence oestrogens are involved in the bone modelling, initialling pubertal bone 
growth and limiting longitudinal bone growth in women (Migliaccio et al, 1996). In 
adults oestrogens are important in bone maintenance by promoting bone formation 
through the stimulation of osteoblasts, and repressing bone resorption by repressing 
osteoclasts. ERa is involved in the growth promoting effects of oestrogens and ERP is 
involved during puberty, limiting longitudinal and radial bone growth in females 
(Nilsson et al, 2001). 
The action of oestradiol on bone maintenance and homeostasis is evident in women 
during menopause as decreasing oestrogen levels is associated with a higher incidence 
of oaeoporosis (Turner et al, 1990; 1992). 
Central Nervous System 
Oestmgens are also thought to have neumprotective actions (Behl and Holsboer, 1999). 
In brain tissue h m  adult rats, estrogens induce synaptic and dendritic remodeling and 
cause glial activation. In neurons of the hippocampus, an area involved in memory, 
estrogens increase the density of N-methyl-D-aspartate receptors and increase neuronal 
sensitivity to input mediated by these receptors. In cultured human neurobhma cells, 
estrogens have neuroprotective effects and reduce the generation of beta-amyloid 
peptides (reviewed in Gruber et al, 2002). 
Vascular Effects 
Oestrogens act as natural vasoprotective agents, and this is ER dependant (Baku et al, 
2000). Oestrogens cause short-term vasodilation by increasing the formation and 
release of nitric oxide and pstacyclin in endothelid cells (reviewed in Gruber et al, 
2002). 
1.3.2. Progesterone Receptors 
There are two natural isoforms of the progesterone receptor: PR-A (94 kDa) and PR-B 
(104 kDa) (Horwitz & Alexander, 1983) (Figure 2.22.). One gene, PGR on 
chromosome 11 position q22, codes for both isoforms of the progesterone receptor, 
unlike the oestrogen receptor, which uses separate promotors (both oestrogen receptor 
inducible) and translational start sites to generate the two isoforms (Kastner et al, 1990). 
Figure 1.12. Sequence similarities between human PR-A andPR-B 
'Ihe progesterone receptor has multiple discrete, differentially conserved structural and 
function regions, designated A-F, similar to the oestrogen receptors (Beato, 1989). The 
non-conserved region AB contains the transcription activation function region 1 (AF-I) 
which is present in both PR-A and PR-B. Region C contains the DNA binding domain 
(DBD), consisting of 2 zinc fingers that function to b i d  to DNA and enable recognition 
of the progesterone responsive element (PRE) located in the promoter elements of 
progesterone responsive genes. Region E contains the hormone binding domain (HBD) 
which functions to prevent the DBD from binding to the responsive element. Ligand 
binding induces receptor dimerization prior to DNA binding and creates an 'active 
surface', within the HBD, thus generating a second transcriptional activating function 
(Webster et al., 1988, 1989; Tora et al., 1989). Region D is a hinge region, and Region 
Fs function is currently unknown, both described in more detail in Section 1.2.1. 
Transcription of one gene from multiple promoters provides advantages in gene 
expression; one or more of the resultant transcripts may be truncated causing the 
different transcripts to convey a variety, and sometimes opposing, biological actions. 
Thereby one gene is used to transcribe a number of isoforms, which'can be expressed by 
different transcription factors, the products of which elicit a number of varied biological 
responses. The progesterone receptor gene is oestrogen inducible yet the promoter 
regions for PR-A and PR-B do not contain consensus oestrogen responsive elements 
(EREs), however the PR-A promoter region does contain a half-palindromic ERE site 
which may be involved in the oestrogen responsiveness of PR-A (Kastner et al, 1990). 
PR-B differs from PR-A by an additional stretch of 164 amino acids at the N-terminal 
end of PR-B, known as the PR-B specific domain which encodes a third transactivation 
function domain (AF-3) which is absent from PR-A (Figure 1.12.) (Sartorius et al, 
1994; Wen et al, 1994). Additionally, they both share important structural and 
functional domains, with similar DNA and ligand binding affinities yet they are not 
functionally identical and have been shown to exhibit functionally distinct 
transcriptional activation properties specific to cell types, ligands and promoters (Tora 
et al, 1988; Vegeto et al, 1993; Meyer et al, 1990; Kastner et al, 1990). 
PR-A and PR-B isoforms can have been isolated in both homodimer and heterodimer 
forms, the heterodimer form may have transcriptional activation properties that differ 
h m  those of PR-A or PR-B homodimers (Meyer et al, 1990; Mohamed et al, 1994). 
PR-A has been identified as a cell and promoter specific functional repressor of PR-B. 
PR-A has been seen to act as a potent trans-dominant repressor of PR-B mediated 
transcription. Additional PR-A was also capable of inhibiting glucocorticoid, androgen 
and minemlocorticoid receptor-mediated genetranscription. This suggests a specific 
role for the hPR-A isoform in thisregulatory process. This trans-dominant activity of 
PR-A originates fiom the extreme N-terminal140aa region. 
The different biological effects of PR-A and PR-B may function to generate tissue 
specific regulation of progesterone, whereby different cell types can provide a differing 
response to progesterone depending on the balance of PR-A and PR-B present in the 
cell. 
Allan et a1 identified a hormone-specific confonnational change in the LBD of PR 
which is required for events that follow PRE binding (such as transcriptional activity or 
receptor recycling). The conformational change may trigger HSP dissociation as well 
as DNA binding. However this confonnational change is similar to that seen in nuclear 
receptors that bind to their response elements in DNA independently of a ligand (Allan 
et al, 1992). 
1.3.2.1. Physiological Roles of Progesterone Receptor 
Progesterone receptor has a major role in the functioning and maintaining of the 
menstrual cycle (Figure 1.2.) as well as the functions mentioned below. 
Mammary Glands 
Progesterone has a major developmental role in the normal mammary tissue, and it is 
hypothesised that it controls mammary gland proliferation and development (in 
partnership with oestrogen) via the secretion of paracrine growth factors (Anderson, 
2002). It also is believed to be involved in the formation of lobular alveolar structures 
during pregnancy (Topper and Freeman, 1980). The influence of progesterone is likely 
to be proliferative in this process, mediated by progesterone regulation of cell cycle 
genes, growth factors, and growth factor receptors. Progesterone also exerts a 
differentiating effect on the breast through its role in lactation (reviewed in Graham and 
Clarke, 1997). 
Brain 
Oestrogen and progesterone control specific brain functions involved in reproductive 
behaviour. Progesterone regulates signals in the brain involving sexually responsive 
behaviour. The most well defined aspect of progesterone effects on this process are PR 
mediated effects in the hypothalamus and pre-optic area (reviewed in Graham and 
Clarke, 1997). 
Bone 
Expression of PR in normal human osteoblast like cells has been reported (Wei et al, 
1993), and it may have a role in bone matrix regulation, via its effect on 
metalloproteinases. 
Anti-oestrogen Action of Progesterone 
Many of the effects of progesterone are thought to be due to its ability to oppose the 
action of oestrogen, particularly in the uterus. Progesterone abolishes oestrogen 
induction of many of the known hormone-responsive genes (reviewed in Clarke and 
SutherIand, 1990, Green and Clarke, 1997). 
Progesterone directly reduces ER concentration, and additionally opposes ER-mediated 
gene-regulatory events, although the molecular mechanisms of this antagonism are not 
clear. However, the repressive effects of progesterone appear to be promoter- and cell- 
specific, and there is considerable variability between reports (reviewed in Graham and 
Clarke, 1997). 
PR-A has been demonstrated to have similar repressive effects on other members of the 
nuclear receptor family, including those for androgens, mineralocorticoids, and 
g~ucowrticoids (McDomell et al, 1994a; 1994b; Wen et d 1994), although the 
physiological significance of this observation remains to be determined. 
1.3.3. Additional Transcription Factors 
The Paired box 4 (PAX4) gene was fust identified in mice, and was subsequently 
cloned h m  humans @ohman et al, 2000). PAX4 is a member of the PAX family of 
transcription factors ( D o h a n  et al, 2000; Chi and Epstein, 2002) 
PAX4 contains a paired box domain (a highly conserved DNA binding domain), an 
octapeptide and a paired-type homeodomain (homeodomain found only in PAX4 and 
PAX6) (Dahl et al, 1997; Dohrman et al, 2000). Pax proteins are key regulators of 
vertebrate organogenesis since they play major roles in embryonic pattern formation, 
cell proliferation and cell differentiation (Chi and Epstein, 2002; Dahl et al, 1997; 
Dohrman et al, 2000; Epstein et al, 1994). 
PAX4 is a transcriptional repressor that binds to a common element in the glucagon, 
insulin and somatostatin promoters and it has been found to bind to an 8 bp consensus 
sequence: AA(T1A)AATTA (Smith et al, 1999) 
Additionally, it is also involved in pancreatic islet cell development, specifically the 
differentiation of insulin producing beta cells (Dohrman et al, 2000; Soso-Pineda, 
2004). 
1.3.3.2. SNAIL 
SNAIL is a zinc finger protein transcription factor transcribed from the Snail gene and 
is 264 amino acids in length. The Snail gene was first isolated from Drosophila 
(Simpson, 1983) after which the protein was isolated from human cell lines (Okaru et 
al, 2001). SNAIL belongs to the SNAIL C2H2-type zinc-finger protein family (which 
includes Slug) and contains 4 C2H2-type zinc fingers. It is involved in DNA, metal and 
zinc binding. SNAIL is expressed in a variety of tissues, including placenta and adult 
heart, lung, brain, liver, and skeletal muscle, with the highest expression in kidney 
(Paznekas et al, 1999). 
Drosophila SNAIL is a transcriptional repressor (Hemavathy et al, 2000; Nieto, 2002) 
that acts to maintain the proper germ layers by repressing the expression within the 
mesoderm of regulatory genes involved in ectodermal development (Leptin, 1991). 
Snail bas an NH2-terminal domain containing a seven-amino acid SNAG domain. 
Okaru et al used s i t e k t e d  mutagenesis experiments to confirm that this domain is 
important for the repressor activity of SnaH (Okaru et al, 2001). 
SNAIL zinc-finger protein was thought to be required zygotically for mesoderm 
formation (Boulay et al, 1987; Sipson, 1983). 
A SNAIL binding site was identified in the CREaroCF region of the human aromatase 
gene (CTGATGAAGT) and, when SNAIL interacts with this site, was found to repress 
the activity of this promoter (Okary et al, 2001) thereby repressing the production of 
aromatase, one of the enzymes involved in the synthesis of oestrogen (Section 1.2.2.). 
Quenching is a form of gene regulation whereby repressors occupy neighbouring sites 
in a target promoter and prevents the ability of the activator to gain contact with the 
DNA bound transcription complex (Gray et al, 1994). Gray et al reported that this is the 
mechanism used by Snail. 
Normal breast epithelial cells and fibroblasts express SNAIL at relatively high levels, 
however these levels drop significantly in breast cancer tissue (Okaru et al, 2001). 
Okaru et al suggest that high expression of SNAIL in normal breast epithelial cells and 
fibroblasts prevents proteins fiom biding to CREaro, the promoter element in the 
mmatase gene. This prevents excessive synthesis of estradiol. However, low levels of 
SNAIL expression in breast cancer tissue results in low levels of SNAIL binding to the 
CREaro site in the aromatase promoter, enabling tramxiption factors to build up and 
expression of mmatase which leads to synthesis of estradiol. 
Additionally SNAIL has been implicated in the repression of Vitamin D receptor 
expression in human colon cancers (Palmer et al, 2004). 
1.3.3.3. RORa 
Retinoid-related Orphan Receptor-a, or RORa, is an orphan nuclear receptor encoded 
by the RORA (chromosome 15 q22.2) gene which encodes a protein between 468 and 
548 aa in length depending on the isofonn. 
The RORa gene generates four isoforms that share common DBDs and putative LBDs 
but are distinguished by different N-tenninal domains (Gigue're et al, 1994) (Figure 
1.13.). 
LBD 
4 t Human Mouse 
DBD A n  
RORal 523 + + 
RORa2 556 + 
RORa3 - -548 + 
RORa4 0468 + + 
The RORa isoforms bind to monomeric RORE (RORa responsive element) found in the 
regulatory region of target genes. These ROREs are generally composed of a 5' 6 base 
pair A/T-rich sequence that precedes a 3' AGGTCA core half-site motif (Gigue're et al, 
1994). It is thought that RORa binds DNA as a monomer, however it remains a 
possibility that it could form heterodirneric complexes with an unidentified partner in 
vivo (Gigue're et al, 1995). 
Most RORa isoforms are tissue-specific and are involved in the regulation of different 
physiological processes and have different target genes. Human RORa3 is only found in 
human testis (Steinmayr et al, 1998). RORa is found ubiquitously expressed in mouse 
tissue with highest levels of expression have been observed in the Purkinje cells of the 
cerebellum, retina, lens, spleen, skeletal muscle, and testis (Retnakaran et al, 1994; 
Matsui et al, 1995; Hamilton et al, 1996; Sashihara et al, 1996; Nakagawa et al, 1997; 
Koibuchi et al, 1998; Koibuchi et al, 1998). 
The structure of RORs is typical of nuclear receptors. They consist of four major 
functional domains: an N-terminal domain in the Ail3 region followed by a highly 
conserved DBD, a hinge region and a C-terminal ligand binding domain (Figure 1.13.). 
The A/B region has been demonstrated to play a critical role in conferring DNA binding 
specificity on the various isoforms (Gigue're et al, 1994; Gigue're et al, 1995). The 
promoter context, in conjunction with the RORE sequence and the amino terminus, may 
be responsible for which of the isoforms is recruited. 
RORa has been implicated in a number of physiological roles (Figure 1.14.). 
Cholesterol (7 dehydrocholesterol and cholesterol sulphate) have been identified as 
RORa agonists (Kallen et al, 2004; Kallen at al, 2002), and have been found to regulate 
the expression of genes involved in lipid metabolism (Kallen et al, 2002). These factors 
suggest that RORa has a role in the regulation of lipid metaholism.High levels of RORa 
has been seen in cerebellar Purkinje cells (Matsui et al, 1995), and knockout studies 
have demonstrated that RORa deficient mice have display severe cerebellar atrophy, 
characterized by a signifigant reduction in Purkinje cells and a loss of cerebellar granule 
cells (Hamilton et al, 1996). Additionally, RORa has been implicated in spinocerebellar 
ataxia type 1 (SCAI), an autosomal dominant inherited neurodegenerative disorder 
characterized by progressive loss of motor coordination, speech impairment, and 
problems swallowing (reviewed in Jetten, 2009). 
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Figwe 2.14. PhysioIogitdfunctions of ROR (Jetten, 2009) 
1.3.3.4. COUP TF I and I1 
Chick Ovalbumin Upstream Promoter-Transcription Factor (COUP-TF) is one of the 
best chrnacterized orphan nuclear receptors. It was first identified as a homdie r ,  
found to b i d  to a direct repeat regulatory element, containing an imperfect direct repeat 
of AGGTCA, in the chicken ovalbumin promoter (Pastorcic et al, 1986; Sagami et al, 
1986; Wang et al, 1989). Each factor has the ability to generate its own distinct 
expression profile during mammalian development (Qiu et al, 1994). COUP TF I is 
identical to EAR? (Miyajima et al, 1988) while COUP TF I1 has been found to be 
identical to ARP-1 (Ladias and Karathanasis, 1991). 
Both COUP TF I and I1 are expressed in many human tissues, being involved in many 
biological regulation processes such as neurogenesis, organogenesis, determination of 
cell fate and metabolic homeostasis (Tsai et al, 1994; Ladias and Karathanasis, 1991; 
Wang et al, 1991 ; Mangeldorf et al, 1995; Ritchie et al, 1990; Qui et al, 1994). 
COUP TF contains a 66-amino cis region which contains two conserved Zinc finger 
motifs, this is the DBD region. 
COUP TF I and I1 are identical but for one amino acid difference in within the DBD 
which is a conservative change from Ser to Thr (Miyajima et al, 1988; Wang et al, 1989). 
1.4. Coregulators: Coactivators and Corepressors 
As stated previously in Section 1.3., nuclear receptors comprise of ligand-regulated (e.g. 
estrogen receptors and progesterone receptors) and orphan transcription factors (a total 
48 receptors in humans). These proteins play a central role in the bodys' ability to 
transduce steroid, retinoid and other lipophilic endocrine hormone signals to the 
genome (Tsai and O'Malley, 2004; Mangelsdorf et al, 1995). Nuclear Receptors have 
the ability to recognise specific sequence motifs within the promoter, or enhancer, 
regions of their target genes, generally associating with the ligand binding domain and 
with the AF-1 and AF-2 domains of certain nuclear receptors. However, the ability of 
the NR receptor to bind to the specific sequence motifs is dependant on, firstly, the 
ability of the NR to access the motif through chromatin and, secondly, the relationship 
of the NRs with the RNA Polymerase I1 holocomplex. (Roeder, 2005). These 
difficulties are overcome, or exacerbated, by coregulators. Coregulators are molecules 
that are directly recruited by nuclear receptors and either activate (coactivator) or 
repress (corepressor) the transcription of specific genes (Lonard and O'Malley, 2005). 
Coactivator recruitment is generally ligand dependant while corepressors repress gene 
expression primarily via interaction with NRs not bound to ligand to repress 
transcription (Glass and Rosenfeld, 2000). Corepressor associated proteins such as 
histone deacetylases, prevents transcription by creating a local chromatin environment 
which hinders association of transcriptional machinery, this opposes the transcriptional 
promoting activities of coactivators (such as acetyltransferases). The opposing actions 
between pro-transcription and anti-transcription creates an equilibrium which can be 
tipped either way according to the signals received (Reviewed in Lonard and O'Malley, 
2007; 2006). 
Core coregulators, those that interact directly with nuclear receptors, exist in large 
steady-state complexes with multiple secondary co-coregulator partners. Each 
component may possess multiple enzymatic capabilities such as acetyltransf&ase, 
methyltransferase, phosphokinase, ubiquitin ligase, and ATPase activities, ultimately 
making these complexes versatile enzymatic 'machines' for regulating gene expression 
(Lonard and O'Malley, 2006) (Figure 1.15.). 
Currently, approximately 300 coactivators and corepressors have been reported 
(http://www.NURSA.org), some examples are listed in Figure 1.15.. 
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Figure 1.15. Selected Coregthtor Posthrmslatio~l Modijications @om Lonard ond 
1.4.1. Nuclear Receptor Coactivators 
Coactivators associate with ligand bound activated NRs (or other DNA biidiig 
transcription factors) and are required both for the transcriptional activation process to 
occur (Drapkin et al, 1993; Tijan and Maniatis, 1994; Guarente, 1995; Verrijzer and 
Tijan, 1996), and for enhanced gene expression. 
Coactivators are diverse, both structurally and through their biochemical processes. 
Coactivators function via numberous enzymatic means, including acetylation, 
methylation, ubiquitination and phosphorylation. These enzymatic properties of the 
coactivators enable them to function as chromatin remodelers (reviewed by Lonard and 
O'Malley, 2006). 
A family of coactivators, known as the pl60/SRC family, currently consists of 3 
members, described below. The common domains of this family of coactivators can be 
seen in Figure 1.16.. 
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Figure 1.16. Schematic diagram of the common structural andjimctional domains of SRC 
family of coactivators. The lines above the bar identi% the regions containing conserved 
strwtwal and functional feuhues among SRCs. These include: the bmic-helix-loop 
helir/Per/ARNT/Sim (bHLWPAAS); the sermelthreonine-rich regions ( i ;  the LXkZL motii 
responsible for interaction with nucIear receptors (RID); the intrinsic transcription activation 
domains of SRCs (ADI cad AD2); the glutamme-rich regions (e); and the HAT domain 
idem$& in SRC-I and SRC-3. 
The lines under the bar indicate regiom that are responsible for interaction with transcription 
fmtars or other coreguIators. W, k@ocyte enhancer factor-2C; TEF, lrbonriptiond 
enhancer factor; RID, receptor-interacting domain (Wu et al, 2005). 
There are 3 members of the pl60lSRC family of coactivators, namely; SRC-I, SRC-2 
and SRC-3 (Figure 1.1 7.) 
CBP intaacIian 
- Aatylation 
Basic helix-Imphelix domaim 
PAS (PerlAmtlSim) domains 
NR boxes (eoasensus W[U motifs) 
GluIamine-rich regions 
Figure 1.1 7. Multiple members of the SRC family. The proteins have been aligned according to 
major structural similarities and to emphasize both the structural divergence of the carboxy 
termini and the conservation of the amino-terminal dornains of SRC family members. Regions to 
which specific functions of individual coactivators have been assigned are it~dicated. Only SRC- 
I contains a consensus LXXLWNR box motif in this region. (McKenna et al, 1999b) 
1.4.1.1. SRC-I 
SRC-I was the first NR coactivator to be successfully cloned (Onate et al, 1995). This 
coactivator exhibits a broad range of specificity in the coactivation of ligand dependant 
transactivation of nuclear receptors, including PR, GR, ER, TR and RXR (Onate et al, 
1995). The interaction of hSRC-1 with the LBD of the progesterone receptor is ligand 
dependent (Onate et al, 1995) and is abolished in the presence of the antiprogestin 
RU486. In addition, a hSRC-1 mutant, containing only the C-terminal receptor- 
interacting domain, suppresses PR coactivation by hSRC-1 in a dominant-negative 
fashion, both in transient transfection and by in viho transcription assay Onate et al, 
1995; McKenna et al, 1999b) indicating that the C-terminal domain is not involved in 
the coactivation capabilities of the molecule. 
Previous studies indicate that hSRC-I has the ability to mediate functional interactions 
between the N-tenninal AF-1 (not conserved in sequence in nuclear receptors) and C- 
terminal AF-2 (located within the hormone-biding domain, highly conserved among 
the nuclear receptors) domains of nuclear receptors. Individual hSRC-I domains are 
required for 111  functional cooperation between AF-I and AF-2 of the progesterone 
receptor (Onate et al, 1998), as well as the oestrogen receptor (McInemey et al, 1996). 
This suggests that that the efficient assembly of the preinitiation complex by steroid 
receptors is dependant on an SRC-1 assisted interaction between their individual AF 
domains (McKenna et al, 1999b). 
Additionally, research conducted by Xu et al suggested that peripheral steroid target 
organs of mice containing a targeted disruption of the SRC-1 gene have a decreased 
response to steroid hormones (Xu et al, 1998). Therefore, SRC-1 is responsibe for 
causing an effective steroid hormone response. 
In addition to the full-length SRC-1 (termed SRC-IA), several splice variants have been 
described. SRC-lA, SRC-lC, SRC-1D and SRC-IE (Kamei et al, 1996; Yao et al, 
1996; Takeshita et al, 1996). SRC-IA and SRC-IE are most studied. 
SRC-le is a more potent coactivator for oestrogen receptor than SRC-1A (Robyr et al, 
2000). For instance, the oestrogen-regulated rat oxytocin promoter is coactivated by 
SRC-LE but not by SRC-IA, whereas both SRC-1 isoforms stimulate oestrogen 
receptor-mediated transcription from an artificial ERE-containing promoter. Therefore, 
SRC-1A coactivation appears to rely on the promoter context of the receptor target gene 
(Robyr et al, 2000). 
Both isoforms contain three nuclear receptor interacting motifs (LXXLL) found in 
many co-factors (Heery et al, 1997). SRC-1A however possesses a fourth LXXLL 
motif at its C terminus (Kalkhoven et al, 1998). Mutation of the fourth LXXLL in 
SRC-1A does not affect transcription and its function is currently unknown (Robyr et al, 
2000). 
Additionally, SRC-I has histone acetyltransferase activity (HAT) (Spencer et al, 1997). 
HATS are enzymes that acetylate conserved lysine amino acids on histone proteins by 
transferring an acetyl group from acetyl CoA to form E-N-acetyl lysine. Acetylation of 
histone molecule in DNA is generally linked to transcriptional activation. 
SRC-2, also known as GRIP1 (glucocorticoid receptor-interacting protein l), TIF2 
(transcription intermediary factor 2) and NCoA-2, are 160-kDa nuclear receptor- 
interacting proteins with considerable sequence and functional similarity to SRC-1 
(Voegal et al, 1996; Hong et al, 1996, 1997; Torchia et al, 1997). 
GRIPl(mSRC-2) and TIF2 (hSRC-2) associate in a ligand-dependent manner in vitro 
with several receptor LBDs (Voegal et al, 1996) and, in vivo, with RARa, oestrogen 
receptor and progesterone receptor in the presence of hormone, but not hormonal 
antagonists (Voegal et al, 1996; Hong et al, 1996, 1997). 
The identification of a third member of the SRClpl60 family was a highly polymorphic 
protein isolated as pICIP @300/CBP cointegrator-associated protein) (Torchia et al, 
1997), ACTR (activator of thyroid receptor) (Chen et al, 1997), RAC-3 (receptor- 
associated coactivator 3) (Li et al, 1997), AIB-1 (amplified in breast cancer-1) (Anzick 
et al, 1997), TRAM-1 (thyroid receptor activator molecule 1) (Takeshita et al, 1997) and 
SRC-3 (Suen et al, 1998), illustrates complex nomenclature in the SRC family 
(McKenna et al, 1999b). 
hSRC-3 interacts with and coactivates a wide variety of nuclear receptors in a ligand- 
dependent manner, including RAR, thyroid receptor, RXR, glucocorticoid receptor 
(Chen et al, 1997), progesterone receptor (Li et al, 1997) and oestrogen receptor 
(Anzick et al, 1997). 
mSRC-3 exhibits greater promiscuity than other SRC family members by enhancing the 
transcriptional activity of a number of different activators, including interferon-a and 
CAMP regulatory element binding protein (CREB) (Torchia et al, 1997), which were 
previously shown to be dependant primarily on CREB-binding protein (CBP) for 
efficient activation. 
Additionally, SRC-3 selectively enhances the transcriptional activity of ERa over that 
of ERP, possibly reflecting a 60% difference in homology between the LBDs of these 
isoforms (Suen et al, 1998). 
SRC-3 is both regulated by phosphorlyation and distinct phosporylation patterns on the 
SRC-3 molecule determine its specificity for different transcription factors (Wu et al, 
2004). 
Phosphorylation is required for SRC-3 activity, and the specificity of SRC-3 for 
different transcription factors further depends on where phosphorylation is induced on 
SRC-3 by a respective stimulus (Wu et al, 2004). It is proposed that a specific 
phosphorylation-dependent code allows SRC-3 to activate gene expression specifically 
and accurately (Wu et al, 2005). 
1.4.3. Mechanism of Coactivator Action 
Figure 1.18. demonstrates the various signalling pathways the SRC family are activated 
by and their preferential targets. 
The pl60lSRC family of caoctivators have multiple methods of activating genomic 
transcription. Their two main mechanisms of action is to manipulate chromatin to 
enable access to the transcription machinery and also to activate the nuclear receptor via 
AF-I and AF-2 domains in the nuclear receptor. 
SRC-1 and SRC-3 has been identified as possessing HAT activity (Spencer et al, 1997; 
Lemon and Freedman, 1999; McKenna et al, 1999b). 
C A M - 1  (Coactivator-associated arginine methyltransferase 1) functions as a 
secondary coactivator through its associationwith the carboxyl-terminal region 
of pl60 coactivators. C A M - 1  can methylate histone H3 in vitro, and though mutation 
analysis was deemed necessary for the full coactivation activity of the p160 family. 
Thus, coactivator-mediated methylation of proteins in the transcription machinery may 
contribute to transcriptional regulation (Chen et al, 1999). 
Figure l.1& Signaling to SRCs. Kinase-mediated signalingpathways activated by a variety of 
stimuli (including steroid hormones, cytokines, andgrowth factors) that can communicate with 
SRCs, me  displqyed o h .  Although seven olqior phmphorylation sites (serines372, 395. 51 7, 
569, 1033, 1185 and threoninell79) were identrBed on SRC-I, it is mlear  whether 
phosphorylation is fleeted by steroid hormones (as indicated by ?; same is mfo* SRC-2), 
and only phosphorylaiion at threoninell79 and soinell85 induced by CAMP were shown. 
SRC-3 was wed as a model molecule as there is a deeper understanding of SRC-3 
phosphmyIation. However, it is hypohesized thal this same mode of operation from SRC-3 
could also apply to SRC-I and SRC-2. Although each SRC is able to coactivate with the 
various recepfors in lransienl transfeetion assays, the preferred SRC parfner for diferent 
receptor signaling is connected by an amw. (Wu et al, 2005) 
1.5. Steroids, Nuclear Receptors, Steroid Receptor 
Coactivators and Cancer 
1.5.1. Breast Cancer 
Breast cancer is the most common malignancy of women residing in, industrialized 
countries and it is the most common cause of cancer associated morbidity and mortality 
(Giacinti et al, 2006). Sixty five percent of primary breast cancers are ER positive 
(Giacinti et al, 2006). 
Oestrogen is involved in the growth and differentiation of epithelial cells in normal 
mammary tissue. The mitogenic effects of oestrogens on breast epithelial cells are due 
to, at least in part, increased expression of genes involved in the regulation of the cell 
cycle (Vendrell et al, 2004). However, very little is known about the actual mechanism 
of oestrogen mediated proliferation. 
Target genes have been identified, through studies on oestrogen regulated gene 
expression in breast cancer cells, which may be involved in mammary cell proliferation. 
NOV, a gene that encodes for a negative regulator of cell proliferation, is down 
regulated by oestrogen in breast cancer cells (Vendrell et al, 2004). WNT2 is a gene 
whose expression is associated with abnormal proliferation in human breast tissue 
(Huguet et al, 1994). WNT2 expression has been seen to increase following oestrogen 
exposure (Vendrell et al, 2004). Oestrogen has also been shown to induce the down 
regulation of the TACC gene family members, TACCI, EFNAI and ZNF217 (Vendrell 
et al, 2004). The TACC gene family contain a TACC domain, which forms a coiled- 
coiled region in their carboxy terminus (Lappin et al, 2002). The TACC gene family 
has been reported to contribute to the development of cancer (Raff, 2002), and a down 
regulation in TACCl mRNA has been observed in breast tumors (Conte, 2002). 
Prolonged stimulation of oestrogen receptor on breast ductal epithelium contributes to 
the development and progression of breast cancer. Reducing oestrogen receptor levels 
or altering its activity has been found to induce tumour regression. In these cases 
treatment that are. designed to block the effects of oestrogens are important in halting 
cancer progression (Osbome et al, 2000). (Discussed further in Section 1.5.2.) 
While sixty five percent of primary breast cancers are ER positive, the remaining thirty 
five are ER negative. ER negative breast tumours are associated with more malignant 
and more drug resistant tumours. 
Additionally, breast tumours that are initially identified as ER positive can loose their 
ER expression during tumour progression (Yang et al, 2001). This can indicate that the 
tumour is becoming more malignant. 
Some ER positive breast cancers also contain progesterone receptors, whose presence 
may indicate that the ER remains responsive to oestrogen and can still control specific 
protein synthesis (Honvitz and McGuire, 1978). 
1.5.2. Selective Oestrogen Receptor Modulators - A treatment and 
preventative agent for Breast Cancers 
Treatments designed to block the effects of oestrogens are important in halting cancer 
progression in ER positive breast cancers (Osbome et al, 2000). 
Selective oestrogen receptor modulators (SERMs) perform this function and are 
designed to be effective in breast cancer prevention and treatment as they inhibit the 
proliferative effects of oestrogen that are mediated through the oestrogen receptor. 
SERMs bind to the oestrogen receptor, alter its conformation, and thereby facilitate the 
binding of coregulatory proteins that can activate or repress the transcriptional 
activation of oestrogen target genes (Osbome et al, 2000). 
1.5.2.1. Subdivisions of SERMs 
SERMs can be divided into three major categories: Triphenylethylene derivatives, other 
nonsteroidal compounds and steroidal compounds that have more complete 
antioestrogenic activity. Tamoxifen and Raloxifene are the two major SERMs currently 
used as a treatment for hormone responsive breast cancer. 
Tamoxifen (Figure 1.19.), a member of the Triphenylethylenes group of SERMs, was 
first synthesized in the 1960s, demonstrated to have antiproliferative effects in breast 
tissue (Jordan, 1994) and shown to be an effective therapy in patients with ER positive 
metastatic breast cancer (Osbome, 1998). The major metabolites of tamoxifen are N- 
desmethyltarnoxifen and trans-4-hydroxytamoxifen, which has an affinity for ER 
similar to that of 17-P oestradiol (Buckley et al, 1989). 
Figure 1.19. Chemical Structure of Tamoxifen (www.pharmacology2000.com) 
Tamoxifen has both oestrogenic and anti-estrogenic effects. It has agonist effects on 
bone (Love et al, 1992), blood lipids and also the endometrium (Osbome, 1998) while 
having antioestrogenic effects on the CNS and vaginal mucosa. The mixed oestrogenic 
and antioestrogenic effects of Tamoxifen are species, tissue and cell dependent. 
, Tamoxifen has also been shown to have both oestrogenic and antioestrogenic effects on 
specific subsets of genes within a singe cell type (Osbome et al, 2000). 
Tamoxifen binds to the ER in breast cancer cells and antagonizes the effect of oestrogen 
on a variety of growth-regulatory genes (Dhingra, 1999). The predominant effect it has 
is cytostatic with the induction of a GI cell cycle block thereby slowing cell proliferation 
and inhibiting cancer growth (Osborne, 1998). Tamoxifens dual activities provide some 
advantages for patients receiving Tamoxifen treatment. Not only is there a beneficial 
effect through inhibition of proliferation of breast ductal epithelium and breast cancer, 
but due to Tamoxifens oestrogenic effects in certain tissues, women may also benefit 
from maintenance of bone density and a reduction in cholesterol. The associated 
reduction in cholesterol is due to its oestrogenic activity in the liver, as serum 
concentrations of total cholesterol and low-density lipoprotein are reduced by 
tamoxifen, while the preservation of bone density is due to tamoxifens oestrogenic 
effect in bone. 
However, due to its varying activity in different tissues there are side effects associated 
with Tamoxifen. The most serious of these side effects are associated with its 
oestrogenic activity in the endometrium, which can result in endometrium hyperplasia 
and also low-grade endometrial cancers (Wilking et al, 1997). Additionally, due to its 
antioestrogenic effects on the vaginal mucosa, treatment may result in menopausal 
symptoms (Love et al, 1991). 
Raloxifene 
Raloxifene (Figure 1.20.) is in the group of nonsteroidal compounds. It is a 
b t h i o p h e n e  derivative and it b ids  to the ER with an equal sanity to that of 
oestradiol (Black et al, 1983). Raloxifene is an inhibitor of cultured breast cancer cells 
and possesses antitumor activity in rat mammary tumour models similar to that of 
Tamoxifen (Poulin et ai, 1989). 
1.5.3. Nuclear Receptor Coregulators and Human Disease 
Nuclear receptor coregulators are central to the regulation of NR-mediated transcription 
and in the coordination of intercompartmental metabolic processes (Lonard et al, 2007). 
Knockout studies have demonstrated the importance of SRC-1, SRC-2 and SRC-3 in a 
wide variety of biological functions (Table 1.1.) 
Consequently, disruptions in the SRC family of coactivators can lead to a wide variety 
pathological states. The following is an overview of the pathological states which occur 
as a result of these disruptions. 
delayed development of purkinje cells 
control of energy balance 
Knockout 
SRC-1 
I loss of skeletal response to oestrogen 
Phenotype 
moderate motor dysfunction 
I altered hypothalamic-pituitary-adrenal axis function I altered hepatic function 
I essential for the progesterone-dependant uterine and mammary morphogenesis SRC-2 
testicular dysfunction 
spermatogenesis defect and placental hypoplasia 
control of energy balance in white and brown adipose tissue 
I reduced mammary gland development 
SRC-3 
I reduced adipogenesis and inhibition of neointima formation by oestrogen 
animals of smaller size 
delayedpuberty 
I decreased response a IGF-1 
Table 1.1. Consequences of SRC knockout studies (Adaptedfrom Lonard et al, 2007) 
1.5.3.1. Cancer 
Coactivators have been found to be over- and underexpressed in a number of cancers. 
This is the largest group of coactivator related disease. 
Coactivator overexpression may invoke carcinogenesis, enhance its progression or alter 
the biological activities of therapeutic NR ligands (Shang and Brown, 2002). 
Coactivator misexpression can be thought of as a pervasive agent in the progression, or 
etiology, of human cancers. 
SRC-1 has been found to be overexpressed in prostate, breast and gastric cancers. A 
MOZ-SRC-2 fusion protein has been identified in acute myeloid leukaemia. Also, there 
is a brain and breast cancer correlation with oestrogen and progesterone receptor and 
SRC-2 expression. 
SRC-3 has been associated with numerous carcinomas, including breast, pancreatic, 
ovarian, endometrial, oesophageal squamous call and colorectal. Overexpression of 
SRC-3 has been demonstrated in oral squamous cell carcinomas and a smaller isoform 
of the protein has been identified in certain breast and gastric cancers. Additioanlly, 
some polymophisms can protect against breast cancer and influence calcaneal bone 
density. (All reviewed by Lonard et al, 2007) 
1.5.3.2. Metabolic Syn'dromes 
Knockout studies have found SRC-1 and SRC-2 to play opposing roles in energy 
metabolism (Feige and Auwerx, 2007). SRC-l-b knockout mice are prone to obesity 
due to decreased energy expenditure while SRC-2.'- knockouts are leaner due to the 
reduced transcription of PPARy2 (a protein essential for the differentiation of 
adipocytes). SRC-2.'- knockout mice also display a subsequent increase in PGC- 
la/SRC-I interaction which enhances the thermogenic actions of PCG-la in brown 
adipose tissue. SRC-3's role in metabolism has been identified in the promotion of the 
formation of white adipose tissue. SRC-3.'- knockout mice have a decreased adipose 
tissue mass (Louet et al, 2006; reviewed in Lonard et al, 2007) 
1.5.3.2. Coactivator  Fusion Proteins 
Genetic disruptions leading to coregulator fusions with other proteins exist in certain 
cancers (Lonard et al, 2007). A MOZ-SRC-2 fusion protein predisposes an individual 
to acute myeloid leukaemia (Troke et al, 2006). 
1 . 5 . 3 . 3 .  Coregulator  Gene Polymorphisms 
Coregulators function to control the extent of gene expression from nuclear receptors so 
that fluctuations in their expression or small changes in their biological activity will lead 
to significant differences in target tissue responses to hormone ligands. Individual 
variations in secondary sex traits, obesity and susceptibility to cancer may be attributed 
to alterations in the primary protein amino acid sequence and the cellular concentration 
of coregulators (Lonard et al, 2007). 
Generally, coregulator SNPs (small nuclear polymorphisms) are located in the 
coregulator gene promotors or intronic or synonymous non-coding variants, however, 
SNPs can, if infrequently, occur and affect the coregulator amino acid sequence (Lonard 
et al, 2007). 
There are 10 SNPs found in SRC-3 that affect its coding sequence and hence the 
translated protein (Sheny et al, 1999; Lonard et al, 2007). A Q586H variant allele, one 
of the 10 SNPs that affects the coding sequence of the SRC-3 protein, confers a 
protective effect against breast cancer (Burwinkel et al, 2005) 
1.64. Relationship of SERMs and SRCS 
According to Lonard et al, SERMs have the ability to upregulate the expression of SRC- 
1 and SRC-3 in cells and, additionally stimulate the transcription of other nuclear 
receptors. They hypothesize that the differential agonist or antagonist action of SERMs 
is dependant on the coactivator expression in oestrogen target tissues (Lonard et al, 
2004). Shang and Brown have demonstrated that elevated expression of SRC-1 in the 
uterus-derived Ishikawa cell line contributes to the increased agonist action of 
Tamoxifen in the uterus, while lower levels of SRC-1 in the breast derived MCF-7 cell 
line allow for Tamoxifen to function as an antagonist (Shang and Brown, 2002). 
1.6. Identification of Transcription Factor Binding Sites 
Current techniques available to enable the isolation of transcription factor binding sites 
include chromatin immunoprecipitation combined with microarray detection (ChlP-on- 
chip) and DamID. These two techniques are based on fundamentally different 
principles. 
ChIP-on-chip analysis utilizes antibodies to identify genomic transcription factor 
binding sites. An overview of the methodology can be viewed in Figure 1.21.. 
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Figure 1.21. Step by step methoak fir performing Chiponchip analysh 
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Cells are isolated from tissue and fixed using 1% Formaldehyde which functions to 
cross link and preserve transcription factor DNA binding. Cells are then lysed and the 
nuclei isolated, following isolation the nuclei are lysed and the resultant lysate is 
sonicated or enzyme treated to fragment the DNA into 300 to 1000 bp fragments. 
An antibody directed against the transcription factor of interest is then added to the 
sonicated lysate followed by cross linking reversal to release the antibody bound 
proteins, proteins are removed by Proteinase K treatment, DNA is purified, amplified 
using LM-PCR and labelled. They are then hybridized to a microarray after which 
image and data analysis is performed. 
The microarray used contains fragments of the 111 human genome and the locations of 
the labelled sequences can be further malysed using a variety of techniques, including 
bioinformatics. 
1.6.2. DamID 
The DamID technique relies upon the low level in vivo expression of a fusion protein 
consisting of a protein of interested fused to Dam (DNA adenine methylation) isolated 
from Escherichia coli. Dam methylates adenines in the sequence GATC, a trait unique 
to this prokaryotic protein. When the Dam h i o n  protein is bound to DNA the Dam 
will methylate nearby GATC sequences (Figure 1.22.). 
Once Dam methylation has occurred the transcription factor biding sites can be 
isolated. Genomic DNA is isolated and methylated GATC sequences are cut between 
GAme and TC nucleotides using the methylation-sensitive restriction enzyme DpnI. 
This digestion step creates a pool of blunt-ended DNA fragments that have 5' TC and 
3'GAm sequences. A double stranded adapter oligonucleotide with a 32 bp 5' overhang 
(dsAdR; formed using oligos AdRt and AdRb) is ligated to the blunt ends 5' overhang 
ensuring directional ligation. Double strand adapter is used as double stranded DNA is 
ligated more efficiently than single stranded oligonucleotides. This is followed by 
DpnII digestion, a methylation sensitive enzyme that only cuts unmethylated GATCs. 
A PCR primer identical to the 15 most 3' nucleotides of the AdRt nucleotide sequence 
and the 5'TC nucleotides of the gDNA fragment is used to amplify adaptor-ligated 
sequences (Vogel et al, 2007). 
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Figure 1.22. % methylation of GATC sequences of gDNA adjacent to Dam fusion protein 
binding sites, 
1.6.3. Bioinformatics 
Bioinformatics encompasses a wide range of techniques that utilise statistics, 
mathematics and IT to analyse biological information, such as genetic sequences. The 
internel is the backbone to a variety of bioinformatical tools and following the 
completion of the HGP (human genome project) a range of information can be obtained 
from just one DNA sequence. 
1.6.3.1 MotifViz 
MotifViz is an interactive web server which serves to identify overrepresented known 
transcription factor binding motifs (Fu et al, 2004). The identification of short sequence 
motifs, such as transcription factor binding sites, in a set of given sequences may aid in 
the understanding of transcriptional regulation. Overrepresented regulatory motifs in 
promoter elements of genes often reflect the factors to which the promoter is responsive 
to. The MotifViz programme uses algorithims to identify these overrepresented motifs. 
MotifViz offers four algorithms to analyse genomic sequences; Rover, Clover, Motifish 
and Possum (Fu et al, 2004). These four algorithms use different methods to find the 
overrepresented motifs. 
According to Fu et al, Clover uses a thermodynamic model with permutation or 
background input for statistical evaluation of cis-element over-representation. Clover 
screens a set of DNA sequences against a precompiled library of motifs and assesses 
statistical over- or under-representation in the sequences (Frith et al, 2004). One of the 
precompiled libraries that can be used is called JASPAR, which is a database of 
eukaryotic transcription factor binding sites (Sandelin et al, 2004). The JASPAR 
profiles contain non-reduntant transcription factor binding sites derived from published 
collections of experimentally defined sites (Sandelin et al, 2004). JASPAR profiles 
cover a variety of transcription factor classes; including the nuclear receptors. The 
MotitViz algorithms, including Clover, have the option of using the JASPER profiles 
when searching for over-represented sequences. Therefore, searches can be performed 
to isolate any one of the JASPAR profiles, for example Nuclear Receptors. Utilizing 
the Clover algorithm with the JASPER nuclear receptor profile enables identification of 
overrepresented nuclear receptor biidiig sites in the genome sequences of interest. 
The MEME Suite comprises of a set of Motif-based sequence analysis tools, which 
includes MEME, TOMTOM and GOMO. The MEME Suite enables elucidation of 
over-represented sequence motifs in a set of given sequences using MEME (Bailey and 
Elkan, 2004). MEME analyses a set of given sequences and using a defined algorithm. 
The algorithm discovers one or more motifs applying a technique known as 
"expectation maximkation to fit a two-component finite mixture model" to the set of 
sequences (Bailey and Elkan, 2004). The motifs discovered by MEME (an example 
displayed below) can then be analysed further using other MEME Suite programmes, 
such as TOMTOM. 
TOMTOM uses the MEME motifs to search for transcription factor binding motifs 
within them (Figure 1.23.). 
Figure 1.23. A: MEME mots B: TOMTOM Oestrogen Receptor binding mots  C: TOMTOM 
Oestrogen Receptor binding mofiffoundin MEAB motg(A) 
Critical cellular processes rely upon protein DNA interactions. Protein DNA binding 
may trigger transcription initiation or repression, DNA repair or may alter the structural 
conformation of chromatin an enable, or hinder, the binding of other proteins to the 
DNA. Elucidation of the regions of DNA where specific proteins bind to could enable 
us to gain a m  greater understanding of the proteins being investigated and also of the 
genes they may regulate. 
Oestrogen mediates its effects through the activation of its respective nuclear receptor. 
The activated receptor then has the ability to translocate to the nucleus and regulate the 
expression of genes controlled by oestrogen. The genes regulated by oestrogen are 
determined by the cell type and the conformation of the chromatin. 
Initially, the aim of this project was to investigate a reporter library of oestrogen 
responsive elements (EREs) (Jennings, 2009). This library was constructed by Jemings 
(Jemings, 2009) using DamID technology. Investigations on this library were to focus 
on the identification of SERM responders and perform further tests to analyse the 
isolated reporters. This would provide a deeper understanding into the role of 
Tamoxifen as an oestrogen antagonist. An overview of the aims are listed below: 
. To isolate SERM responsive reporter plasmids from an ERE reporter library 
. To assess the ability of the isolated sequences to mediate transcription in 
conjunction with other nuclear receptors and coactivators to establish potential 
novel interactions 
To investigate the mechanism by which SERMs have the ability to activate certain 
genes via the oestrogen receptor using mutant oestrogen receptor expression 
plasmids. 
The extent of gene activation by oestrogen is also controlled by coactivators and 
corepressors. Coactivaors, such as the SRC family of coactivators, bind to DNA bound 
nuclear receptor ligand complexes and fuaher increase the rate of gene transcription. 
Due to interesting results obtained during initial investigations into the SERM 
responders, it was decided to perform novel investigations into the SRC family of 
coactivators. The aims of the investigation into the SRC family of coactivators is 
described below. 
To isolate sequences from the genome that associate with SRC-1A:Dam and SRC- 
3 in association with either ligand bound oestrogen or progesterone receptors 
To use bioinfonnatics to identify DNA cis elements, repetitive sequences and 
overrepresented transcription factor binding sites in these isolated sequences 
To assess the ability of the isolated sequences to mediate transcription in 
conjunction with other nuclear receptors and coactivators to establish potential 
novel interactions 
Performing these investigations would enable a greater understanding in the relationship 
between the effect of the coactivator molecules SRC-1A and SRC-3 and oestrogen and 
progesterone receptor mediated transcription. 
An additional aim, encompassing reporter plasmids from both the ERE, SRC-IA and 
SRC-3 libraries, was to attempt to identify the location of transcription start sites in 
selected isolated reporter plasmid sequences. The ability to obtain this information 
would enable a deeper understanding of the binding sites that a variety of transcription 
factors of transcriptional coregulators associate with. 
3.0. MATERIALS AND METHODS 
3.1. Investigation of ERE (oestrogen responsive element) 
Reporter Library 
Construction of the ERE library was performed previously using DamID (Jennings, 
2009). A hERa:Dam expression plasmid was constructed to enable the expression of an 
ERa:Dam fusion protein when transfected into a cell line. 
EREs were isolated under three conditions; those that interact with ERa:Dam and EtOH 
(so to isolate EREs that associate with ERa not bound to ligand), those that interact with 
ERa:Dam and Oestrogen (to isolate EREs that associate with oestrogen bound ERa) and 
those that interact with ERa:Dam and Tamoxifen (to isolate EREs that associate with 
tamoxifen bound ERa). Transfection of pCR3.1 ERa:Dam to HeLa cells was 
performed and cells were treated with above mentioned treatments (EtOH, oestrogen or 
tamoxifen) to generate three separate libraries of sequences. The Dam portion of 
ERa:Dam, when DNA bound, methylated GATC sites adjacent to the binding sites. 
This was followed by DpnI and DpnII digestion to isolate the methylated GATC 
sequences, adapters were ligated to these isolated sequences and LM-PCR was 
performed. This was followed by insertion of the amplified sequences to a TOPO 
library where analysis was performed including sequencing of the inserts. Further 
analysis was enabled by transferring the TOPO library insert to a pGL3 Basic library. 
Upon the transfer trans-activation assays were performed to gain information of the 
promoter activity of the sequences. 
Detailed information on the materials and methods used to generate these ERE reporter 
libraries can be found in Jennings, 2009. 
3.1.1. Transactivation Assays 
Transactivation assays were used to further analyse the ERE reportcr library. The 
methods for transactivation assays are described below, the example provided is for the 
investigation of ERa and oestrogen on the ERE reporter library using HeLa Cells. 
3.1.1 . l .  HeLa Cell Preparation for Transfection 
HeLa Cells (Baylor College of Medicine, Houston, Texas) were plated in 24 well plates 
(xlO), with 50,000 cells/well in DMEM (with 4.5g/L D-Glucose and L-Glutamine, 
without Sodium Pyruvate or Phenol Red) with 5% Charcoal Stripped Serum (Gibco) 
and grown overnight at 37'C in 5% COz. All initial cell cultures were prepared by the 
BCM cell culture core. Prior to transfection cells were checked, using Inverted 
Microscope, to assess cell health, growth and distribution. 
3.1.1.2. Plasmid Preparation for Oestrogen Transfection 
Plasmid premixes were prepared as follows. Ependorfs were labelled appropriately with 
24 tubes for test (with reporter plasmid, hormone receptor and hormone) and 24 for 
controls (reporter plasmid only). Reporter plasmid was added to each of the control 
tubes at a concentration of 200ng/well while 200ng/well reporter plasmid was added to 
the test ependorfs as well as 5ng/well hERa. These were left to incubate at 4'C 
overnight. 
A 1:50 lipofectamine dilution was prepared using DMEM (with 4.5g/L D-Glucose and 
L-Glutamine, without Sodium Pyruvate or Phenol Red) without 5% Charcoal Stripped 
serum (Gibco). To the test samples 2 0 0 ~ 1  was added and 50p1 to the control. These 
were then left to incubate at RT "C for 30 mins. 
3.1.1.3. Hela Cell Transfection 
Hela Cell cultures were removed from the incubator and placed in a Laminar Flow 
Hood where the medium was aspirated and replaced with 200~1  DMEM (same as used 
in premixes). Each well also received 5 0 ~ 1  of either test or control reporter plasmid 
premix (Figure 3.1. and Figure 3.2.). 
Reporter Plasmid 1 
Reporter Plasmid 2 
Reporter Plasmid 3 
Rsparter Plasmid 4 
00 Reporter Plasmid 5 - - - -  
a Reporter Plasmid 6 
Total Volume in each well 2 5 0 ~ 1  
Each weU contains: 
HeLa cells grown overnight 
200~1 DMEM 
Sop1 reporter plasmid Lipofectamine DMEM mix 
Figure 3.1. Transfeetion protocol: Plate organisation - Test plate 
Plates were placed on a plate rocker for 10 mins and then moved into a 37OC incubator 
with 5% COz for 4 hrs. During the incubation hormone/EtOH premixes were made 
using DMEM (with 4.5& D-Glucose and without L-Glutamine, Sodium Pyruvate or 
Phenol Red) with 5% Charcoal Stripped serum. EtOH was made to a final concentration 
of 1 0 - ' ~  in 12mls while 24mls E2 was prepared at a concentration of 1 0 ' ~ ~  control 
wells were given only DMEM with 5% Charcoal Stripped Serum. 
Figure 3.2. Transfection protocol: Plate organisation Control plate 
When the incubation was complete plates were removed fiom the incubator, medium 
aspirated and 500pl of the required hormoneEt0H premix (pre-warmed to 37'C) was 
added to each well (Figrrre 3.3.). Plates were incubated for 24 hrs at 37OC with 5% 
coz. 
500pl EtOH Dilution 
500pl Oestrogen Dilution 
(Control plate had only DMEM) 
Figure 3.3. Hormone and EtOH Dilutions 
3.1.1.4.  Luciferase Assay 
If the plasmid contains a sequence with a promoter element and the relevant 
transcription activators, oxyluciferin will be produced. The amount of oxyluciferin 
produced is proportional to the strength of the promoter elements (See Section 4.1.1.1. 
for further details). 
Procedure 
Following 24 hr incubation with hormonelEtOH, luciferase assay was used to assess 
transcriptional activity in the HeLa cell line. 
Medium was removed following the incubation and HeLa cells were lysed using 1 0 0 ~ 1  
Luciferase Lysis Buffer (Appendix I) per well. The plates were- rocked on a plate 
rocker for 10 mins. Cell lysate (25~1) from each well was pipetted into 96 well plates. 
One-Glo Luciferase Assay System (Promega) was used to assess the luciferase activity 
in each of the wells. The firefly luciferase enzyme (stored away from light at -20°C) 
was brought to RT°C in darkness. The plates were read using a Luciferase Microplate 
Lurninometer and the results analyzed. 
3.2. Construction and Investigation of  Library of sequences 
which interact indirectly to SRC-1A and SRC-3 
A library of sequences that interacts with SRC-1A and SRC-3 via ligand bound ERa or 
PR-B was constructed and investigated as follows. 
3.2.1. Generation of pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam. 
pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam fusion plasmids were constructed to 
enable production of the SRC-1A:Dam or SRC-3:Dam fusion protein upon transfection 
to cell cultures. 
3.2.1.1. Generation of Dam PCR product 
Genomic template DNA was obtained from Escherichia Coli bacteria (gDNA 
previously isolated); long was added to 1pl 10X Accuprime Buffer I (Invitrogen), 2p1 
lpM 50:50 primer mix (Figure 3.4.) (Invitrogen), 5 .5~1  dH20 and 0.25~1 Taq DNA 
Polymerase (Invitrogen). Primers were designed to amplify the full length Dam gene 
generating a PCR product of 800bps. 
Forward orimer 
SaU: 5' ATC GCA 
"T"rCLe": r' E.Coli Dam 5' end AAG AAA AAT CGC GCT m TTG AAG 3 3  
SalI restriction site 
Reverse orimer r' Stop codon E.Coli Dam gene ApaI: 5' ATC GCA GGG ccc GAA TTA m m CGC GGG TGA AAC GAC 3' 
I..ApaI restnmon slte 
Figure 3.4. Forward ondReverse Primers for Dam PCR 
PCR was performed (Table 3.1.) for 30 cycles. PCR products were stored at 4OC until 
required. 
Step 
Initialization 
Denaturation 
Annealing 
Elongation 
Hold 
Temperature Time 
94°C 2 min 
94OC 15 sec 
56OC 15 sec 
68°C I min 
4°C infinity 
Table 3.1. PCR Programme Details for amplification of Dam from E. coli gDNA. 
3.2.1.2. Purification of  PCR Product 
QIAquick PCR Purification Kit (Qiagen) was used to purify the PCR product. 
QIAquick Kits contain a silica membrane assembly for binding of DNA in high-salt 
buffer and elution with low-salt buffer or water. The purification procedure removes 
primers, nucleotides, enzymes, mineral oil, salts, agarose, ethidium bromide, and other 
impurities from DNA samples. Silica-membrane technology eliminates the problems 
and inconvenience associated with loose resins and slurries. Specialized binding 
buffers are optimized for specific applications and promote selective adsorption of DNA 
molecules within particular size ranges. 
The QIAquick system uses a simple bind-wash-elute procedure. Binding buffer (PBI) is 
added directly to the PCR sample or other enzymatic reaction, after which the mixture is 
applied to the QIAquick spin column. The binding buffer contains a pH indicator, 
enabling easy determination of the optimal pH for DNA binding. Nucleic acids adsorb 
to the silica-gel membrane in the high-salt conditions provided by the buffer while 
impurities are washed away. Pure DNA is eluted with a small volume of low-salt buffer 
(EB Buffer). 
Procedure 
The Microcentrifuge protocol was followed and all reagents were from the Qiagen Kit. 
PBI Buffer (100~1) was added to lop1 PCR product. This was applied to a 2ml 
QIAquick spin column, inserted into a QIAquick collection tube, centrifuged at 13,000 
rpm for 45 secs and the flow through discarded. PE Buffer (75pl) was applied to the 
column and centrifuged as before. Flow through was discarded and sample centrifuged 
as before. The column was then placed in a clean eppendorf tube and DNA eluted by 
adding 5 0 ~ 1  EB (Elution Buffer) to the column, incubating for 1 min and centrifuging as 
before. 
3.2.1.3. Restriction Digestion of pCR3.1 SRC-1 A:Luc, pCR3.1 SRC- 
3:Luc and amplified Dam PCR product 
Construction of pCR3.1 SRC-1A.Luc and pCR3.1 SRC-3:Luc plasmids have been 
previously described (Lonard et al, 2004). A vector map can be viewed in Figure 3.5.. 
SRC-1A:Luc Gene 
T 
-1 Bmnl 
I I GCTir&TACC GAKTCGGAT 
CGWCCATGG CTCGAGSCIA 
M l ~ l  Prtl m v  
I I 
708 CCAC?AG?CC AGTGTGGTGG A A T ~ c G G ~  AGCCG MTTCIrXAG I AIATCSAGCA I 
GGTGATCAGG TCACACSLCC T?PSGCC TTCGGC TIAAGACGTC TA~AGGICGT 
Bm(l Mot1 & I  Mol r\psl Rrrl 
I I I J BGH rewne priming 
,.a m m ~  C ~ T O Z X T C  ~ w A m x &  G T ~ . A L I C ~ ~  GCTGATCAI-G- 
GiCACCGCCG GCGAGCTCAG ATCTCtiGGG SIUULTTiGG-5 CGACTAGT G GACXTGAbAC GGMGAT 
\ / 
Figure 3.5. Vector map of pCR3.l. (Invitrogen). Isolated genes for SRC-IA or SRC-3 were 
inserted upstream of an isolated Luc gene in the highlighted 'PCR Product' region of the 
polylinker sequence (Lonard et al, 2004). 
ApaI digestions of pCR3.1 SRC-1A:Luc and pCR3.1 SRC-3:Luc were set up as 
follows: lpl pCR3.1 SRC-1A:Luc or pCR3.1 SRC-3:Luc (from stock with a 
concentration of 0.2pg/ml) was added to 1p1 NEB Buffer 4 (New England BioLabs), 
7p1 dH20 and 1p1 ApaI (10U/p1) (Invitrogen). The Dam PCR product digestion 
consisted of 30p1 purified Dam PCR product, 3 . 4 ~ 1  NEB Buffer 4 (New England 
BioLabs) and 1p1 ApaI (10UIpI) (Invitrogen). These were mixed, briefly spun in a 
centrifuge to ensure all liquid was in the base and incubated for 1 hr at 25OC. Both 
samples were frozen at -30°C until required. 
QIAquick PCR Purification Kit (Qiagen) was used to purify the digested plasmid. 
Microcentrifuge protocol was followed as described in Section 3.2.1.2. DNA was 
eluted using 3 0 ~ 1  EB. 
Sall digestions were set up as follows. DNA (previously ApaI digested and purified 
pCR3.1 SRC-lA:Luc, pCR3.1 SRC-3:Luc or Dam PCR product) was added at a 
quantity of 30pl to 3 .5~1  NEB Buffer 3 (New England BioLabs) and 1 . 5 ~ 1  SalI (10UIpl) 
(Invitrogen). These were again mixed, centrifuged briefly to ensure all liquid was at the 
base and incubated at 37°C for 1 hr. 
3.2.1 .4 .  Excision of  Luc fragment from pCR3.1 SRC-1A:Luc and 
pCR3.1 SRC-3:Luc 
Luc removal was performed to enable ligation of full length Dam to the plasmid in 
place of Luc to generate a SRC-INSRC-3:Dam fusion construct. To each digestion 
(Section 3.2.1.3.) 3 . 5 ~ 1  10X DNA loading dye was added. Agarose gel was made to a 
concentration of 1% with 10% Ethidium Bromide (Sigma) and 1X TAE Buffer poured 
over when set (detailed in Appendix I). Each sample was applied to the gel as well as 
2pl 1 Kb Plus DNA Ladder (Invitrogen) to assess fragment size and the gel was run for 
45 mins at 90V. A UV trans-iluminator (photographic) was used to detect the bands. A 
UV trans-iluminator (non-photographic) was used to view bands and enable removal. 
Required bands bCR3.1 SRC-IA, pCR3.1 SRC-3 and Dam PCR product) are excised 
using a sharp blade and purified using QIAquick PCR Clean Up Kit (Qiagen). Bands 
not required (-1600 bp Luc) are discarded. 
3.2.1.5. Isolat ion and Purification o f  gel-bound DNA 
QIAquick PCR Clean Up Kit (Qiagen) was used to isolate and purify the gel-bound 
DNA. Gel slices are dissolved in a buffer containing a pH indicator, allowing easy 
determination of the optimal pH for DNA binding, and the mixture is applied to the 
QIAquick spin column. Subsequent to this step the kit has the same principle as the 
QIAquick PCR Purification Kit. 
Procedure 
Protocol was as follows; 450pl QC buffer was added to the agarose gel bound DNA and 
heated to 37OC until the agar melted. The solution was then transferred to a QIAquick 
spin column, inserted into a collection tube and centrifuged at 13,000 rprn for 1 rnin. 
QIAquick PCR Purification Kit (Qiagen) was used to purify the isolated DNA. 
Microcentrihge protocol was followed as described in Section 3.2.1.2. DNA was 
eluted using 30p1 EB. 
3.2.1.6. Ligation of  isolated Dam PCR product  with Plasmid DNA 
The following reactions were set up to ligate the Dam PCR product to pCR3.1 SRC-1A 
and pCR3.1 SRC-3. Digested pCR3.1 SRC-1A or pCR3.1 SRC-3 plasrnid to a volume 
of 11.11 was mixed with 3p1 Dam PCR product, 3p1 dH20, 2p1 T4 DNA Ligase Buffer 
(Invitrogen) and 1p1 T4 DNA Ligase (Invitrogen). A control rcaction was also 
performed which involved replacing 3pl PCR Dam insert with an additional 3p1 dH2O. 
These were both incubated at RT°C for 1 hr. Following incubation the four samples 
were heated to 70°C to inactivate enzyme activity. 
3.2.1.7.  Transformation of  Plasmid DNA 
Each ligation reaction, from Section 3.2.1.6., was added to 20p1 One Shot@ TOP10 
chemically competent E.Coli (Invitrogen), flicked gently, put back on ice immediately 
and left for 30 min. The cells were then placed in a 42°C H20 bath for 45 secs and 
returned to ice. After 1 min on ice 500p1 SOC Medium (Invitrogen) was added to each 
transformation reaction and incubated at 37OC for 1 hr. The samples were centrifuged at 
7500 rpm for 1 min, 450pl prewarmed SOC Medium was removed and cell pellets 
resuspended in the remaining SOC Medium. Each cell suspension was plated Agar 
plates with 50pg/pl Ampicillin (Appendix I), prewarmed to 37OC and grown overnight 
at 37OC. 
Individual colonies were picked from the pCR3.1 SRC-IA:Dam, the pCR3.1 SRC- 
3:Dam and grown overnight in 3ml LB Broth with 100pg/pl Ampicillin (Appendix I) 
on a shaking incubator at 37°C. 
3.2.1.8. Isolat ion of  Plasmid DNA 
Plasmid DNA was isolated from the cultures using Chargeswitch Pro Plasmid Mini 
Prep Kit (Invitrogen). 
Chargeswitch@ Technology employs a novel mechanism that combines the strengths of 
current plasmid prep methods while overcoming the inherent limitations. The use of 
harsh reagents such as chaotropic salts, ethanol, or organic reagents, and isopropanol 
precipitation, are replaced with a simple ion exchange procedure. In this method, 
plasmid is bound to a surface ligand that is positively charged at low pH, and eluted 
when the pH is raised to 8.5 (Figure3.6.). 
Procedure 
The LB Broth culture was centrifuged for 10 mins at 7500 rpm, supernatant discarded 
and pellet resuspended in 250p1 chilled Resuspension Buffer premixed with RNase A. 
This was followed by the addition of 250p1 Lysis Buffer and samples were mixed by 
inversion until the solution became viscous (3 min). Precipitation Buffer (250~1) was 
added and samples were mixed by inversion until a white precipitate formed. Samples 
were centrifuged for 1 min at 15000 rpm to pellet cellular debris. Supernatant was 
transferred onto a Chargeswitch Protein Mini Prep Column inserted into a collection 
tube and centrifuged at 15000 rpm for 1 min. The flow though was discarded and 7 5 0 ~ 1  
Wash Buffer I added and centrifuged at 15000 rpm for 1 min. Wash Buffer I1 (250~1) 
was added to the column followed by the same centrifugation procedure. The column 
was placed into a clean, labelled Eppendorf tube where 50pl Elution Buffer was added 
to elute the purified plasmid DNA. This was centrifuged at 15000 rpm and the column 
was discarded. 
I DNA Elution 1 ! 
I pH is raised topH 8.5. Pw$ed DNA 
, I  
A 
elutes direct& into the solution 
i 
I 
- 
- - - I 
Figure 3.6 Descriprion of the steps involved in the ChargeSwitch Pro Plasmid Miii Prep Kit. 
3.2.1.9. Plasmid Analysis 
The plasmid DNA was digested with BamHI and EcoRI to determine if the plasmid had 
the correct insert. 
Restriciton digestions were set up as follows; 7pl purified plasmid DNA, was added to 
1 pl NEB 4 Buffer (New England BioLabs), 1p1 BarnHI (IOUlfi) (Invitrogen) and 1p1 
EcoRI (10UIpl) (Invitrogen). This was incubated at RTC for 1 hr, after which it was 
run on 1% Agarose gel (section 3.2.1.4.). 
3.2.1.1 0. Amplification o f  pCR3.1 SRC-IAISRC-3:Dam Plasmids 
E.Coli cells transformed with pCR3.1 SRC-1A:Darn and pCR3.1 SRC-3:Dam plasmid 
DNA grown in Section 3.2.1.7. were used for further analysis. 
100p1 of the original culture of E.Coli cells containing pCR3.1 SRC-1A:Dam or pCR3.1 
SRC-3:Dam plasmids was transferred to 3ml pre-warmed LB broth with 100pg/pI 
Ampicillin (Appendix I). These were swirled gently and incubated overnight at 37°C 
on a shaking incubator. 
3.2.1.1 1. Purif icat ion of  Plasmid DNA 
Highspeed Plasmid Midi Kit (Qiagen) was used to purify the plasmid DNA. Midi-preps 
are used to obtain what is effectively a permanent supply of a certain plasmid, either for 
transformation, or for later modification. Additionally, midi-preps remove endotoxins; 
toxins found in bacteria which may lead to cell cytotoxicity during transfection. 
Endotoxin-free DNA will improve transfection into sensitive eukaryotic cells and is 
essential for gene therapy research. 
QIAGEN Plasmid Kits clear bacterial lysates by centrifugation. The cleared lysate is 
then loaded onto the anion-exchange tip where plasmid DNA selectively binds under 
appropriate low-salt and pH conditions. RNA, proteins, metabolites, and other low- 
molecular-weight impurities are removed by a medium-salt wash, and ultrapure plasmid 
DNA is eluted in high-salt buffer. The DNA is concentrated and desalted by 
isopropanol precipitation and collected by centrifugation. 
Procedure 
The LB culture containing pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam plasmids in 
E.Coli cells was centrihged at 10,000 rpm for 5 mins after which the supernatant was 
removed and the cell pellet resuspended in 4mls of Resuspension Buffer PI. P2 Lysis 
Buffer (4mls) was added, mixed gently and left incubate for 5mins. P3 (4mls) was 
adaed to the sample which was immediately poured into the barrel of the QIAfilter 
cartridge, and left for l0mins. Buffer QC (4mls) was placed into HiSpeed Tip 
(qualibration column) and left to flow through to calibrate it. After the incubation the 
plunger was used to push the cell lysate into the previously calibrated HiSpeed Tip. 
This was washed twice with lOmls Wash Buffer. DNA was eluted from the column 
using 5mls Buffer QF and collected in a lOml tube. DNA was precipitated by adding 
5.5mls Isopropanol (Fisher Scientific) to the eluate and this was incubated for 15 mins 
at RT°C. This was centrifuged for 20 mins at 3500 rpm at 4°C. The supernatant was 
discarded, lml70% ethanol (Pharmco-Aaper) added, sample was centrifuged for 2 mins 
at same speed and temperature as previously described, 70% ethanol was aspirated and 
the pellet was left to dry carefully. The cell pellet was dissolved in 500~1 TE buffer 
(Appendix I). 
3.2.1.12. Determination of DNA Concentration 
The concentration of DNA was then analyzed in a spectrophotometer using a 
programme for double stranded DNA. 
A 1 in 50 dilution of all DNA solutions was prepared by adding 2 p1 of DNA to 98 pl of 
HzO. The spectrophotometer was blanked using 100 p1 of HzO. The dilution entered 
87 
into the machine and the absorbance set at 260 nm (A260). The A260 I A280 ratio was 
also measured to determine the purity of the DNA contained in the samples. 
3.2.1.13.  Comparing pCR3.1-SRCl A-Dam and pCR3.1-SRCl A-Luc 
Two digests were set up to compare pCR3.1-SRCIA-Dam and pCR3.1-SRClA-Luc. 
7pl pCR3.1-SRC 1 A-Dam was added to I p1 NEB Buffer 4 (New England BioLabs), 1 p1 
ApaI (10UIpI) (Invitrogen) and 1p1 SphI (10Ulpl) (Invitrogen). The other digestion 
contained 1 pl pCR3.1 -SRCl A-Luc, 7p1 dH20, 1 p1 NEB 4 (New England BioLabs) and 
lp l  SphI (10UIpI) (10Ulpl) (Invitrogen). These were both incubated for 1 hr at 37'C 
and run, along with 1 Kb Plus DNA Ladder (Invitrogen), on a 1% Agarose gel with 
10% Ethidium Bromide (Sigma) for 30 mins at 90V (Section 2.2.1.4.). 
3.2.1.14. Concentration of  DNA for Sequencing 
Sequencing was used to confirm the presence of Dam in the plasmid and to confirm that 
it was inserted in the correct direction. A minimum DNA concentration of O.lpg/pl was 
required for sequencing. DNA (500~1) was added to lml 100% EtOH (Pharmco-Aaper) 
and 30p1 3M Sodium Acetate pH5.5 (Ambion) and incubated at -2OoC for 30 mins. The 
sample was centrifuged at 15000 rpm for 5 mins and the supernatant aspirated. 200p1 
70% EtOH was added and centrifuged at 15000 rpm for 30 secs and the supernatant 
aspirated. The pellet was left until dry after which it was dissolved in a sufficient 
volume of TE Buffer pH8.0 (Appendix I) to make approximately 0.2pg/pl DNA 
concentration. A sample of this along with the reverse Dam primer (Figure 3.4.) was 
sent to the BCM sequencing core for analysis. 
3.2.2. Construction of Library of genomic sequences which interact 
indirectly with SRC-1A:Dam 
This process utilizes the SRC-1A:Dam expression vector (pCR3.1 SRC-1A:Dam) 
constructed according to protocol described in the Section 2.2.1. to make a genomic 
library of sequences which interact (mdirectly) to SRC-1A:Dam via, either, Oestrogen 
Receptor a (ERa) or Progesterone Receptor-B (PR-B). 
HeLa cell transfections, using the SRC-1A:Dam expression vector co-transfected with 
ERa or PR-B expression vectors, with subsequent treatment of the corresponding 
hormone were used to cause in vivo methylation of GATC sequences in genomic DNA. 
Only GATC sequences next to where the SRC-1A:Dam fusion protein bound would be 
methylated and could subsequently be isolated and amplified using PCR 
3.2.2.1. Hela Cell Preparation for Transfection 
HeLa Cells (Baylor College of Medicine, Houston, Texas) were plated in 6 well plates 
(x2), with 200,000 celldwell in DMEM (with 4.5& D-Glucose and LGlutamine, 
without Sodium Pyruvate or Phenol Red) with 5% Charcoal Stripped Serum (Gibco) 
and grown overnight at 37T in 5% (2%. All initial cell cultures were prepared by the 
BCM cell culture core. Prior to transfection cells were checked, using Inverted 
Microscope, to assess cell health, growth and distribution. 
3.2.2.2. HeLa Cell Transfection 
Transfections were canied out in duplicate. Premixes were prepared prior to 
transfection. 
Each pCR3.1 SRC-1A:Dam plasmid and hormone receptor plasmid premix was 
prepared with enough in each for 4 wells. They were made by adding the appropriate 
volume of plasmids to separate Eppendorf tubes and 400pl DMEM (with 4.5& D- 
Glucose and L-Glutatnine, without Sodium Pyruvate or Phenol Red) without 5% 
Charcoal Stripped Senun (Gibco) (Table 3.2.). 
1 OOng pCR3.1 hPRB 
Well 
1 & 4 
TabIe 3.2. Plasmid Premix Preparation. Column number I represents the wells the premix is 
required for (all in duplicate). Column number 2 represents the total volume of the premix. 
Column 3 represents the fd concenhation ofplasmidrequiredin the total volume (Column 2). 
Column 4 represents the h a 1  concenhation of Hormone Receptor, or the absence of it in the 
negative control for each well. 
TotalVol Plasmid - SRC 1A Hormone Receptor 
400pl 1 OOOng pCR3.1 SRC-1A:Dam 1 OOng pCR3.1 hERa 
Lipofectamine premix was made by adding 12pl Lipofectamine (Invitrogen) to 1,200p1 
DMEM without 5% Charcoal Stripped Serum (Gibco). 
Rior to trausfection 400pl Lipofectamine premix was added to each pCR3.1 SRC- 
1A:Dam plasmid and Hormone Receptor plasmid premix giving a total volume of 
800~1. All ependorfs were centrifuged at 7,500 rpm for 10 sees to get the liquid to the 
bottom and incubated at RTC for 30 mins. 
Cells were removed from incubator and under Laminar Flow Hood medium was 
aspirated from each well. This was replaced with 200pl of each appropriate premix 
(Figure 3.7.). Plates were rocked for 30mins and then incubated for 4 hrs at 37'C in 5% 
cQ2- 
Total Volume in each well is 400 p1. 
250ng pCR3.1 SRC-1A:Dam & 25ng pCR3.1 hERa 
250ng pCR3.1 SRC-1A:Dam & 25ng pCR3.1 hPRB 
250ngpCW.I SRC-1A:Dam 
F i g m  3.7. HeLa Cell Transfection Layout. Figure demonstrates the jnaI trrmsfection 
concentrotion of all expression plasmids wed. 
3.2.2.3. Hormone Treatment of Transfected Cells 
During the incubation hormone/EtOH premixes were prepared in DMEM (with 4.5 g& 
D-Glucose and L-Glutamine, without Sodium Pyruvate or Phenol Red) with 5% 
Charwal Stripped Serum (Gibco) to a final volume of lOmls for Oestrodiol and 
Progesterone and 20mls for EtOH at the following concentrations: EtOH ~W'M, E2 10' 
M and Progesterone ~W'M. 
Following incubation the media was aspirated from each well in a Laminar Fume Hood 
and 5mls of the appropriate hormone premix was added to the appropriate wells (Table 
3.3.). The plates were then incubated at 37°C with 5% COz overnight. 
Well 
1 
4 
2 
5 
EtOH 
EtOH 
Plasmid - SRC 1A Hormone Receptor HormoneBlank 
250ng pCR3.1 SRC IA Dam 25ng pCR3.1 hERa EtOH 
250ng pCR3.I SRC 1A Dam 25ng pCR3.1 hERa E2 
250ng pCR3.1 SRC 1A Dam 25ng pCR3.1 hPRB EtOH 
250ng pCR3.1 SRC 1A Dam 25ng pCR3.1 hPRB Progesterone 
3 
6 
Table 3.3. Addition of Hormones to the transfected HeLa cells. 
250ng pCR3.1 SRC 1A Dam 
250ng pCR3. I SRC 1A Dam 
3.2 .2 .4 .  Isolation of  genomic DNA 
The gDNA of the Hela cells should be methylated following the previously described 
transfections. In principle SRC-1A:Da.m fusion protein will have bound indirectly to 
specific genomic sequences and methylated the nearby GATC sequences. Genomic 
DNA isolation was performed using an alcohol based precipitation technique. 
Procedure 
HeLa cells were harvested with HeLa Cell Lysis Buffer (Appendix I). To each well 
5 0 0 ~ 1  of the Lysis Buffer was added. Duplicate wells were combined to give a total of 
5 groups. The lysate from each group was transferred to individual ependorf tubes, 
mixed and incubated at 55°C for 2 hrs after which 2 0 4  5M NaCl (Ambion) was added 
to each tube. 
Phenol:chloroform:isoamyl alcohol extraction was performed, 5 0 0 ~ 1  
Phenol:chloroform:isoamyl alcohol (25:24:1) (Invitrogen) was added to each tube, 
agitated gently for 5 min and centrifiged for 10 min at 10000 rpm. The top phase was 
removed and placed in a clean ependorf tube. This step was repeated; the top phase was 
separated and 2004  chloroform (Fisher-Scientific) was added to each tube. The 
samples were placed in 55°C heating block for lhr to evaporate all chloroform and the 
samples refrigerated. 
When all chloroform had evaporated 10pg RNase A (Invitrogen) was added to the tubes 
and they were incubated at 37OC for 1 hr. Phenol:chloroform:isoarnyl alcohol extraction 
was performed again using 2 0 0 ~ 1  Phenol:chloroform:isoamyl alcohol (25:24:1) 
(Invitrogen), agitating gently for 5 mins and centrifuging for 10 mins at 10000 rpm. 
The top phases were removed and placed in clean ependorf tubes. DNA was 
precipitated by adding iml 100% EtOH (Pharmco-Aaper) and 'spooling' the fine 
threads of DNA that formed with a pipette tip. The tips were then washed in 70% EtOH 
(Pharmco-Aaper) for 5 mins and transferred to 100pl TE Buffer (Appendix I). The tips 
were left in the Buffer overnight at RTOC to enable the DNA to dissolve fully. 
Following incubation the samples were put in a 55°C water bath to ensure all DNA was 
dissolved before the tips were removed. 
3.2.2.5. Analysis of  DNA Concentrat ion 
Samples were analysed for DNA concentration using a spectrophotometer (Section 
3.2.1.12). 
3.2.2.6. DpnI Digestion 
The methylated GATC sequences in the isolated gDNA are digested by DpnI, which 
specifically recognizes methylated GATC sequences, thus generating a pool of blunt- 
ended DNA fragments with 5'TC and 3'GAme', allowing their subsequent amplification 
by ligation mediated methylation specific PCR 
Procedure 
DpnI digestion was performed by adding 0 . 5 ~ 1  DNA from each of the samples into 2p1 
NEB Buffer 4 (New England BioLabs), 2p1 DpnI (New England BioLabs) and the 
appropriate amount of dH20 to make the total reaction volume to 20p1. These were 
incubated at 37'C for 2 hrs followed by 80°C for 20 mins to inactivated DpnI. 
3.2.2.7. Adapter  Ligation 
The purpose of the adapter ligation step was to ligate double stranded linkers to the 
DpnI digested DNA. To allow PCR amplification of the DpnI digested sequences, a 
double stranded adaptor nucleotide needs to be ligated to the blunt ends. The double 
stranded adaptor is generated from the ligation of two separate single strand 
oligonucleotides, with one strand having a S'overhang. The S'overhang of the.double 
strand adaptor ensures directional ligation to the blunt end of the DNA sequences. A 
double stranded adaptor was used in this step as the ligation of double stranded DNA is 
more efficient than that of single stranded DNA (Figure 3.8.). 
I .  Formation of Adaptor 
AdRT S'CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGA 3' 
AdRb 3'GCCGGCTCTC 5' 
DpnI Digested 
Methylated gDNA 
2. Adaptor Li~ation Sequence 
1 
5'CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGATChWNN 
3'GCCGGCTCTC GNNNN I' Me 
Figure 3.8. Formation of double strunded adapter and its ligation 
DpnI digested DNA (204) was added to 4pl 5X T4 DNA Ligase Buffer (Invitrogen), 
2p1 ds adaptor AdR (comprising of Oligonucleotide AdR and AdRb, Figure 3.9., details 
of procedure to construct in Appendix I) (50pM) (Sigma) and 2 . 9 ~ 1  T4 DNA Ligase 
(Invitrogen), giving a total reaction volume of 29p1. A control reaction was also set up 
using 20p1 Undigested DNA from one of the samples rather than the DpnI digested 
DNA. These were left to incubate for 2 hrs at RTDC and then heated to 80°C for 20 
mins. 
Right Adaptor (Top strand) 
AdRT S'CTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAGGA 3' 
Right Adaptor (Bonom Strand) 
AdRb S'TCCTCGGCCG 3' 
Figure 3.9. Double stranded adapters sequences 
95 
3.2.2.8. PCR Amplification of Methylated Sequences 
PCR amplification of the methylated sequences with ligated double stranded adaptors is 
performed using an individual PCR primer (Figure 3.IO.) that is identical to the 15 
most 3' nucleotides of the AdRt oligonucleotide sequence and the 5' TC nucleotides. 
- 
PCR Primer 
AdR-PCR S'GGTCGCGGCCGAGGATC 3' 
3. Primer Annealme and Extension 
S'CTAATACGACTCACTATAGGGCAGCOTGGTCGCGGCCGAGGA 
PCR Primer 
\r AdR-PCR S'GGTCGCGGCCGAGGATC -+ 
3'GCCGGCTCTCAGNNNN I 
Me 
Figure 3.10. Sequence of PCR Primer and Annealing andExtension Step 
This primer design prevents the amplification of non specific DNA products which may 
be derived from random DNA breaks, as the PCR primer overlaps with the GA di- 
nucleotide located at the ends of the DpnI digested fhgments. This ensures that only 
these fragments are amplified in the PCR thus suppressing amplification of non-specific 
ligation products, which generally will not have a GA di-nucleotide at their ends. 
PCR (Table 3.4.) was used to amplify isolated sequences, and was set up as follows; 4p1 
Linkered DNA, 2pl Accuprime Buffer I (Invitrogen), 0.5pl Primer AdR PCR 
(Invitrogen), 13p1 dH20 and 0.5pl Taq DNA Polymerase (Invitmgen). 
Step 
Initialization 
Denaturation 
Annealing 
Elongation 
Hold 
Temperature Time 
94OC 3 min 
94°C 30 sec 
58°C 15 sec 
I min 
72°C (5 min last cycle) 
4°C infinity 
Table 3.4. PCR Programme for ampli$cation of melhylated sequences 
3.2.2.9. Analysis  of  PCR products o n  Agarose Gel 
The products were run on 1% agarose gel with 10% Ethidium Bromide (Sigma) at 90V 
for 45 mins (Section 3.2.1.4.). 
3.2.2.10. Purification of  PCR Products 
PCR products were purified as per protocol described in Section 3.2.1.2. DNA was 
eluted using 50p1 EB Buffer. 
3.2.3. Cloning of PCR Products using pCRSlGWlTOP0 TA Cloning 
Kit  
The pCR8lGWlTOPO TA Cloning Kit (Invitrogen) was used due to its gateway cloning 
compatibility. This combines TOP0 cloning and gateway technology to facilitate a 5 
min, one step cloning of Taq Polymerase amplified PCR products into a plasmid vector 
with greater than 95% efficiency. The resultant clones can then be sequenced and 
chamcterid without difficulty. Also, the clones can be transferred from the 
pCR8/GW/TOPO entry vector to a Gateway destination vector of choice to enable 
expression of the gene of interest in a number of systems. Figure 3.11. describes the 
process flow. 
+c. ma- S h C . .  r) 
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Figure 3.11. &hematic of Topoisomerase Method. Topoisomerase I recognition sites are 
prepared on the Gateway Cloning Vector which ligates to the Tag amplified PCR products in a 
5 min incubation at R E .  The resultant ligatohohon then c m e s  the release of the 
Topoisomerase I. 
The pCR8/GW/TOPO vector (Figure 3.12.) is supplied with single 3'-thymidine 0 
overhangs for TA Cloning and also with Topoisomerase I covalently bound to the 
vector. Taq polymerase has a non-template-dependent tenninal transferase activity that 
adds a single deoxadenosine (A) to the 3'ends of PCR products. The linearized vector 
supplied in this kit has single, overhanging deoxythymidine (T) residues. This allows 
PCR inserts to ligate efficiently with the vector. 
Topoisomerase I from Vaccinia virus binds to duplex DNA at specific sites (CCCTT) 
and cleaves the phosphodiester backbone in one strand (Shuman, 1991). The energy 
from the broken phosphodiester backbone is converted by formation of a covalent bond 
between the 3' phosphate of the cleaved strand and a tyrosyl residue (Tyr-274) of 
topoisomerase I. The phospho-tyrosol bond between the DNA and enzyme can 
subsequently be attacked by the S'hydroxyl of the original cleaved strand, reversing the 
reaction and releasing topoisomerase. TOPO Cloning exploits this reaction to 
efficiently clone PCR products 
Figure 3.12. Vector map of pCR8/GWnOPO 
3.2.3.1. Cloning reaction using pCR8IGWlTopo Vector 
Dpnl digested DNA (lpl) were mixed with lpl Salt Soultion (Invitrogen), 3pl a 2 0  and 
lpl TOPO Vector (Invitrogen). This was mixed and incubated for 15 mins at RTOC and 
then placed on ice. 
3.2.3.2. Transformation of  Cloning Reactions 
Transformation was performed using 2 ~ 1  TOP0 cloning reaction and adding it to 2 0 ~ 1  
Chemically Competent E. Coli (Invitrogen) and incubating on ice for 30 mins. This 
was followed by a 30 sec heat shock at 42'C and then the samples were placed back on 
ice. SOC medium (250~1) was added and the samples were incubated at 37OC for 1 hr. 
The bacteria were then spread on labelled Agar plates with 100pg/ml Spectinomycin 
(Appendix I) pre-warmed to 37'C and incubated at 37°C overnight. Following 
incubation, one of two steps took place. 
Either individual colonies were picked (for analysis) and grown in 3mls LB Broth with 
100pg/ml Spectinomycin followed by overnight incubation on agitating incubator at 
37OC. Alternatively plates were washed with 5mls LB Broth with 100pg/ml 
Spectinomycin (Appendix I). 
3.2.3.3.  Purif icat ion of  Cloned Plasmids 
Charge Switch-Pro Plasmid MiniPrep Kit (Invitrogen) was then used to purify the 
plasmid DNA (Protocol described in Section 3.2.1.8.). 
3.2.3.4. Concentrat ion analysis 
The purified plasmids were analysed using the spectrophotometer (Section 3.2.1.12.) to 
assess the DNA concentration and purity. 
3.2.3.5. P lasmid Analysis 
The plasmids were analyzed for the presence of an insert by enzyme digestion using the 
restriction enzyme. The digest was set up as follows; 8pl purified DNA was added to 
1 p1 EcoRI (IOUIpl) (Invitrogen) and I p1 NEB Buffer 4 (New England BioLabs). 
3 . 2 . 3 . 6 .  Visualizat ion of Digested Plasmid Products  
The reactions containing the digested vectors were run on a 1% Agarose gel with 10% 
Ethidium Bromide (Sigma) at 90V for 45 mins (Section 3.2.1.4.). 
3.2.4. Creation of Expression Vector Containing Isolated Sequences 
3.2.4.1. Generat ion of  Destination Vector 
In order to functionally test the isolated genomic sequences they had to be transferred 
from the pCR8IGWITOPO cloning vector to an adapted destination vector with reporter 
capabilities. This is achieved by ligating a blunt ended cassette containing attR sites 
flanking the ccdB gene and the chloramphenicol resistance gene into the multiple 
cloning site of the chosen destination vector (Figure 3.13.). 
Figure 3.13. Newly construcledpGL3-Basic Vector 
The destination vector of choice is the pGL3-Basic vector, a vector 41 18bp in length 
which also contains a luciferase gene and lacks a promoter element. The isolated 
sequences are shuttled from the entry vector to the multiple cloning site of the pGL3- 
Basic vector which is located upstream of the Luc gene. If the sequence of interest 
contains a promoter element it will enable Luc expression when transfected to HeLa 
cells. It is this feature, plus its Gateway compatibility, that makes this a desirable 
destination vector. . 
Initially, the vector linearized by digestion with the restriction enzymes NheI and Hind 
111, followed by an alkaline phosphatase treatment to remove 5'phosphates, thus 
decreasing the chance of vector religation. The reading frame shown below is then 
ligated to the vector following a ligation reaction using fast link ligase. 
Procedure 
(This procedure was performed by Dr. David Lonard and Cormac Jennings) 
To enable ligation of the cassettes the pGI3-Basic vector was digested with restriction 
enzymes NheI and HindIII as follows: 1p1 pG13-Basic, 1p1 HindIII (10UIpI) 
(Invitrogen), 1pI NheI (10UIpl) (Invitrogen) and 7pl NEB Buffer 4 (New England 
BioLabs). 
The digested vector was then treated with APex Heat-Labile Alkaline Phosphatase, a 
novel Phosphatase that dephosphorylates 5'-phosphates. To the completed restriction 
digest, 1p1 of Apex Heat-Labile Phosphatase was added. This was incubated at 37OC 
for 10 mins followed by heat inactivation of the Phosphatase at 70°C for 5 mins. 
3.2.4.2. Casset te  Ligation 
(This procedure was performed by Dr. David Lonard and Cormac Jennings) 
The reading cassette was ligated to the digested pGL3-Basic Vector using Fast Link 
ligase. The following ligation reaction was set up: 1 pl Dephosphorylated pGL3-Basic, 
2pl Gateway Reading Cassette, lpl Fast Link Ligation Buffer, 0 .75~1  lOmM ATP, lpl 
Fast-Link Ligase and 10.25~1 H20. The ligation reaction was incubated for 1 hr at 
RPC.  
3.2.4.3. Transformation of  One Shot ccdB Survival  Competent  Cells  
(This procedure was performed by Dr. David Lonard and Cormac Jennings) 
Following the previous steps, the ligation reaction was transformed into One Shot ccdB 
Survival Competent Cells. 1p1 of the ligation reaction was added to 1 vial of the One 
Shot ccdB Competent Cells and then mixed gently. The vials were incubated on ice for 
30 mins followed by heat shock for 30 secs at 42C.  The vials were then placed back 
into the ice for another 2 mins. 250~1  of SOC medium was added to the vial that was 
then incubated for 1 hr at 37'C. 25p1 of the transformation reaction was spread on an 
ampicillin plate and incubated ovemight at 37'C. Resulting colonies were picked and 
grown ovemight in LB medium containing 30pgIml chloramphenicol. 
3.2.4.4. Plasmid DNA Isolation 
(This procedure was performed by Dr. David Lonard and Cormac Jennings) 
The plasmid DNA was isolated using the Qiagen Chargeswitch-Pro Plasmid MiniPrep 
Kit, protocol according to Section 3.2.1.8. 1.5ml of the overnight bacterial culture was 
processed. 
3.2.5. Transferring the isolated cloned sequences to the adapted 
Destination Vector 
Once the destination vector is prepared, the gene of interested can be easily moved from 
the entry vector to the destination vector. The gateway system takes advantage of the 
site-specific recombination reactions enabling the bacteriophage to intergrate and 
excise itself out of a bacterial chromosome. This reaction is mediated by the LR 
Clonase mix, consisting of integrase, integration host factor, and the phage excisionase 
which catalyses the LR recombination reaction. The end result is the excision of the 
gene of interest from the entry clone, pCR8IGWITOPO entry vector, and integration of 
it into the p-d destination vector, pGL3 Basic Vector, which then becomes the 
expression clone (Figure 3.14.). 
PCR~IGWITOPO 
Entry Vector Adapted fiu 
(Containing isolated Destination 
sequences) Vector 
PGL3 Basic Vector, 
now an expression clone PCRIIIGW~OPO 
containing the isolated 
sequences (now empty) 
F i g m  3.14. Transfewing the isolated sequences from the entry clone to the destination vector 
In this case the LR clonase mix transfers the isolated sequence which is flanked by 
attLl and attL2 sites in the pCRS/GW/TOPO entry vector into the newly generated 
pGL3 Basic destination vector with ligated cassette containing two attR sites. 
Following recombition of the matching attR and the attL sites the DNA hgment of 
interest is flanked by attB sites. LR recombition reactions were set up for all 
pCR8/GW/TOPO vectors. 
3.2.5.1. LR Recombination Reaction 
The pCRS/GW/TOPO Libraries (Song) were mixed with 50ng adapted pGL3-Basic 
Dest (Promega), added to 4pI dH2O and lpl 5X LR Clonase Reaction Buffer 
(Invitrogen) and incubated at RTOC for 2 hrs. Following the incubation 0.5d Proteinase 
K (2gpJpI) (Roche) was added and incubated at 37OC for a further 10 mins. The 
Clonase reaction (1p1) was transformed to 2 0 ~ 1  Chemically Competent E. Coli 
(Invitrogen) and incubated on ice for 30 mins followed by 30 sec heat shock at 42 OC 
and then placed back on ice. SOC medium (250~1) (Invitrogen) was added and the 
samples were incubated at 37'C for 1 hr. This was then spread on LB plates with 
100pglml Ampicillin prewarmed to 37'C and grown overnight in a 37°C incubator. 
3.2.5.2. Growth of  Library Plasmids 
Each individual colony growing on the LB agar plates (Appendix I) was picked (using 
a pipette tip) and placed in a lOml Falcon Tube with 5mls LB Broth (100pglml 
Ampicillin) (Appendix I). These were grown overnight at 37'C on an agitating 
incubator. 
3.2.5.3. Plasmid Purification 
The Zuppy Plasmid Miniprep Kit (Zymo Research) was used to extract plasmid DNA 
from 3mls of each culture, the remaining culture was stored, in an air-tight tube, at 4OC 
until required. The 3ml culture was centrifuged at 7500 rpm for 5 mins, supernatant 
aspirated and the bacterial cell pellet re-suspended in 600pl of TE buffer (Appendix I). 
Cells were lysed by the addition of loop1 7X lysis buffer and mixed by gentle inversion 
for 2 mins. Neutralization Buffer was chilled to 4'C and 3 5 0 ~ 1  of was added and mixed 
by inversion until the entire sample turned yellow, this was then centrifuged at 15000 
rprn for 4 mins. The supernatant was transferred into a zymo-spinTM I1 column which 
was placed into a collection tube and centrifuged at 15000 rpm for 15 secs. The 
supernatant was discarded, 2 0 0 ~ 1  of Endo-Wash Buffer added and the samples were 
centrifuged at 15,000 rprn for 30secs. Zuppy Wash Buffer (400~1) was added and 
centrifuged at 15,000 rpm for 30secs. The column was then removed fiom the 
collection tube and placed in a clean, labelled ependorf tube after which 30p1 of Zuppy 
Elution Buffer was added directly to the column matrix, left to stand for 1 min at RTaC 
and centrifuged at 15,000 rpm for 15 secs. 
3.2.5.4. Concentration analysis 
The purified plasmids were analysed using the spectrophotometer (Section 3.2.1.12.) to 
assess the DNA concentration and purity. 
3.2.5.5. Sequencing 
A selection of the library constructs were sent for sequencing at BCM sequencing 
facility. 
3.2.6. Functional Analysis of newly constructed SRC-1A:Dam 
Libraries 
Libraries were analysed using Luciferase Assays. Details of the methodology used can 
be found in Materials and Methods Section 3.1.1. Additional infonuation of plasmid 
concentrations in the luciferase assays performed can be found in Appendix U. 
Expression plasmids used were constructed previously by David Lonard and are as 
follows: 
pCR3.1 hERa - encodes full length human ERa 
pCR3.1 hPR-B - encodes full length human PR-B 
pCR3.1 COUP-TFI -encodes full length human COUP TFI 
pCR3.1 COUP-TFII -encodes full length human COUP TFII 
pCR3.1 RORa - encodes full length human RORa 
pCMV5 SNAIL - encodes full length human SNAIL 
pCR3.1 PAX4 -encodes full length human PAX4 
3.3. Locating Transcription Start Sites 
Reporter plasmids were analysed to assess where the transcription start site is located. 
A modified GeneRacer Kit (Invitrogen) protocol was followed. 
3.3.1. Modified Gene Racer Protocol 
GeneRacer uses an advanced RACE (rapid amplification of cDNA ends) technique and 
super~cripta I11 RT to improve the efficienct of amplifying full-length 5' and 3' cDNA 
ends. GeneRacer ensures that only transcripts containing full-length cDNA ends are 
amplified. The advanced protocol begins at the RNA level by specifically targeting 
only 5' capped mRNA, subsequent steps result in the removal of the cap which is then 
replaced with the GeneRacerTM RNA Oligo. During reverse transcription this RNA 
oligo sequence is incorporated into the cDNA and only cDNA that is completely reverse 
transcribed will contain this known sequence. 5' RACE PCR is then performed using 
the homologous GeneRacerTM primer that is specific to the RNA oligo sequence and a 
gene-specific primer. The result is amplified DNA that contains the full-length 5' 
cDNA sequence. In addition to capturing the full-length 5' end of genes with known 
transcriptional start sites GeneRacerTM captures additional 5' end sequence of genes 
with unknown start sites 
3.3.1.1. Transfection Protocol 
An experiment was performed to locate the position of transcription start sites in the 
COUP-TF responsive plasmid sequences (PI 1, P26, P27, P33) as well as 10 reporter 
plasmids from the hERa library (-2p, -17, T29, T32, E30, T22, T31, T14, -30, E12) and 
also pERE-Elb-LUC as a control. A modified GeneRacer (Invitrogen) protocol was 
used to accomplish this. 
HeLa Cells (Baylor College of Medicine, Houston, Texas) were plated in 5 x 6 well 
plates at a density of 200,000 cells per well in DMEM (with 4.5g/L D-Glucose and L- 
Glutamine, without Sodium Pyruvate or Phenol Red) (Gibco) with 5% Charcoal 
Stripped Serum and grown overnight at 37'C with 5% C02. All initial cell cultures 
were prepared by the BCM cell culture core. Prior to transfection cells were checked, 
using Inverted Microscope, to assess cell health, growth and distribution. 
Each reporter plasmid was prepared in duplicate; 8p1 lipofectamine was added to 
1,500ng reporter plasmid and 1.6ml DMEM (with 4.5g/L D-Glucose and L-Glutamine, 
without Sodium Pymvate or Phenol Red) (Gibco) without 5% Charcoal Stripped Serum. 
COUP TFII (20ng) was also added to each COUP TFII responsive reporter plasmid and 
20ng pCR3.1 hERa was added to the other 11 reporter plasmid samples. These were 
incubated at R P C  for 30 mins. Following incubation plates were removed from the 
incubator and remainder of the protocol was carried out in a Laminar Flow Hood. 
Medium was aspirated from each of the wells and replaced with 800pl of each reporter 
plasmid premix (duplicate). The plates were returned to the 37°C with 5% C 0 2  
incubator and left for 4 hrs. Medium was removed, again in a Laminar Flow Hood, and 
2 ml 'DMEM (with 4.5gIL D-Glucose and without L-Glutamine, Sodium Pyruvate or 
Phenol Red) (Gibco) with 5% Charcoal Stripped serum was added to each well. The 
plates were returned to the incubator and left overnight. 
3.3.1.2. RNA Isolation 
The following day RNA was isolated as follows. HeLa cells were harvested using 
7 5 0 ~ 1  TEN Buffer (Appendix I) per well (TEN Buffer added, plates were checked 
using a microscope to ensure all cells had dislodged from the base of the wells), 
duplicate wells were combined into a single ependorf tube. Tubes were spun at 7,500 
rpm for 20 sec to form a cell pellet. Liquid was aspirated and 250pl Trizol (Invitrogen) 
was added to 2 tubes at a time and immediately vortexed to resuspend the pellet. 
Chloroform (50~1) (Fisher Scientific) was added to each tube and vortexed for 30 secs. 
Tubes were centrifuged at 15,000 rpm for 10 mins. The top phase was removed, 
avoiding interface or lower layer, and transferred to a clean, labelled ependorf. 1 2 5 ~ 1  
Isopropyl alcohol (Fisher Scientific) was added to each tube, vortexed and centrifuged 
at 12,000 rpm for 5 mins. Liquid was aspirated and pellet was rinsed with 250pl 70% 
EtOH (Pharmco-Aaper), vortexed and centrifuged at 12,000 rpm for 20 secs. EtOH was 
removed and pellet was air dried at RTOC. RNase-free Hz0 (50p1) was added to each 
tube, incubated for 30 mins and vortexed. 
3.3.1.3. Concentrat ion analysis 
RNA concentration was quantified using a Spectrohotopmeter (Section 3.2.1.12.). 
Sample T14 had no RNA and so was removed from the remainder of the GeneRacer 
protocol. 
3.3.1.4. Dephosphorylating RNA 
This step involves RNA treatment with calf intestinal phosphatise (CIP) to 
dephosphorylate non-mRNA or truncated mRNA. 
Procedure 
The RNA samples were combined, using 0 .43~1 from each of the 14 RNA samples 
(total 6 ~ 1 ) .  To this 1p1 10X CIP buffer, lpl RNaseOut, lpl CIP and 1p1 DEPC 
(diethylpyrocarbonate) water (all Invitrogen) were added to give a total reaction volume 
of 1 0 ~ 1 .  This was mixed gently by pipetting, briefly vortexed and centrifuged for 2 secs 
to collect the fluid. This was incubated at 50°C for 1 hr. Following incubation it was 
vortexed briefly and placed on ice. 
3.3.1.5. RNA Precipitation 
When chilled, 50p1 Trizol was added and vortexed, then lop1 chloroform was added and 
the sample was again vortexed. The upper phase was removed and transferred to a 
clean, labelled ependorf and 25pl Isopropyl Alcohol (Fisher Scientific) was added, 
sample vortexed and placed at -20°C for 30 mins. The sample was then centrifuged at 
15,000 rpm for 5 mins and the supernatant aspirated. The pellet was rinsed with 50p1 
70% EtOH (Pharmco-Aaper), votexed and EtOH aspirated. The pellet was dried at 
RT°C and resuspended in 7p1 RNAse free H20. 
3.3.1.6. Decapping Reaction 
A lop1 decapping reaction was set up using 7p1 of the dephosphorylated RNA, 1p1 IOX 
TAP Buffer, Ipl RNaseOut and lyl TAP (all Invitrogen). This reaction was mixed 
gently by pipetting, briefly vortexed, centrifuged to collect the fluid and incubated for 1 
hr. Following incubation the sample was placed on ice. RNA precipitation protocol was 
repeated. 
3.3.1.7. Ligation Reaction 
Dephosphorylated, decapped RNA (7p1) was added to the tube (from the GeneRacer 
Kit) containing pre-aliquoted, lyophilized GeneRacer Oligo (0.25pg) (Invitrogen). This 
was mixed gently by pippetting up and down to resuspend the RNA Oligo and 
centrifuged briefly to collect the fluid. A 5 min incubation at 65'C was performed to 
relax the RNA secondary structure, this was then placed on ice to chill for 2 min and 
centrifuged to collect the fluid. When chilled 1p1 10X Ligase Buffer, 1p1 lOmM ATP, 
1pl RNaseOut (40Ulpl) and lpl T4 RNA ligase (5UIpI) (all Invitrogen) were added to 
the tube (total volume of 10p1) and mixed together gently by pipetting. This was 
incubated at 37'C for 1 hr, centrifuged gently and placed on ice. RNA precipitation 
protocol was repeated. 
3.3.1.8. Reverse Transcription 
The ligated RNA (1Op1) was added to lpl Luc Reverse primer (50pM) (Figure 3.15.) 
(Invitrogen), 1p1 dNTP mix and 1p1 RNase free Hz0 (all Invitrogen) and incubated at 
65°C for 5 mins. Then, 4p1 5X First Strand Buffer, 1pl DTT 0.1M, 1pI RNaseOut and 
1pI Superscript I11 RT°C was added (total reaction volume 10p1) (all Invitrogen), 
centrifuged briefly and incubated at 55OC for 45 mins. 
5' CGTATCTCTTCATAGCCTTATGCA 3'  
Figure 3.15. Luc Reverse primer sequence 
To inactivate the enzymes the sample was then placed at 70°C for 15 mins, placed on 
ice for 2 mins and centrifuged briefly to collect the fluid. To the reaction 1p1 RNase H 
(2 U) (Invitrogen) was added and incubated at 37'C for 20 mins. This was stored at - 
20°C until ready for PCR. 
3.3.1.9. PCR Amplif icat ion o f  cDNA 
PCR was performed using 1p1 cDNA, 0 . 5 ~ 1  Luc Reverse Primer (detailed previously) 
(1OmM) (Invitrogen), 0 .5~1 5' GeneRacer Primer (Figure 3.16.), 2 . 5 ~ 1  10X Accuprime 
Buffer I, 0 .25~1 Accuprime Taq HIFI and 20.25~1 dHzO (total volume 2 5 ~ 1 )  (all 
Invitrogen). The PCR programme details are outlined in Table 3.5.. 
Figure 3.16. GeneRacerTM 5'primer 
Initialization 
_"'"1. 
Denaturation 
Annealing 1 
Elongation 
Denaturation 
Annealing 
Elongation 
Hold 
Temperature Time 
94°C 2 min 
94°C 15 sec 
62°C 15 sec 
68OC 15 sec 
94°C , 15 sec 
56°C 15 sec 
I x 5  ] 
68°C 15 sec 
4°C infinity 
Table 3.5. PCR Programme for AmpliJcafion of cDNA 
3.3.1.10. Analysis  of PCR Products  
PCR products and I Kb Plus Ladder (Invitrogen) were run on 3% Metaphor Agarose 
Gel (Appendix I) at 90V for 45 mins (Section 3.2.1.4.). 
3.3.1.1 1 .  Purification of  PCR Products  
PCR products were purified using QIAquick PCR Purification Kit (Qiagen) following 
protocol described previously (Section 3.2.1.2). DNA was eluted from the column 
using 30p1 EB. 
3.3.1.12.  Amplification of  Plasmid 
Purified DNA (2~1)  was added to 20p1 One Shot@ TOP10 Chemically Competent 
E.Coli (Invitrogen), flicked gently, put back on ice immediately and left for 30 min. 
The cells were then placed in a 42°C H20 bath for 45 secs and returned to ice. After 1 
min on ice 500pl SOC Medium (Invitrogen) was added to each transformation reaction 
and incubated at 37OC for 1 hr. The samples were centrifuged at 7500 rpm for 1 min, 
450p1 SOC Medium was removed and cell pellets resuspended in the remaining SOC 
Medium. Each cell suspension was plated on Agar plates with 50 pg/pl Ampicillin 
(Appendix I), prewarmed to 37'C, and grown overnight at 37OC. Following incubation 
the plates were observed. Colonies growing were picked, using a pipette tip, and the tip 
placed in 5mls LB Broth with 50pglpl Ampicillin (Appendix I). This culture was 
grown on an agitating incubator at 37°C overnight. 
3.3.1.13.  Plasmid Purification 
Following incubation 3mls of the culture was purified using Zuppy Plasmid MiniPrep 
Kit following protocol described in Section 3.2.5.3. 
3.3.1.14. Analysis of  DNA 
The eluate was analysed for DNA concentration using a spectrophotometer and diluted 
to give a concentration of 200ng/pl. 
3.3.1.15. Sequencing 
The diluted DNA was sent to the BCM sequencing core for sequencing analysis. 
3.4 Statistical Analysis 
Analysis was conducted using Microsoft Excel. Student's t-test was used for analysis of 
transfection data in cell lines. 
This study aimed to examine an oestrogen responsive element (ERE) reporter library 
generated by DamID to identify and investigate SERM responders. Subsequent to this, 
DamID was employed to create a library of human genomic regions where SRC-1A 
associates with ligand bound ERa or PR-B. 
4.1. ERE Reporter Library Investigation 
The oestrogen receptor binds to EREs to mediate gene expression. An ERE reporter 
library was generated using the DamID technique described in the Materials and 
Methods Section, using a ERa:Dam fusion protein (Jennings, 2009). The ERa:Dam 
fusion protein was used in conjunction wit .  hormone treatment with EtOH (V Libmy), 
Oestrogen (E Library) or Tamoxifen (T Library) to generate three separate reporter 
libraries. 
The function of this was to address questions such as; what adjacent transcription factor 
binding motifs are found co-associated with EREs, and also whether the level of gene 
expression varied between ERa and ER$ biding. 
Initial screening investigatio~~s were performed on these Libraries (20 reporter plasmids 
h m  each library were investigated) to assess the differential response of reporter 
plasmids in this library to Oestrogen, Tamoxifen and Raloxifene. Tamoxifen and 
Raloxifene are selective oestrogen responsive elements (SERMs) which are used in the 
treatment of Oestrogen responsive tumours such as breast. The results of these 
investigations are described below. 
4.1.1. Iden t i f i ca t ion  a n d  Inves t iga t ion  of S E R M  R e s p o n d e r s  f r o m  
E R E  r e p o r t e r  L i b r a r i e s  
Initial ERE Library construction was previously performed using transfection protocol 
to transfect an ERa:Dam plasmid to HeLa Cells as described by Jennings (Jennings, 
2009). This was followed by cell treatment with Oestradiol, Tamoxifen or Ethanol. 
The cells were incubated and during this time the ERa:Dam protein formed a nuclear 
receptor complex with either oestradiol or tamoxifen, this enabled in vivo targeted 
methylation of GATC sequences close to ERa binding sites. Selective amplification of 
isolated sequences was perfomed using LM-PCR, cloned using a TOP0 entry vector 
(pCRSIGWITOP0) and the sequences sub-cloned to an adapted gateway compatible 
reporter vector @GL3-Basic) via LR recombination reaction (Figure 4.1.). 
pGL3-Basic was the reporter vector of choice, which contains no promoter element, and 
the isolated DNA sequence is inserted into a multiple cloning site, upstream from a Luc 
gene (Figure 4.2.). The absence of a promoter site and the presence of a Luc gene 
upstream from the insert enables the use of assays to examine the functional activity of 
the insert. 
Ran- Hela C m  hERa:Dam mroclde¶ 
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Figun 4.1. Overview ofthe construction ofthe ERE reporter libraries (Jennings, 2009) 
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Figure 4.2. pGL3-Basic Vector displaying Ampicillin gene for selectivity, the location ofwhere 
the genomic insert ir ligated to rhe vector and the location ojrhe Lucifrme gene, upstream of 
the genomic insert. 
The result of these steps is three separate ERE reporter libraries. Each is obtained from 
transfecting ERa:Dam to HeLa cells and treating these cells with EtOH, Oestradiol (E2) 
or Tarnoxifen (4HT). These served as the starting point for further investigations 
described below. 
4.1.1.1. Initial Screening of ERE Reporter Plasmid Libraries ' 
Initial screening trans-activation assays were performed on 20 plasmids from each of 
the three ERE Reporter Libraries (Ethanol, Oestrogen and Tamoxifen), described 
previously. These assays were used to identify reporter plasmids whose promoter 
responded more favourably to Tamoxifen (4HT) or Raloxifene (Ral) (SERMs) than to 
Oestrogen. This response may indicate the presence of a SERM responsive sequence, 
where Tamoxifen or Raloxifene has the ability to induce gene expression when it 
associates with the particular region of DNA that is isolated in the reporter plasmid. 
The luciferase assay was then used to quantify functional activity for each plasmid. As 
stated previously, the pGL3 Basic reporter vector does not contain a promoter site and 
contains a luciferase gene upstream of the insert. Therefore, if the isolated sequence 
that was inserted into the pGL3 Basic vector contains a functional promoter sequence it 
will drive the expression of luciferin in the HeLa cells, the amount of oxyluciferin 
expressed will be proportional to the strength of the promoter (Figure 4.3.). The 
Luciferase Assay was performed as per Materials and Methods Section 3.1.1.4. 
Figure 13. Theory of the Dunsactivation Lucifeme Assay 
The luciferase assay is based on the fact that luciferin (or flouroluciferin), when mixed 
with oxygen and firefly luciferase, produces oxyluciferin (or oxyflouroluciferin) 
(Figure 3.4.), levels of which can be quantified using a luminometer. 
Figure 4.4. Chemical reaction thar occurs during the Luciferme Assay @romega.com) 
Figure 4.5. displays the results from initial luciferase assays. 
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Figure 4.5. Luciferase assay results following co-transfection of pGL3-Basic reporter 
constructs withpCR3.I hERa followed by 24hr hormone treatment: 10-7M EtOH (Ethanol), 10- 
9ME2 (Oesh.odiol), 10-7M4HT (Tatnarifen) or 10-7MRal (Raloxifne). 
Nine reporter plasmids were found to display this SERM response (E5p, E2, E73, E78, 
E82, T4p, T8, T77, T100). All nine were sent to sequencing to confirm they are of 
genomic origin. However, upon sequencing only two were found to be of genomic 
origin, E5p and T4p (highlighted in purple boxes in Figure 4.5.b. and Figure 4.5.c). 
The plasmids of non-genomic origin did not undergo further investigations. 
Figure 4.6. displays more detailed results of the transactivation assay of the two 
genomic SERM responsive plasmids (highlighted in purple boxes in Figure 4.5.: T4p 
and E5p). 
Figure 4.6. Lucifrase assay results following co-transfection of pGL3-Basic reporter T4p or 
E5p with pCR3.1 hERa followed by 24hr hormone treatment. (Same assay as in Figure 4.5.- 
close up of results) 
Oestrogen responsive reporter plasmids were used as a comparison (highlighted in blue 
boxes in Figure 4.5.: El2 and V17). Figure 4.7. displays more detailed results of two 
E2 responsive reporter plasmids, of genomic origin, which were to be used as a 
comparison. 
Figure 4.7. Lucifease assay results following co-transfiction ofpGL3-Basic reporter El2 or 
V17 withpCR3.1 ERa followed by hormone treatment. (Close up of results from Figure 4.5.) 
f i e  oestrogen responsive reporter constructs, El2 and V17 (Figure 4.7.), were used as 
a comparison to the SERM responsive reporter constructs T4p and E5p (Fkure 4.6.). 
The difference in the two responses can be seen from obmation of Figure 4.6. and 
Figure 4.7.. In the SERM responsive plasmids Tamoxifen and Raloxifme response is 
much greater than that of the Oestrogm response. This is the opposite of the Oestrogen 
responders. The response observed in the Oestrogen responders is one that would be 
expected due to the antagonistic activity of Tamoxifen and Raloxifene. Locating these 
SERM responsive sequences could be important in identifying the factors that result in 
Tamoxifen resistance during the treatment of breast cancers and also could be used to 
identify which genes are activated following Tamoxifen biding and in which tissues 
these SERM responsive sequences are active in. 
The two SERM reporter plasmids, T4p and E5p, were investigated further to observe 
the effects of other transcription factors and ERa mutations on their transcriptional 
activity. 
4.1.1.3. Investigation of Mutant ERa on SERM Responders 
Mutant ERa reporter plasmids were employed to assess which sites are required for the 
S E W  responsive plasmids to continue to cause transcription. C205H is a DBD (DNA 
Binding Domain) mutant, L539A is an AF-2 defective mutant and S118A is an AF-1 
defective mutant. 
E t O H  mE2 R d  4HT A 
g 12 
% 9 -  
e -  ** t. B * W  * rr ** 
3 -  
. - - 
z MRa C205H L53BA S118A 
E t O H  mE2 .Rd W4HT B 
E 3 
" 
Y 9 9 n W *. * 
i? KRa C205H L539A SI I8A 
Figure 4.8. Lucifrare assay results following co-iransfection of pGL3-Basic reporter 
constructs (T4p in Panel A; ESP in Panel B) with pCR3.I hERa or hERa expression mutants 
WR3.1 C205H, pCR3.1 LS39A or pCR3. I SlI8A). This war followed by 24hr hormone 
treatment with ~ ( T ' M E ~ o H  @thatroo, IU'M ~2 (Oeshadioo, IU'M ~ H T  ( amoxifn) or IU'M 
Ral (Raloxifene):p<O.OS, .*p<0.01 mutant ERa compared to w i l d - ~  ERa 
A significant reducation in transcriptional activity was observed when mutant ERa was 
compared to wild-type ERa following corresponding hormone/drug treatment w0.05, 
p<0.01) (i.e.: wild type ERa transfection followed by Raloxifene treatment is compared 
to C250H transfection followed by Raloxifene). Furthermore, analysis of the wild-type 
ERa result itself indicated the significance of the SERM responsive plasmids response 
to Raloxifene (p<0.05) and Tamoxifen @<0.01), in the case of T4p, and of Raloxifene 
(~10.05)  alone in the case of E5p compared to E2 treatment. 
The results (Figure 4.8.) demonstrate that all ERa mutant domains tested are required 
for promoter activity in the SERM responsive reporter plasmids indicating a fully 
functional ERa molecule is required for this SERM response to occur. 
4.1.1.4. Investigation of Transcription Factors and Co-Factors on SERM 
Responders 
SNAIL and PAX4 are nuclear receptors, while SRC-3 is a nuclear receptor co-activator. 
These nuclear receptors and nuclear receptor co-activators were used due to information 
obtained from bioinformatic studies (Lonard, 2009; unpublished observations). PAX4 
binding sites were found in a number of the isolated ERE reporter plasmids, as was 
SNAIL. SRC-3 was investigated due to its proven co-activation of ERa (Anzick et al, 
1997). 
Figure 4.9. shows the results of the two SERM responsive reporter plamsids 
transfected to HeLa cells with pCR3.1 (control; blank plasmid), pCR3.1 hERa, pCR3.1 
hERa with pCMV5 SNAIL, pCR3.1 hERa with pCR3.1 PAX4 and pCR3.1 hERa with 
pCR3.1 SRC-3. Each transfected group of cells were incubated for 4 hrs and then 
underwent a 24 hr treatment with either EtOH, Oestrogen, Tamoxifen or Raloxifene. 
Statistical analysis on this data was investigated as was Figure 4.8.. The results in this 
case indicate that E5p and T4p both result in a significant response to Raloxifene and 
Tamoxifen when compared to E2 treatment @<0.05, p<O.01). 
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Figure 4.9. Luciferase assay results following co-transfection of pGL3-Basic reporter 
constructs with pCR3.1 (empty vector), pCR3.1 hERa, pCR3.1 hERa and pCMV5 SNAIL, 
pCR3.1 hERa andpCR3.1 PAX4 or pCR3.1 hERa andpCR3.1 SRC-3. This was followed by 
24hr hormone treatment: 10-7M EtOH (Ethanol), 10-9M E2 (Oesiradiol), 10-7M 4HT 
(Tamoxifen) or 10-7M Ral (Raloxifene). *p<0.05, **p<O.01 hERa alone compared to hERa co- 
transfected with respective nuclear receptor/co-activator 
It is apparent from Figure 4.9. that the isolated SERM responsive sequences are 
activated by the transfection of pCR3.1 hERa alone followed by hormone/drug 
treatment. pCR3.1 PAX4 and pCMV5 SNAIL exert a significant co-repressive effect 
on the sequences (p<0.05, p<0.01) and pCR3.1 SRC-3, interestingly, does not co- 
activate transcription in these sequences, in fact SRC-3 appears to significantly co- 
repress these SERM responsive reporter plasmids (p<0.05, p<O.01). 
The effect of SNAIL and SRC-3 on oestrogen responsive reporter constructs (El2 and 
V17) was also investigated and results can be seen in Figure 4.10. The repressive 
SNAIL response seen in SERM responsive reporter plasmids (Figure 4.9.) is mimicked 
in the oestrogen responsive reporter plasmids (Figure 4.10.) with a significant 
reduction in transcriptional activity observed in both constructs (p<O.OS, p<0.01) 
The effect of SRC-3 on the oestrogen responders was investigated to identify whether 
there is differential regulation of SRC-3 on the two groups of reporter constructs. It can 
be seen (Figure 4.10.) that SRC-3s transcriptional coactivator ability is restored in 
these plasmids, cooperating only with E2 treated cells co-transfected with ERa and 
SRC-3, not with Raloxifene. These results correlate to previous findings that SRC-3 is 
a coactivator of ligand bound ERa (Anzick et al, 1997). 
Figure 4.10. Lucifrase assay results following co-transfection of pGL3-Basic oestrogen 
responsive reporter consfructs, VI 7 and EI2, withpCR3.1 hERa andpCR3.1 (empty expression 
vector) orpCR3.1 hERa rmdpCR3.1 SRC-3fbllowed by 24hr hormone treatment: 10-7MEtOH 
(EthanoI), 10-9M E2 (Oestradio~, 10-7M or 10-7M Ral (Raloxvme). *p<0.05, **p<O.Ol hERa 
alone compared to hERa co-transfected with SNAn 
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Two SERM responsive plasmids were identified from the ERE reporter library 
constructed by Jennings (Jennings, 2009). Transactivation assays were performed to 
assess the mechanism by which these SERMs (Tamoxifen and Raloxifene) function to 
activate, rather than repress, ERa. The initial investigative assay used mutant ERa 
expression plasmids to determine is transcription could still be activated by a mutant 
ERa. The results indicated that the DNA-Binding, AF-1 and AF-2 domains were all 
necessary in order to activate transcription, indicating that the SERMs are interacting 
with ERa in a similar mechanism to Oestrogen. 
Transcription factors and transcriptional coactivators were investigated next to assess if 
there was any differential response found to SERMs as compared to the oestrogen 
responsive constructs. A differential SRC-3 response was observed. SRC-3 has been 
previously reported to be an ERa co-activator. The results obtained indicated that, for 
the SERM responsive reporter constructs, SRC-3 has the ability to co-represses 
activities of ERa. 
It was decided to investigate the SRC family of 'co-activators' further. 
4.2. S R C - 1 A  and SRC-3IERa and PR-B Reporter Library 
Generation and Investigation 
Due to the interesting results obtained from the investigation of SRC-3s effect on 
SERM responsive ERE reporter constructs it was decided to investigate the SRC family 
of coactivators in further depth, generating a library of reporter plasmids that bind 
indirectly to SRC-1A or SRC-3 via ligand bound ERa or PR-B. SRCs bind to promoter 
elements in DNA via ligand bound nuclear receptors (Onate et al, 1995). More 
information on this family of molecules, and coregulators in general, can be found in 
Section 1.4. Investigations focused on SRC-1A and SRC-3, chosen due to their ability 
to bind to a range of nuclear receptors, including ERa and PR-B. 
The purpose of this study was to generate a reporter plasmid library of genomic 
sequences which associate, via steroid hormone receptors (ERa or PR-B), with SRC-1A 
or SRC-3 and further to this, evaluate the sequences ability to regulate transcription. 
This should enable a greater understanding of the involvement of these two SRC 
molecules in the regulation and transcription of SRC regulated genes. An overview of 
the steps involved in this process can be viewed in Figure 4.11.. 
Step 1: Generation ofSRC-IA : Dam andSRC-3:Dom exuression vectors 
 cation of methylated genomic sequences using LM-PCR I 
Top0 Cloning of the Generated PCR Products 
Plasmid Isolation 
&p& Generation of Reporter Vectors containing DamID isolatedsequences 
Sequencing of reporter plasmid inserts 
StreB; Bioitformatid Amtysis 
Functional Analysis of the newly generatedSRC-IA:Dam Reporter Vectors 
StcD Locoting Transcription Start Sites using GeneRacer 
Figure 4.11. Overview of the D a d D  mediated SRC-IA gDNA interacting sequence isolation 
process. 
4.2.1. Generation of pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam. 
Reporter plasmid library construction fustly began with the generation of an SRC-1A 
(or SRC-3) Dam fusion protein. A pCR3.1 SRC-1A Luc Vector underwent SalI and 
ApaI digestion (Materials and Methods Section 3.2.1.3), effectively cutting out the Luc 
gene. The Dam gene was amplified from genomic Escherichia coli by PCR, 
purification of PCR product and subsequent complimentary restriction digestions (ApaI 
and SalI) (Materials and Methods Section 3.2.1 .l. to 3.2.1.3.). This left corresponding 
digested ends which during a ligation reaction c o m b i i g  the isolated Dam gene and the 
SRC-1A vector minus the Luc gene resulted in a vector which was composed of the 
SRC-1A gene located upstream and next to the Dam gene (Figure 4.12.). 
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Figure 4.12. The process of conshuctingpCR3.1 SRC-1A Dam plasmid 
4.2.1.1. Generation of Dam PCR product, pCR3.1 SRC-1A and pCR3.1 
SRC-3 
The Dam gene was amplified from E. coli by PCR. The Dam forward primer contained 
a SalI restriction recognition site at the 5' end and the Dam reverse primer contained a 
ApaI restriction recognition site at the 5' end (Materials and Methods Section 3.2.1.1.). 
Following PCR amplification and DNA purification (Materials and Methods Section 
3.2.1.2.) the PCR products were digested with SalI and ApaI, as were plasmids pCR3.1 
SRC-1A:Luc and pCR3.1 SRC-3:Luc (Materials and Methods Section 3.2.1.3.). 
Figure 4.13. presents a 1% agarose gel which displays the bands of the isolated Dam 
PCR products (Lanes 2 and 3) along with digested pCR3.1 SRC-1A:Luc (Lanes 4 and 
5) and pCR3.1 SRC-3:Luc (Lanes 6 and 7). 
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Figure 4.13. 1% Agarose Gel. Lane 1 is molecular weight marker. Lane 2 and 3 are Dam PCR 
Products. Lane 4 and 5 are the restriction digestedpCR3.1 SRC-1A:Luc plasmids and lane 6 
and 7 are digestedpCR3. I SRC-3:Zucplasmids. 
The gel demonstrates that both the PCR amplification of Dam and the digestion of 
pCR3.1 SRC-1A Luc were successful as the Dam PCR product (Lane 2 and 3) was 
present at the expected size (800 bp) and the SRC-1A:Luc (Lane 4 and 5) vector 
backbone is present at 7500 bp with the excised Lec insert at 1600 bp. The gel also 
shows the unsuccessful digestion of pCR3.1 SRC-3 Luc (Lane 6 and 7) as there is no 
band at the expected 1600 bp site, which would be indicative of successful restriction 
digestion and release of Luc fragment. 
4.2.1.2. Removal o f  the Luc fragment 
The Luc fragment (1600 bp) was removed from the gel and discarded (Materials and 
Methods Section 3.2.1.4. and 3.2.1.5.). 
4.2.1.3.  Ligation of  Amplified Dam PCR Product  and pCR3.1 SRC- 
I AJSRC-3 
The pCR3.1 SRC-IA plasmid minus the Luc fragment was ligated to the Dam PCR 
product (Materials and Methods Section 3.2.1.6.). A control ligation was also 
performed for each plasmid which involved performing a second ligation for each 
plasmid, excluding the amplified PCR product. 
E. coli cells transformed with ligated plasmids were plated on agar containing 
ampicillin (Materials and Methods Section 3.2.1.7.) and incubated overnight. The 
results of growth can be seen in Table 4.1.. 
There was an absence of growth on the pCR3.1 SRC-IA Control plate which was 
indicative of inefficient restriction digestion (which confirms the lack of a Luc band in 
Figure 4.1 1.). A small number of colonies were present on the pCR3.1 SRC-IA Dam 
plate. The high number of colonies on the pCR3.1 SRC-3 Control plate was an 
unexpected result, further analysis was required to confirm ligation was successful in 
the case of pCR3.1 SRC-lA:Dam, and to confirm all steps were successful in the case 
of pCR3.1 SRC-3:Luc ApaIISalI digestion (as there was no evidence of initial Luc 
removal from the pCR3.1 SRC-3:Luc plasmid). 
Colonies of interest (two from pCR3.1 SRC-1A:Dam plate and two from pCR3.l SRC- 
3:Dam plate) were picked and cultured (Materials and Methods Section 3.2.1.7.). 
Plasmid DNA was isolated as per Materials and Methods Section 3.2.1.8. and analysed. 
Plasmid 
pCR3.1 SRC-1A Dam 
pCR3.1 SRC-1A Control 
pCR3.1 SRC-3 Dam 
pCR3.1 SRC-3 Control 
4.2.1.4. Analysis of Constructed Plasmids 
Colonies Observed on Agar Plate 
2 : / 
None / 
/ 
17 
Plasmid DNA was assessed using EcoRI and BamHI enzyme digestions (Figure 4.14.) 
to determine if the plasmid had the correct insert (Materials and Methods Section 
3.1.9.). 
Table 4.1. Observation of Agar Plate Growth following ligation of ampliJied Dam fragment 
and digestedpCR3. I SRC-la!SRC-3 plasmid. 
It appears that the BamHI and EcoRI digestion did not successfully reveal a Dam insert 
as no band at the expected 535 bp was observed. 
Figure 4.14. 1% Agarose Gel with products of BamHI and EcoRI Digestion.' Lane I is the 
molecular weight marker. Lane 2 and 3 are digestedpCR3.I SRC-1A:Dam. Lane 4 and 5 are 
pCR3. I SRC-3:Dam. No Dam fiagment visible around the expected 535 bp size. 
Digestion analysis was then repeated using BamHI and EcoRI (Materials and Methods 
Section 3.2.1.9.). and only pCR3.1 SRC-1 A Dam showed evidence of containing a Dam 
fragment at the expected size of 535 bp (Figure 4.15.) 
Figure 4.15. 1% Agarose Gel, with products following BamHl andApal Digestion. Lane I is 
molecular weight marker. Lane 2 is pCR3.I SRC-1A:Dam. Lane 3 and 4 is pCR3.1 SRC- 
3:Dam. Damj?agment faintly visible at 535 bp size in lane 2 only, no band visible for pCR3.1 
SRC-3:Dam 
4.2.1.5. Optimisation of Techniques to Construct pCR3.1 SRC-3:Dam 
Due to unsuccessful construction of pCR3.1 SRC-3:Dam adjustments were made to the 
methods used. 
Protocol was repeated from the initial digestion with ApaI and SalI (Materials and 
Methods Section 3.2.1.3.). Electrophoresis was performed on the digested pCR3.1 
SRC-3:Luc plasmid ( ~ i g u r e  4.16.). There was no evidence of the L U ~  gene at the 
expected 1,600 bp site. 
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Figure 4.16. 1% Agarose Gel, following restriction digestion with ApaI and Sall. Lane I is a 
molecular weight marker. Lane 2, 3, 4 and 5 are restriction digestedpCR3.I SRC-3:Dam. 
Adjustments were made to the original protocol to enable successful construction of 
pCR3.1 SRC-3:Dam. The ApaI digestion step was adjusted as well as the ligation step. 
The ApaI digestion was performed with 3p1 pCR3.1 SRC-3:Luc, 1p1 NEB Buffer 4 
(New England BioLabs), 5p1 dHzO and 1p1 ApaI (Invitrogen) and the ligation time was 
extended from 1 hr to 2 hrs. 
The ApaI digestion was performed with 3 times the amount of pCR3.1 SRC-3 Luc to 
provide more plasmid DNA and thus give a higher chance of obtaining sufficient 
amounts of plasmids, also ligation time was extended from 1 hr to 2 hrs to provide more 
time for the PCR DNA Dam to ligate to the plasmid. Results from the gel (Figure 
4.1 7.) confirmed that the Luc gene was cut from the pCR3.1 SRC-3:Luc plasmid. 
Figure 4.1 7. 1 % Agarose Gel; following Luc excision. Lane I is molecular weight marker. 
Lane 2 and 3 are pCR3. I SRC-3:Luc. The Lucjiagmenr has been excised. 
However, following ligation and transformation to chemically competent E. coli cells 
and overnight incubation on agar plates neither the test or control plates obtained any 
growth. A 6 hr ligation at RYC was performed on the digested pCR3.1 SRC-3 plasmid 
(no Luc gene) in an attempt to successfully ligate the Dam PCR product to the pCR3.1 
SRC-3 plasmid. This also yielded no growth following transfection to chemically 
competent E. coli cells. Attempts to construct pCR3.1 SRC-3 Dam were suspended. 
4.2.1.6. Further Analysis of  pCR3.1 SRC-1A:Dam plasmid 
The agar plates growing E. coli colonies with pCR3.1 SRC-1A:Dam plasmids were 
purified and plasmid DNA isolated (Materials and Methods Section 3.2.1.10 and 
3.2.1.1 1). The resulting purified plasmid DNA was assessed using restriction digestion 
to compare pCR3.1 SRC-1A:Dam and pCR3.1 SRC-1A:Luc using the restriction 
enzyme SphI (Materials and Methods Section 3.2.1.13). Figure 4.18. displays a 1% 
agarose gel following electrophoresis of the restriction digestions (of pCR3.1 SRC- 
1A:Luc and pCR3.1 SRC-1A:Dam) and confirms a difference in the banding pattern of 
the pCR3.1 SRC-1A:Dam and the pCR3.1 SRC-1A:Luc plasmids. 
Figure 4.18. 1% Agarose Gel containing SpI restriction digested plasmids. Lane I contains 
molecular weight marker. Lane 2 contains the pCR3. I SRC-1A;Dam digestedplasmid. Lane 3 
contains the pCR3. I SRC-1A;Luc digestedplasmid. 
Sequencing was used to confirm the directionality of the gene and to confirm that the 
full length gene for both SRC-IA and Dam are present (Materials and Methods Section 
3.2.1.14.). 
A minimum DNA concentration of O.lpg/pl was required for sequencing. 
Spectrophotometric analysis of the plasmid DNA revealed the concentration of DNA to 
be 0.068pg/pl with a 260/2so ratio of 1.75. DNA had to be concentrated to enable 
sequencing to be performed (Materials and Methods Section 3.2.1.12.). Following 
concentration of the plasmid spectrophotometric analysis determined the DNA 
concentration to be 0.177pg/pl with a 260/2go ratio of 1.44. DNA was more concentrated 
but was not as pure. 
Sequencing confiied presence of Dam downstream and adjacent to the SRC-1A gene 
(Figure 4.1 9.). 
Primar SRC-1A Dam Sequence Unknown sequence 
3'ACCGTGGGGmGTACAAAGCCAGCAAGTTCGTCCACCrmTACGTGTGCCGCCGTTGCTGCnATACTG 
CGTCGAACmGACGACATGCAAmGCGCGCTGATACCACTCACGCGTTAACATCGTATCGTGAnGGAGA 
TCAGCACTGGAATATGGCGCTCAACCAGACCTTCGGCGATCTCCGCCAGATGCGCTTGmGTTCAAGCGTAAA 
ACTGmGTGTGATACGCCGTAAAGTTGGCGGTCGCAGACAGCGGTGCATAAGGCGGATCGCAATAGACGAC 
GGATGCATCATCTGCGCGCGCCATGCTATC~GTMMCTCACAATAUGGCATTCTGCGCWCA 
GCGAAGTGATACAACTCTGCTTCCGGGAAATAGGOrCrmGTAGCGGCCGAACGGCACGTTAAACTCACCGC 
GCAGATTGTAACGACACAGGCCGTTGTAACCGTAGCGGmCAAATAT~CAGTACCGCCCGACGGAAcG 
G A T C C T G G C l l l T G T T G A A C T C T T ' C G C G G A A C T G A T A G T A A  
CTCGCGTGCGGCCTGTACGTACTCATCAGTACGCATC~CACAATG~ATAGAGACTGATCAGGTCGCTATTG 
A T A T C G G C A A G G A T A T A A C G A G A A A A G T C G G T G A G A A C  
AGACATTCGCCCTTGGGCAAATGCCGmAATATCATCAAGCAGGGGATACnGCCCCCTGCCCACUM 
AAGCGCGA~CTTGTCGACTTCAGTCAGTAGCTGCTGACGGAGGCTCTTCTGCTGGGCCTGGGOGGTCT 
GTGGTCCTGACGTGGGC~GAGTTCCCAGTGGACCAGGCTGGmCAGGTMGGGTCCCCGCCTACCAGAT 
TCACTGTACACTGGACGTCAGWCACCTWCCTGTTGCACCTGCTGGGTTCCATCTGCTTCTG~MG 
AAGGTCAGTGGATGAGAGCTGGTTGCAGTAGAGGCCTGTGTGTCTCAGTGCGGGATCAmATCTGCCTCA 
GGGCCMCACAGTGmCAmCCTGGCCA~CTGCAAAGAAGCTTCATCTTGCAATCTGGGCATCAAmGG~ 
CATGGmC~GAACATCCGTAmCCACCTGCAATGGAACCCGGCGGGAAGTGCTCTCATCAAGAGTTS 
Figure 4.19. Plasmid insert sequence displaying correct direction of SRC-1A and Dam genes. 
Red nucleotides depict the SRC-IA gene, underlined red indicated the location of the primer 
sequence used, blue indicates the Dam sequences and the black nucleotides me of unknown 
origin, possibly originatingfrom the plamid. 
Confinnation of the Dam gene insertion downstream of the SRC-1A gene in the 
plasmid enabled the DamID procedure to begin. The newly created plasmid containing 
the SRC-1A:Dam fusion gene (Figure 4.20.) was used in HeLa cell transfections, 
which, upon transfection would express the SRC-1A:Dam fusion protein. 
(Fusion Gene) 
t 
pCR"3.1 
5060 bp 
. Comments for pCR.J.1 
5060 nucleohdes 
Figure 4.20. Vector map of pCR3.1. (Invitrogen). This figure details the insertion of the newly 
formed SRC-1A:Dam fision gene to the 'PCR Product' region of the polylinker sequence. SRC- 
3:Dam fusion gene was inserted to the same site. The SalI digestion site is located in the end of 
the SRC-1A and SRC-3 sequence which was already present in the plasmid lie Dam is then 
linked to that SaN site in the SRC-IA or SRC-3 genes to the ApaI site located in the polylinker 
sequence (highlighted in red). 
4.2.2. Construction of Library of genomic sequences which interact 
indirectly with SRC-1A:Dam via hERa or PR-B 
The purpose of this section was to investigate the involvement of SRC-1A in hERa and 
hPR-B mediated transcription. Figure 4.21. demonstrates the DamID process whereby 
the SRC-1A:Dam fusion plasmid is transfected to HeLa cells along with an expression 
plasmid for hERu or hPR-B. Following 4 hr incubation the cells were treated with 
either oestradiol, progesterone or ethanol. In vivo binding of the steroid and its receptor 
occur, followed by translocation to the nucleus where the complex associates with the 
hormone response elements in the genome and SRC-1A:Da.m interacts indirectly with 
the genome via the receptor ligand complex. When bound, the Dam can then methylate 
the proximal GATC sequences. The DNA is then isolated and undergoes analysis. UV 
spectrometry is used to analyse the concentration of the DNA' and its purity. The end 
result of this step is isolated gDNA some of which contains methylated GATC 
sequences marking where the SRC-1A:Dam associated with the genome via either 
hERu and E2 or hPR-B and progesterone. 
8 8 h-*n-on of 8 8 
either ERa or PR-B 
expression plasmid 
b L a  Cells 
4 hr incubation 
1 1 Hormone or EtOH 
8 8 Treatment 
1 
EtOH me. • EtOH 
ortndiol 24 hr incubation 
1 1 Adenine methylation of sites adjacent to indirect Dam binding 1 
Isolation of 
grnomlc DNA 
1 1 isoiatlon of GATc 1 I 
methylatd G;+i 
A ~ t d ;  :ntsequences SRC-1A:Dam where , ,, 
CH' CH3 CH' indllactly bound to 
gDNA by Dpnl 
Dlgestlon 
Figure 4.21. Construction of library of sequences found to associate indirectly to SRC- 
1A:Dam. 
4.2.2.1. Transfection of HeLa Cells with SRC-1A:Dam Expression 
Plasmid 
The following steps were performed to enable SRC-1A:Dam expression in HeLa cells, 
which via indirect binding of SRC-1A to the DNA will permit Dam methylation of 
nearby GATC sequences. 
250ng SRC-1A:Dam was transfected to Hela cells with co-transfection of 25ng hERa or 
hPR-B expression vectors. The transfected HeLa cells were incubated for 4 hrs after 
which hormone treatment was performed with Oestradiol or Progesterone for 24 hours. 
A subset of the transfected cells were also treated with ethanol, which would enable the 
isolation of SRC-1A:Dam that binds to DNA bound nuclear receptors that bind in the 
absence of hormone treatment. 
A transfection reaction was also performed transfecting SRC-1A:Dam without a nuclear 
receptor expression vector and treating these transfected cells with EtOH which would 
act as a control during LM-PCR mediated specific amplification of methylated GATC 
sequences, as no GATC specific methylation should occur when cells are transfected 
with SRC-1A:Dam alone. (As per Materials and Methods Section 3.2.2.1. to 3.2.2.3.) 
4.2.2.2. Isolation of Genomic DNA 
Genomic DNA was isolated from the transfected HeLa cells using an ethanol 
precipitation technique as per Materials and Methods Section 3.2.2.4 and the DNA 
concentration and purity analysed using a spectrophotometer as per Materials and 
Methods Section 3.2.2.5. The results of this can be seen in Table 4.2.. 
Transfeetion 
& Hormone Treatment 
ERa & EtOH 
ERa & E2 
PR-B & EtOH 
PR-B & Prog 
Control 
DNA Concentration 
PUP1 
0.135 
0.093 
0.047 
0.030 
0.008 
DNA Purity 
A ~ ~ ~ I ~ ~ .  
1.69 
1.64 
1.63 
1.69 
1.73 
Table 4.2. Spectrophotometric analysis of isolated genomic DNA from HeLa Cells transfected 
with pCR3.I SRC-JA:Dam co-transfected with the noted nuclear receptor followed by 16 hr 
treatment with the noted hormone/EtOH 
4.2.2.3. Specif ic  Amplification o f  Methylated GATC Sequences 
Isolation of the methylated GATC sequences was achieved with the use of the DpnI 
enzyme, which specifically recognizes methylated GATC sequences, thus generating a 
pool of blunt-ended DNA fragments with 5'TC and ~'GA"''' (Materials and Methods 
Section 3.2.2.6) 
The DpnI digested partially methylated sequences were amplified using a methylation 
specific LM-PCR method. The LM-PCR procedure (Materials and Methods Section 
3.2.2.7) ensures only methylated DNA fragments are amplified. DpnII digestion, which 
is typically part of the protocol, was not performed. DpnII destroys (via digestion) all 
fragments containing unmethylated GATC sequences which excludes them from 
amplification, however this DpnII digestion this step was omitted from protocol. The 
activities of DpnI functions to digest only methylated GATC sequences therefore 
unmethylated GATC are not cut, leaving short DNA sequences with digested ends 
(Figure 4.22.). The unmethylated GATC sequences should remain 'hidden' in long 
DNA sequences and therefore 'ignored' during the adapter ligation step. Therefore the 
unmethylated GATC sequences will not interfere with the LM-PCR. In this protocol 
DpnII digestion was not performed. 
CTAG 
CH, CH3 
1 
Dpnl 
Digestion 
Figure 4.22. DpnI digestion of methylated GATC sequences in isolated gDNA 
Additionally, non specific DNA products which may be derived from random DNA 
breaks are excluded from the PCR due to the specificity of Primer design. The PCR 
primer overlaps with the GA dinucleotide located at the ends of the DpnI digested 
fragments, ensuring only these fragments are amplified thus suppressing amplification 
of non specific ligation products, which, generally, will not have a GA dinucleotide at 
their ends. 
The LM-PCR reaction (Figure 4.23.) also incudes a control for DpnI digestion. The 
control is gDNA from one of the samples which did not undergo DpnI digestion, 
therefore no adaptor mediated amplification of these methylated sequences should take 
place as they were never digested and should remain 'hidden' in long strands of gDNA 
(similar to the unmethylated GATC sequences). 
Dpnl 
Digested 
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Ugatlon 
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CY 
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Figure 4.23. LM-PCRprocedure 
Following LM-PCR (Materials and Methods Section 3.2.2.7 and 3.2.2.8) the samples 
are run on a 1% agarose gel (Materials and Methods Section 3.2.2.9.) to enable 
visualisation of LM-PCR products (Figure 4.24.). 
The PCR products create a smear in the gel indicating that there is a variety of sequences 
isolated from the transfected HeLa cells. PCR product sequences all appear to be 
shorter than 500 bp. Transfections treated with EtOH appear to have a larger amount of 
DNA as the bands appear brighter. Primer Dirners are visible in the gel. 
ERa + + -  - ,  
P! 
PR-B - - + + "  
FD 
E2 .- - + - - v  
Prog 5 - - - + -  g 
EtOH + - + - 0  
DNA Smears 
S ~ z e  100 bp - SUO bp 
- Prlrncr Dirncr 
Figure 4.24. 1% Agarose Gel electrophoresis of (LA@-PCR products from LM PCR of DNA 
isolatedfrom the HeLa cells transfected to SRC-1A:Dam with ERdPR-B transfection followed 
by treatment with E2/Prog for I6hrs. Genomic DNA was then digested with DpnI, Adapters 
were ligated to the blunt ends of the isolated sequences and LMPCR was performed. 
Lane 1 (Figure 4.24.) contains molecular weight marker. Lane 6 contains the control, 
that is a control reaction set up during the adapter ligation stage, this a control run as per 
the tests but with undigested (not DpnI digested) genomic DNA from one of the 
samples of isolated genomic DNA from the transfected HeLa cells. 
Lane 2 (Figure 4.24.) contains LM-PCR generated PCR products resulting from the 
amplification of GATC methylated sequences following the transfection of HeLa cells 
with the SRC-1A:Darn expression vector, co transfected with an expression vector for 
ERa followed by treatment with ethanol. The lane shows LM-PCR products ranging in 
size from approximately 100 bp to 500 bp. These LM-PCR products show that not only 
is the fusion product able to indirectly bind to DNA but the Dam fusion protein of the 
SRC-1A:Dam molecule is functioning and can cause GATC methylation. Even though 
the SRC-1A:Dam and ERa transfected HeLa cells were treated with ethanol there are 
still PCR products. It is known that ERa had the ability to bind DNA in the absence of 
hormone. 
Lane 3 (Figure 4.24.) contains LM-PCR generated products resulting from the 
amplification of DNA containing methylated GATC sequences following the 
transfection of HeLa cells with the SRC-I A:Dam expression plasmid and cotransfection 
with ERa with subsequent treatment with oestradiol. PCR products in this lane range in 
size, similarly to Lane 2, from 100 bp to 500 bp. However there is much less LM-PCR 
product in this lane when compared to Lane 2. This could indicate that SRC-IA binds 
preferentially to ERa in the absence of Estradiol, whereas the ERa agonist, Oestradiol, 
enhances ERa genomic binding. Basically, there was less SRC-1A:Dam indirect DNA 
association during the transfection conditions of Lane 3 when compared to Lane 2. 
Lane 4 and 5 (Figure 4.24.) contains LM-PCR generated products resulting from the 
amplification of DNA following the transfection of HeLa cells with the SRC-1A:Darn 
expression plasmid with cotransfection of PR-B followed by treatment with ethanol 
(Lane 4) or Progesterone (Lane 5). Both of these lanes contain less LM-PCR products 
when compared to Lanes 2 and 3 respectively, indicating that the SRC-1A:Dam 
transfections with cotransfection of ERa was more successful than that with SRC- 
1A:Da'm and PR-B. Lane 5 contains the least amount of LM PCR product with LM- 
PCR product size ranging from approximately 100 bp to 400 bp while lane 4 product 
sizes range from 100 bp to 500 bp. 
Lane 6 contains the DpnI undigested genomic DNA following LM-PCR protocol. The 
absence of a banding pattern is due to the fact that the DNA template in this case is 
gDNA from HeLa cells that have been transfected with the SRC-1A:Darn expression 
plasmid, cotransfected with PR-B, and treated with progesterone but DpnI digestion was 
not performed. As no DpnI digestion has taken place, the methylated GATC sequences 
are not isolated and thus double stranded adapters can not ligate and LM-PCR cannot 
occur. Additionally, the primer dimer band at IOObp is the brightest of all lanes 
indicating no primers have been used in the LM-PCR procedure that was performed on 
the contents of this lane. 
A faint band is visable at approximately 100 bp in Lanes 2 through 6 (strongest in Lane 
6). This is a primer dimer band, which result when primers annealing to each other 
forming a dimer, due to the low concentration of target amplicons. 
4.2.3. Cloning of PCR Products using pCR8IGWITOPO TA Cloning 
The isolated, amplified SRC-1A:Dam sequences were then sub-cloned into a gateway 
entry vector. pCR8lGWlTOPO was the vector of choice, chosen due to its function as a 
gateway entry vector (vector map can be seen in Materials and Methods Figure 3.13.). 
This vector contains a TOPO cloning site which can efficiently clone Taq amplified 
PCR products. Taq polymerase has non-template dependent terminal transferase 
activity that adds a single deoxyadenosine (A) to 3' ends of PCR products. The 
pCR8lGWlTOPO vector has overhanging deoxythymidine (T) residues which enables 
efficient ligatation of the Taq amplified LM-PCR products into the TOPO vector 
(Figure 4.25.). 
Topo Clonlng 
Vector 
CCCTT AGGG 
LM-PCR product CH, 
I 
I I 
Tramformation to 
Chemically 
anpetent E . d i  I 
Colonlea of E.coli 
- containing TOP0 plasmids with LM- 
PCR Insert 
Fkuw 4.25. Process involved in inserting the sequences to the TOPO gat- vector and then 
to the speciol~ designed destination vector. 
The TOPO cloning reactions were set up as per Materials and Methods Section 3.2.3.1. 
SRC-1A:Dam cotransfected with ERa, treated with oestradiol 
SRC-1A:Dam cotransfected with PR-B, treated with EtOH 
SRC-1A:Dam cotransfected with PR-B, treated with progesterone 
Sequences iaohted from transformation: 
SRC- I A:Dam cotransfected with ERa, treated with EiQH 
None - 
2 3a and 3b 
1 4a 
No. Denoted 
Colonies 
2 la and lb 
Tabk 4.3. Table displaying the number of colonies following overnight growth of Chemically 
Competent E. coli cells hansformed with TOPO cloning reaction products. 
The products of the cloning reactions were transformed into chemically competent E. 
coli according to Materials and Methods Section 3.2.3.2 and plated onto spectinomycin 
plates for overnight growth. The plates were examined for the presence of colonies 
(Table 4.3.). 
Colonies that grew were individually picked and grown (to increase plasmid containing 
bacterial numbers) in LB Broth containing 100pg/ml Spectinomycin to select for the 
TOPO Cloning Vector which contains a spectinomycin resistance gene. The cultures 
were purified using a Mini-Prep system and the purified DNA was analysed using 
spectrophotometry (Materials and Methods Section 3.2.3.3. and 3.2.3.4.). The results 
can be seen in Table 4.4.. 
Isolated plasmids were then screened for the presence of inserts by restriction digestion. 
DNA Purity 
A ~ ~ ~ I ~ ~ ~  
1.81 
Sample 
l a  
l b  
3a 
3 b 
4a 
EcoRI restriction digestion sites flank the TOPO cloning sites in the pCRS/GW/TOPO 
cloning vector (Figure 4.26.). Restriction digestion of the plasmids using EcoRI 
enables further assessments of the insert (Materials and Methods Section 3.2.3.5.). 
Table 4.4. Results of speclrophotometric analysis of TOPO Libraries. 
Transfection 
& Hormone Treatment 
ERa & EtOH 
ERa & EtOH 
PR-B & EtOH 
PR-B & EtOH 
PR-B & Prog 
DNA Concentration 
l r g l ~ l  
0.079 
0.176 
0.171 
0.142 
0.107 
L 
EcoRl restriction 
7 , '  
ACGMTTCGCCCT sltsa flank (he MGGGCGMRC LMPCR 
TGCTTAAGCGGGA~ 1 TTCCCGGTTMG amplified inseri 
Restriciton digestion 
of TOPO plasmids 
and electrophoresis 
on 1% agarooe gel I 
-- 
Molecular wight - 
marksr - 
Figure 4.26. EcoRI restriction digestion sites on either site of the M-PCR insert enable 
analysis of the inserts. 
The restriction digested plasmids were then run on a 1% agarose gel (Materials and 
Methods Section 3.2.3.6.) to enable visualization of the presence of inserts (Figrrre 
4.27.). 
Due to the lack of colonies obtained using this protocol, the p d u r e  was optimized. 
To increase the number of TOPO inserts a reduced quantity of LM-PCR product was 
added and the volume replaced with dH2O (lpl PCR Product and 3pl dH2O rather than 
4pl PCR Product). As a result of this adjustment to the TOPO cloning procedure 
approximately 2000 colonies were obtained on each of the 4 agar plates (ERa and 
EtOH, ERa and E2, PR-B and EtOH or PR-B and Prog). 
la l b  3a 3b 4a 
ERa + + - - -  
PR-B - - + + +  
E2 - - - - -  
hog - - - - + 
EtOH + + + + - 
Figure 4.27. 1% Agarose Gel containing a restriction digesfion of TOP0 vectors containing 
ZM-PCR inserts with EcoRI. This step was to screen for colony inserts. Lane 1 contains 
molecular weight marker. The remaining lane contents are described above the gel. 
Each plate was washed with LB Bi.oth containing 100pg/ml Spectinomycin (Materials 
and Methods 3.2.3.2.), plasmid DNA was purified, isolated, and concentration was 
determined using a spectrophotometer (Materials and Methods Section 3.2.3.3 and 
3.2.3.4). 
4.2.4. Crea t ion  of Expression Vector Conta in ing  Isolated Sequences 
Sequences needed to be cloned into a reporter vector to enable functional investigation 
of the promoter activity of the sequence that was isolated. As pCR8IGWlTOPO 
(Figure 3.11.) is not a reporter vector, a LR recombination would have to take place 
between the pCRIGWlTOP0 entry vector containing the cloned sequences and a 
destination vector, which has reporter capabilities. In order to do this a gateway vector 
conversion system with One-shot ccdB Survival competent was used to convert the 
reporter vector of choice @GL3-Basic Vector) into a gateway vector (Figure 3.12.) 
according to Materials and Methods Section 3.2.4.1. to 3.2.4.4. 
Upon successful generation of the pGL3-Basic destination vector, a LR Clonase 
reaction was performed on the TOPO Cloning reaction (Materials and Methods Section 
3.2.5.1.). The LR recombination reaction facilitates the transfer of the DNA inserts 
contained in the pCR/GW/TOPO entry vector into the newly generated pGL3-Basic 
reporter vector. The pGL3-Basic reporter vector was manipulated to enable its function 
as gateway destination vector. 
Following the LR recombination reaction the products were transformed into competent 
bacteria and plated on LB Agar plates with 100pg/ml Ampicillin to select for the 
presence of the pGL3-Basic Dest vector (Materials and Methods Section 3.2.5.2.). A 
record of colony growth can be observed in Table 4.5.. 
Tabh? 4.5. Resultant colonies contahingpGL3-BmicpImmidsfoII~~ing E. coli tranfection 
plate 
No. 
1 
- 
2 
- 
3 
- 
4 
- 
LM-PCR Generated 
Products, following 
TOP0 Cloning and { 
transfer to pGL3-Basic 
Vector 
Initial Tra~~sfection 
From HeLa ceUs transfected with SRC-IA:Dam, 
cotransfected with expression plasmid for ERa 
and treated with Ethanol 
From HeLa cells trwfected with SRC-1 A:Dam, 
whansfected with expression plasmid for ERa 
and treated with E2 
From HeLa cells transfected with SRC-1 A:Dam, 
cotransfected with expression plasmid for PR-B 
and treated with Ethanol 
From HeLa cells transfected with SRC-I A.Dam, 
cohansfected with expression plasmid for PR-B 
and treated with Progesterone 
/ 
No. of 
Colonies 
4 
60 
6 
63 
Colonies were individually picked from plates 2 (El-E60) and 4 (PI-P60), grown 
overnight in LB Broth containing 100pg/ml Ampicillin which was followed by mini 
prep (Materials and Methods Section 3.2.5.3.) to isolate and purify the pGL3 Basic 
reporter plasmids (Figure 4.28.). 
Individual 
colonies 
picked 
Mini prep - - 
pefformed 
on cultures 
to purify 
plasmid 
DNA 
1 1 1  1  1  1 1  
Further Analysis 
Figure 4.28. Isolation andpreparation ofpGL3 Basic Colonies 
Spectophotometric analysis was performed to analyse DNA concentration and purity 
(Materials and Methods Section 3.2.5.4.). Once the concentration of each plasmid 
solution was identified they were diluted with TE Buffer to give a final concentration of 
0.2pgp1. 
4.2.5. F u n c t i o n a l  Analysis  of Newly C o n s t r u c t e d  Express ion  Vec to rs  
The isolated sequences are now contained in a newly generated pGL3-Basic vector 
library. As the sequences are now in a reporter vector, it is possible to identify if the 
isolated sequences are able to bind ERa or PR-B, and if the addition of WT SRC-IA 
will result in increased or decreased transactivational activity. 
To determine the functionality of the individual sequence contained in the pGL3-Basic 
reporter vectors trans-activation assays were performed using HeLa cells transfected 
with individual pGL3-Basic Luc reporter constructs and wild type hERa or hPR-B 
expression vectors. Four hours post transfection cells were treated with Oestrogen (for 
WT hERa transfected cells), Progesterone (for WT hPR-B transfected cells), EtOH or 
no hormone treatment and cells were incubated for a further 24 hrs. (Materials and 
Methods Section 3.1.1.4.). A luciferase assay (see Section 4.1.1.1. for more details of 
Luciferase assay) was then used to measure the functional activity of each plasmid. 
4.2.5.1. Initial Transactivation Assays 
The initial aim of this procedure was to screen the pGL3-Basic Libraries for plasmids 
for functional genomic inserts. Results obtained are displayed in Figure 4.29.. 
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Figure 4.29. Luciferase Assay results following HeLa cell transfection with 2OOng reporter 
plasmid (El-E23; PI-P24) with cotransfection of Sng hERa expression vector for the reporter 
plasmid library of sequences that associate with hERa and SRC-IA and long hPR-B expression 
vector for the reporter plasmid librav of sequences thai associate with hPR-B. Following a 4 
hr incubation the transfections were treated with either 1 0 ~ 1 ~  ~eslrogen or 1 0 ' ~ ~ r o ~ e s t e r o n e  
for 24 hrs. A subset of reporter plasmids were treated with EtOH and another subset received 
no hormone treatment (NHT) as controls. Graph A displays the results from the hERa 
tramfiction, while Graph B is from hPR-B transfection. 
The function of these initial assays was to separate those reporter plasmids that had 
genomic sequences that indirectly bound to SRC-1A via hERa and Oestrogen or hPR-B 
and Progesterone h m  those that did not (ie: vector or bacterial sequences). 
Theoretically the genomic sequences isolated should respond to hERa and Oestrogen 
or hPR-B and Progesterone if a relevant corresponding transcription start site is present. 
The graphs show no differential increase of transcriptional activity in any of the 
plasmids, this can be seen in both of the graphs displayed above where expression with 
EtOH and Hormone remain similar throughout all of the plasmids. If the reporter 
plasmids had a sequence that had a promoter in it in which' SRC-lA, hERa and 
Oestrogen bound to during the DamID assay then a selective activity would be seen. 
Lack of activity could mean a number of things; that the sequences that are inserted in 
the plasmid do not contain a promoter and therefore Luc could not be transcribed, that 
the sequences have some other effect on transcription or that the sites isolated bind to 
SRC-1A in association with other proteins and not specifically the nuclear receptor and 
steroid that was added (endogenous transcription factors). 
Sequencing was performed to differentiate genomic from non genomic sequences and to 
enable further investigation into these sequences. 
4.2.6.  Sequencing of Reporter Library Inserts 
Sequencing was initially performed on a select number of reporter plasmids from each 
library. It was then determined that the PR-B reporter plasmid library worked at a 
higher efficiency than the ERa reporter plasmid library (i.e. there were more genomic 
sequences in the PR-B library) and so further sequencing analysis focused on the PR-B 
library. 
Sequences were analysed using NCBI BLAST (National Centre for Biotechnology 
Information, Basic Local Alignment Search Tool, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences identified as containing genes that 
encode for Progesterone Receptor, SRC-1A or Globin were excluded as they were 
considered to be non-genomic (sequences not from sites that associated with SRC-1A 
when the library was being constructed). Sequencing was performed on the PR-B 
library until twenty one genomic sequences were obtained (PI, P2, P4, P10, PI 1, P15, 
P19, P20, P21, P22, P23, P24, P26, P27, P32, P33, P36, P37, P38, P40, P45). 
Sequences can be viewed in Appendir IZZ. 
4.2.7. Further  Analysis of  Genomic PR-B Library 
A further trans-activation assay was performed on the twenty one selected PR-B 
plasmids using HeLa cell transfections, co-transfecting 21 different hPR-B reporter 
plasmid sequences and expression vectors for hERa, hPR-B, hGRa simultaneously with 
and without SRC-1A. Four hrs post transfection the cells were treated with a 
combination of Oestrogen, Progesterone and Dexamethasone. pGRE-Elb-Luc was 
used as a positive control to confirm that the cells were able to withstand such a high 
level of continued plasmid dNA and hormone treatment. 
Figure 4.30. and Figure 4.31. display the results. The results show a similar pattern to 
that seen in previous transactivation assays. The control, pGRE-Elb-Luc, displayed a 
15 fold increase in luciferase activity following the addition of the hormone mix; none 
of the reporter plasmids displayed the same, or even a similar result. 
RLU I 
Figure 4.30. Lucifrase assay resulfs. HeLa cells were cotransfected with 5OngpCR3.1 (Emply 
Vector), 2OOng S R C - 1 A : h  PR-B reporter plasmidr and expression vectors for hER~(5ng)~ 
PR-B (long) and GR(l0ng). Four hrs post tranasfection cells were treated with a hormone mix 
O ~ E ~ ~ U ~ W ,  Prog (1U7iy) and ~ e x ( l ~ ~ I l Q  and incubatedfor 24 hrs. 
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Figure 4.31. Lucifrase assay results. HeLa cells were cotransfected with 50ngpCR3.1 SRC- 
IA, 200ng SRC-1A:Dam PR-B reporter plasmids and expression for hERa(5n&, PR-B (1Ong) 
and GR(1Ongl. Four hrs post tranasfction cells were treated with a hormone mix of E2(1U 
9A@, Prog (1U7i@ andDex(lU711Q and incubated for 24 hrs. 
The results of this trans-activation assay proved that the SRC-1A Dam protein did not 
bind to the genome in association with either hERa and Oestrogen or hPR-B and 
Progesterone during library construction. Results also c o n f i i  that the methods used 
were functional as pGRE Elb Luc (a reporter plasmid containing a sequence responsive 
to GR). It was then necessary to go through other channels to decide which direction to 
go to next. 
4.2.8. Bioinformatics 
Genomic sequences were analysed using Bioinformatic Tools to assess .the pattern of 
transcription factor binding motifs in the genomic reporter plasmids. 
4.2.8.1. NCBI Blast 
NCBI Blast (mentioned in Section 4.2.6.) was the initial tool used to identify genomic 
sequences located in the reporter plasmids. This programme matches sequences 
provided with possible locations in the genome. It was also used to identify possible 
genes that flanked the isolated sequences (Table 4.6.). 
class 2A, member 1 
member 8 isoform b 
Table 4.6. Genes thatpant the 3' and5' ends of isolated sequences (PI-P45). 
4.2.8.2. MotifViz: Clover 
Clover (Frith et al, 2004) is an web based bioinformatical programme that searches for 
known transcription factor binding sites within a given set of sequences. This 
programme was used to search for 'ALL JASPER' (all receptor sites) and 'ALL 
Nuclear Receptors' (all nuclear receptor sites) and obtained the data displayed in Table 
4.7. and Table 4.8. A threshold is a filter that is put in so it is possible to filter the 
results so only those with the highest values are displayed. For example a threshold of 
four would only display results that have a score of four or more. Motifs from the ALL 
Jasper Clover search were scored according to the best base pair match; a high score 
reflects a good motif match within the sequences. Scores can be seen in Table 4.9.. 
Analysis of Clover results revealed a number of transcription factor binding motifs that 
could be investigated further. 
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Table 4. Z All Jasper Clover Motifs located with a threshold of 4. 
PI + 
232 bp 
- 
PI0 1 1 + 
201 bp 
- 
P20 + 
298 bp 1- 
- 
P21 + 
231bp 
- 
277 "b+ bp - 
326 p23 bp I 
P24 + 
162bp -
- 
P26 + 
284 bp -1- 
- 
P38 + 
343 bp I
- 
P45 + 
218bp 
- 
Color key: 
Androgen 
CFI-USP 
COUP-TF 
PPARgamma-RXRal 
RORalfa-1 
RORalfa-2 
Table 4.8. AN Nuclear Receptor binding motifs present in the reporter plasmid sequences with 
a threshoId of 4 
Table 4.9. Transcription Factor motifs found in the sequences. The 'Score' indicates the extent 
to which the mohyfound in the sequence matches the actual franscription factor binding motif: 
5.89 being the best matched. 
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4.2.8.3. MEME Suite 
MEME identifies overrepresented motifs in a set of given sequences. MEME found 
three repetitive sequences throughout the genomic DNA library analysed. The one most 
prevalent motif (Motif 1) can be seen in Figure 4.32.. Motif 1 was found in P2, P10, 
PI 1, P23, P26, P37, P40 andP45. 
Figure 4.32. MEME Motif1 found in P2, PIO, PII, P23, P26, P37, P40 and P45 
4.2.8.4. TOMTOM 
Each motif MEME finds overrepresented can then be analysed further using 
TOMTOM. TOMTOM finds known transcription factor binding motifs within the 
overrepresented MEME sequence. The best matched TOMTOM transcription factor 
binding motif for MEME 1 Motif 1 can be seen in Figure 4.33.. 
Figure 4.33. TOMTOM Result from MEME Motif l is  a [ranscription factor binding motif for 
Other binding motifs found from TOMTOM are listed in Table 4.10.. 
Table 4.10. TF Binding Motifs in MEME Results found using TOMTOM 
Bioinformatical data obtained from Clover and MEME was reviewed and further 
investigation focused of transcription factors that appeared in both sets of analysis tools. 
These included SNAIL, COUP-TF I and I1 and RORa. 
4.2.9. F u r t h e r  Trans-Activation Assays t o  Inves t iga te  unknown 
Transc r ip t i on  Fac to r  SRC-1A associat ion 
It was a possibility that SRC-1A Dam associated with nuclear receptors endogenously 
present in the HeLa cells when the library sequences were being selected. It was then 
necessary to identify which nuclear receptors were involved. Based on bioinfonnatical 
data range of nuclear receptors were investigated to assess what SRC-1A associated 
with on the genome. Bioinformatical data on the presence of transcription factor 
binding motifs influenced the choice of transcription factor used in the transactivation 
assays, the MotifViz programme Clover was the main programme used. 
SNAIL was the first transcription factor to be analysed and was chosen due the presence 
of a very high score (good match to transcription factor motifs and present in multiple 
reporter plasmids) in the MotifViz results. The luciferase assay was performed to 
assess the influence of SNAIL on the transactivation of reporter plasmids in the 
presence or absence of SRC-1A (Figure 4.34.). It is apparent from the graph that some 
of the plasmids are responsive, regardless of the transfection, and the reporter plasmids 
that are cotransfected with SNAIL and SRC-1A simultaneously in the transactivation 
assay seem to have a similar or lower response than when transfected with SRC-1A 
alone. Levels of transcription induction are not strong enough to conclude that SNAIL 
associates with, and affects transcription of, the sequences contained in the reporter 
plasmids. 
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Figwe 4.34. Lucifrase assq  results following HeLu cells cotrmfection with 200ng isolated, 
sequenced reporter plasmid (PI-P45) with either; 1: pCR3.1 (emptJ.' vector), 2: pCR3.1 and 
pCMVs SNAIL, 3: pCR3.I andpCR3.1 SRC-ZA or 4: pCMV5 SNAIL andpCR3.1 SRC-IA. 
pGL3 Basic (empty vector) was used as a control. The trmj2cted HeLa cells were then 
incubated for 24hrs. 
The next transcription factor to be analysed for its influence on the reporter plasmid 
library was RORa. This is an orphan nuclear receptor whos motif was seen in four of 
the reporter plasmid inserts (p10, p26, p38 and p45) using the MotifViz programme. 
Figure 4.35. displays the results following transfection of the reporter plasmids (Pl- 
P45) and demonstrated some interesting results. Increased transcriptional activity is 
seen in P2, P20, P37 and P45. Out of these responders, only P45 was seen to have an 
RORa binding site in MotiNiz. Neither bioinformatical programme (MotifViz or 
h4Eh-E) identified the presence of a RORa binding motifs in P2, P20 or P37. Levels of 
transcription in pGL3Basic is low indicating there is a high possibility of the presence 
of motifs in the reporter plasmids that cause transcription induction. However, overall 
levels of gene transcription are still relatively low. 
Figure 4.35. Lucifrase assay results following HeLa cell cofransfection with 200ng reporter 
plasmih (PI-P45) and eitherpCR3.1 orpCR3.1 RORa pGL3 Basic (empty vector) was used 
as a negative control andpGRE-Elb-Luc was wed as apositive conhol. 
Normalized results (or fold induction) can be viewed in Figure 4.36. This further 
confirms the transcriptional activation of P2, P20, P37 and P45 by RORa. 
RORa: Normalized Data 
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Figure 4.36. Normalized results for RORa transfection described in Figure 4.35. 
COUP TF motifs were also seen in the bioinformatical results, from both MotifViz and 
TOMTOM. Results obtained following transfection of COUP TFI or COUP TFII 
expression plasmid (Figure 4.37.) demonstrated that both COUP TFI and I1 induced 
transcription in all of the reporter plasmids to some degree while pGL3 Basic (empty 
vector) transcriptional response remained relatively low. 
Figure 4.37. Lucgerase assay results following cotrmfection of HeLa cells with reporter 
plasmid (PI-P45) and either pCR3.I (empty vector), pCR3.1 COUP TFI or pCR3.1 COUP 
TFII. pGL3 Basic was usedas a negarive control. 
Reporter plasmids p26, p27, p33, p40 and p45 appeared to be the best responders 
following COUP TFI and COUP TFII transfection and all had levels of transcription 
higher than that seen in pG13 Basic. These reporter plasmids were focused on in M e r  
tests. 
Interestingly, p10 and p23 were the only two plasmid sequences seen in MotifViz to 
have COUP TF binding motifs and neither of these displayed a higher level of 
transcription induction with COUP. 
To assess the concentration of COUP TFI and COUP TFII that were required for M e r  
transfections titres were performed. Initial COUP TF transfections were performed 
using 25ng (data not displayed) and long per well. Lower concentrations were used for 
the tittes. The results can be seen in Figure 4.38.. 
RLU COUP TF Titres 
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Figure 4.38. Lucifrase assay results jollowing HeLa cell cotransfection with 200ng reporter 
plasmid and O.IngpCR3.l(empry vector) /pCR3.1 COUP TFI /pCR3.I COUP WII or 0.25ng 
pCR3. I /pCR3.I  COUP TFI / pCR3.1 COUP TF II or IngpCR3.1 /pCR3.1 COUP T%I / 
pCR3. I COUP TFII. pGL3 Basic was used as a negative control. 
Following observation of the results in Figure 4.38. and previous results in Figure 4.36. 
its was decided to use 2ng COUP TFI and COUP TFII in further transfections, a 
concentration not tested, however, lng appeared to provide good specific results and it 
was suspected that 2ng would retain the specificity and provide additional activation 
capabilities. 
COUP TF is an orphan nuclear receptor trauscription factor. COUP TF has been seen 
previously to bind to an intermediate and not directly to the genome. It is this capability 
of COUP TF that led to investigations to determine if COUP TF was binding to an 
intermediate transcription factor. RORa in the presence and absence of SRC-1A was 
investigated to see if it cooperated with COUP TFI or I1 to regulate transcription 
(Figure 4.39.). 
The results displayed are normalized fold inductions, obtained by dividing the reporter 
plasmid result by that obtained using an empty pGL3 Basic vector which provides a 
normalized result and then dividing the nornaked result by the normalized result 
obtained from the empty pCR3.1 vector (expression plasmid blank). 
PCW.l • RORa RORa (L SRCIA 
Figure 4.39. Lucifeme arsay results following H e h  cell cotransfection of reporter plosmidr 
(P26, P27, P33, P40, P45) with pCR3.l / COUP TFI / COUP TFII followed by pCR3.1 / 
pCR3.1 andpCR3.I RORa /pCR3.1 RORa andpCRf.1 SRC-IA. pGL3 Basic war wed ar a 
negalive control, and to enable normalked values to be calculated. Statistical malysis wos 
perfonneed by comparing HeLa cell trmfection withpCR3.1 to that with COUP TFI or COUP 
TFII and RORa and SRC-IA. *p<0.05, **p<0.01 negative conaolpCR3.1 compared to RORa 
& SRCIA co transfected with either COUP TFZ or COUP TFII 
The results indicated that COUP TFI and 11, but particularly COUP TFI, were 
displaying an interaction with RORa and SRC-1A to induce gene transcription. This 
was particularly evident with reporter plasmid P45, where both COUP TFI and COUP 
TFII interacted with RORa and SRC-1A to significantly induce gene transcription 
(p<0.01) (Figure 4.39). There appears to be cooperational activity between COUP 
TFIICOUP TFII, RORa and SRC-1A. Certain COUP TF responders (P26 and P45) 
show greater transactivation. Additionally, the results confirm that RORa alone is 
unable to induce gene transcription. 
The final set of transactivation assays performed functioned to assess a variety of 
concentrations of COUP TF I, COUP TF 11, RORa and SRC-1A. The results can be 
seen in Figure 4.40., with normalized values in Figure 4.41.). 
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Figure 4.40. Luciferare results following HeLa cell cotransfection with 200ng COUP 
responsive reporter with transcription fhctorx as described above. pGL3 Basic war w e d  as a 
negative control. 
The results demonstrate that, particularly in P27 and P45, these transcription factors 
work co-operatively in a concentration dependant and site specific manner. 
Figure 4.41. Normalized values for Figure 4.40. (Colour Key crm be viewed in Figure 4.40.) 
Figure 4.42. is a simplified version and can summarize the results obtained from this 
transactivation assay. The pGL3-Basic reporter plasmid chosen to demonstrate the 
results is P45. 
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Figure 4.42. Simplified resultsfrom Graph E in Figure 4.40. using long COUP TFVII. 
It can be seen from this graph that the empty vector provides no response, this is the 
negative control. COUP TF I, COUP TF I1 and RORa did not cause a large increase in 
transcription when transfected alone, while SRC-lA, when co-transfected with RORa, 
displayed a slight increase in transcription. However, when COUP TF I was co- 
transfected with RORa it increased the transcriptional response, when compared to 
COUP TF I alone, by greater than 10 fold. 
Interestingly, when COUP TF I was co-transfected with both RORa and SRC-1A it 
elicited the greatest response, indicating that there is some form of cooperativity 
between the three molecules. This is in contrast to COUP TFII which demonstrated 
only modest transcriptional activity when cotransfected with RORa and SRC-1 A. 
4.2.10. Bioinformatical Investigation of COUP TFI, RORa and SRC- 
1A Responsive Sequences 
Bioinformatical analysis was performed on sequences P26, P27, P33, P40 and P45 to 
ascertain any commonality between these COUP TFI, RORa and SRC-1A responsive 
sequences. The analysis focused on the MEME suite, using both MEME and 
TOMTOM. These are described in more detain in Section 4.2.8. 
Meme analysis presented with three motifs found in the sequences. Motif 1 (Figure 
4.43.) is a motif found in all five sequences. 
Figure 4.43. MoafI 
TOMTOM analysis of Motif 1 revealed just one transcription factor biding motif 
(Figure 4.44.), Chop-cEBP. 
Figure 4.44. Transcription facor binding site for ChopcEBP 
Figure 4.45. Motif2 found in P26, P27, P33, P40 and P45 
TOMTOM found no transcription factor binding sites in Motif 2. Motif 3 was found in 
sequences P26, P33, P40 and P45 (Figure 4.46.). 
Figwe 4.46 Mohy3, present in P26, P33, P4O and P4.5 
TOM TOM isolated a transcription factor binding site for Broad Complex 1 in Motif 3 
(Figure 4.47.). 
Figure 4.47. TOMTOM results from Mohy 3 revealed transcription factor binding site for 
Broad-complex I 
Further analysis is required on the selected reporter plasmid sequences however they 
provide interesting insight into possible cooperation between COUP TFI, RORa and 
SRC-1A. 
4.3. Locating Transcription Start Sites in Reporter Plasmids 
GeneRacer technique (Materials and Methods 3.2.7.) was used to attempt to locate the 
transcription start site in reporter plasmid sequences. This method proved unsuccessful 
in locating the transcription start sites of the COUP TF responsive reporter plasmids or 
reporter plasmids from the ERE library. Sequences obtained can be viewed in 
APPENDIX IV (TSSl to 6 from trial 1, TSS7 to 12 h r n  trial 2). It appeared that the 
LucRev primer was binding non-specifically to endogenous DNA and not to reporter 
plasmid DNA. Attempted optimization of this method still proved unsuccessful. A 
failure to produce PCR products can be seen in Figure 4.4&. 
Primer Dimer 
Figure 4.48. 1% Agarose Gel electrophoresis of Gene Racer transcrtiption start site PCR 
products. Lane I contains molecular weighf marker. Lane 2 contains PCRproducts. No PCR 
products seen, only primer dimers. 
Initially, the aim of this project was to investigate a reporter library of oestrogen 
responsive elements (EREs) which constructed by Jennings (Jennings, 2009) using 
DamID technology. Investigations on this library were to focus on the identification of 
SERM responders and perform further tests to analyse the isolated reporters, including 
assessing the ability of the isolated sequences to mediate transcription,in conjunction 
with other nuclear receptors and coactivators and to perform ERa mutation analysis. 
The purpose of this was to gain a deeper understanding into the role of Tamoxifen as an 
oestrogen antagonist. 
SRC-3, a well documented coactivator and a member of the SRC family of coactivators, 
appeared to repress SERM responsive reporter activity and it was decided to investigate 
the influence of SRC family members further. This body of work aimed to isolate 
sequences from the genome that associate with SRC-1A:Dam and SRC-3 in association 
with either ligand bound oestrogen or progesterone receptors using DamID technology, 
the same technology that was used to construct the ERE library. Following construction 
of the library, further aims included the use of bioinformatics to identify DNA cis 
elements, repetitive sequences and overrepresented transcription factor binding sites in 
these isolated sequences and to assess the ability of the isolated sequences to mediate 
transcription in conjunction with other nuclear receptors and coactivators to establish 
potential novel interactions 
An additional aim, encompassing reporter plasmids from both the ERE, SRC-1A and 
SRC-3 libraries, was to attempt to identify the location of transcription start sites in 
selected isolated reporter plasmid sequences. The ability to obtain this information 
would enable a deeper understanding of the binding sites that a variety of transcription 
factors of transcriptional coregulators associate with. 
5.1. Oestrogen Responsive Element (ERE) Reporter Library 
Investigation 
This portion of the investigations focused on the investigation of SERM responsive 
reporter plasmid sequences, comparing the responses of these sequences to that of 
oestrogen responsive sequences. 
Transfections were performed on the ERE library to identify SERM responsive and 
oestrogen responsive reporter plasmids. Four were selected for further investigations 
following sequencing to ensure the plasmid inserts were of genomic origin. E5p and 
T4p were selected as SERM responsive plasmids, while V17 and El2  were selected as 
oestrogen responsive reporter plasmids to use as a comparison during the investigations. 
Transfections were performed on these reporter plasmids to assess the ERa binding site 
requirements of the SERM responsive plamsids and the oestrogen responsive plasmids. 
These transfections were performed to determine if the differential response of the 
oestrogen and SERM responsive plarnsids was attributed to the SERMs interacting with 
a different area of the ERa molecule perhaps causing ERa to bind in a different way to 
the DNA. It is known that when tamoxifen binds to ERa it causes a different 
conformational change to those that occur when oestrogen binds. The conformational 
change that occurs when Tamoxifen binds repositions Helix 12 of the ERa molecule 
and prevents the binding of coactivators (Shiau et al, 1998), preventing AF-2 activation. 
Therefore Tamoxifen functions as an ERa antagonist to genes which rely on the AF-2 
region for ER-mediated transcription (Ring and Dowsett, 2004). 
It is known that there are three major domains (DNA binding domain, AF-2 domain and 
AF-I domain) required in order for effective ERa meditated transcription to occur. A 
DNA Binding Domain mutant, an AF-2 defective mutant and an AF-1 defective mutant 
were used during the transfections and cells were treated with EtOH, oestrogen, 
tamoxifen and raloxifene. The results (Figure 4.8.) revealed that all three domains were 
required for effective ERa meditated transcription in both subsets of reporter plasmids. 
This contradicts the theory that Tamoxifen does not require the AF-2 domain to activate 
AF-2 independent genes and suggests that in these reporter plasmids there is an 
alterative mechanism operating. 
Following ERa mutant analysis of the SERM responsive plasmids, further investigation 
was performed to assess their response to transfections with hERa alone and hERa with 
either SNAIL, PAX4 or SRC-3. These transfections were then treated with EtOH, 
oestrogen, tamoxifen or raloxifene. 
The results revealed interesting results. The results obtained from transfections with 
SNAIL and PAX4 were as expected and both have been previously demonstrated to act 
as transcriptional repressors (Hemavathy et al, 2000; Nieto, 2002; Smith et al, 1999) 
and the levels of transcription from both transfections were lower than that of the ERa 
transfections (for all treatments, EtOH, oestrogen, tamoxifen and raloxifene). However, 
the result obtained from transfection with SRC-3 revealed SRC-3 also acted as a 
repressor when it associated with the sequences contained in the reporter plasmids E5p 
and T4p. This result was surprising as SRC-3 has only previously been reported to act 
as a transcriptional coactivator (Wu et al, 2002, 2004, 2007; Feng et al, 2006; Naeem et 
al, 2007; Chen et al, 1999). Oestrogen responsive reporter plasmids E l 2  and V17 were 
then used to assess their responsiveness to SRC-3. These transfections produced a 
'typical' response of a coactivator, producing approximately a 3 fold increased 
transcriptional response with the addition of SRC-3. 
The interesting results obtained using SRC-3 led the project to further investigate the 
family of SRC coactivators. 
5.2. SRC-1A and SRC-3 Library Construction and 
Investigation 
SRC-1A and SRC-3 are two of the members of the SRC family of coactivators that 
were focused on in this section. The major aim of this section was to construct four 
reporter plasmid libraries (using DamID technology), containing sequences that 
interacted with SRC-1A or SRC-3 via either ERa and oestrogen or PR-B and 
progesterone. Construction of these libraries would enable further analysis of the 
libraries to be performed to gain a greater understanding in the relationship between the 
effect of the coactivator molecules SRC-1A and SRC-3 and oestrogen and progesterone 
receptor mediated transcription. Additionally, if successful, it would enable a new 
method for investigating a broad range of coactivators and reveal more about the 
sequences that these molecules influence. 
The primary step was to construct SRC-1A: and SRC-3:Dam fusion plasmids. This 
process used a pCR3.1 SRC-1A:Luc plasmid or a pCR3.1 SRC-3:Luc plasmid, whereby 
the Luc gene was excised from the plasmid and replaced with a Dam gene, which was 
inserted directly downstream of the SRC-IA or SRC-3 gene, forming a fusion gene. 
The Dam gene was isolated from E.Coli DNA and amplified using PCR. 
Results of the Luc excision step revealed successful removal of the Luc fragment from 
the pCR3.1 SRC-1 A:Luc plasmid, however, removal of the Luc fragment from pCR3.1 
SRC-3 appeared to be unsuccessful. Protocol was continued however for both 
plasmids, the Luc fragment was removed and discarded and a ligation reaction was 
performed to ligate the amplified Dam gene to the pCR3.1 SRC-1A and pCR3.1 SRC-3 
plasmids and transformed to chemically competent E.Coli cells and ncubated on agar 
containing ampicillin overnight. Controls were also transfected which involved 
transfecting the pCR3.1 SRC-1A or pCR3.1 SRC-3 plasmids without a Luc or Dam 
gene. The results demonstrated successful excision of the Luc gene from the pCR3.1 
SRC-1A:Luc plasmid as there was no growth on the control agar due the the pCR3.1 
SRC-1A being in linear form and thus unable to express its ampicillin resistant gene. 
pCR3.1 SRC-1A:Dam therefore was successfully constructed. 
On the other hand, a high number of colonies observed on the pCR3.1 SRC-3 control 
plate indicated that the Luc excision step was unsuccessful, as the control plasmid was 
able to express the ampicillin resistant gene. 
pCR3.1 SRC-1A:Dam and pCR3.1 SRC-3:Dam colonies were picked and purified for 
further analysis. 
Further analysis confirmed the successful construction of pCR3.1 SRC-1A:Dam and the 
unsuccessful construction of pCR3.1 SRC-3:Dam. Sequence analysis confirmed the 
directionality of the Dam gene in the pCR3.1 SRC-1A:Dam plasmid. 
Due to difficulties in constructing the pCR3.1 SRC-3:Dam expression plasmid the 
attempts to do so were suspended. However, as construction of the pCR3.1 SRC- 
1A:Dam was successful, this SRC-1A:Dam fusion plasmid was used to construct a 
genomic library containing sequences that the SRC-1A:Dam fusion protein interact 
indirectly with via either hERa and oestrogen or hPR-B and progesterone. 
Once the pCR3.1 SRC-1A:Dam plasmid was constructed and processed DamID 
protocol could proceed. 
The DamID protocol involved in vivo targeted methylation of GATC sequences 
adjacent to the indirect binding sites of the SRC-1A:Dam fusion protein. This was 
achieved by cotransfecting HeLa cells with the pCR3.1 SRC-1A:Dam plasmid along 
with expression plasmids for either hERa or hPR-B, followed by treatment with the 
respective hormones (either oestrogen, progesterone or EtOH). 
Following the transfection protocol genomic DNA was isolated from the transfected 
HeLa cells and DpnI digestion was performed to enable isolation and amplification of 
methylated sequences. 
LM-PCR amplification was performed and the resultant sequences were analysed to 
ensure a variety of sequences were amplified (successful LM-PCR products will appear 
as a smear on agarose gel). Smears were present for all four LM-PCR reactions, 
however the sequences obtained using the receptors plus EtOH contained more DNA 
than that obtained from receptors plus hormone. This could indicate that SRC-1A:Dam 
preferentially binds indirectly to DNA via unbound receptor, however this has not been 
previously reported and in fact the action of SRC-I has been found to be ligand 
dependant (Onate et al, 1995). However, the appearance that there is more LM-PCR 
product in the lanes that did not contain hormone does not indicate that SRC-1A has the 
ability to activate promoter elements contained in these sequences, it merely suggests 
that SRC-1 A has the ability to bind to unligand bound ERa and PR-B. 
Protocol was adjusted, using a reduced amount of LM-PCR product and as a result of 
this optimization the TOPO cloning procedure obtained approximately 2000 colonies. 
Rather than perform restriction digestions on this TOPO library, colonies containing 
sequences obtained with ERa with oestrogen and PR-B and progesterone were directly 
transferred to an expression vector library. 
The expression vector used was pGL3-Basic, which was adapted to be gateway 
compatible by Jennings (Jennings, 2009) and enables functional analysis of the isolated 
sequences. This vector contains a Luc gene located downstream of the sequence insert 
site. Additionally, it does not contain a promoter sequence, thereby the sequence insert 
can be investigated to assess for promoter activity. 
Isolated sequences were transferred from the TOPO vector to the pGL3-Basic vector 
using gateway cloning technology. 
The pGL3-Basic reporter library was fuctionally tested using HeLa cell transfections 
followed by the luciferase assay. 
This protocol was used initially to screen plasmids for genomic inserts. In theory, if the 
plasmids contained sequences that bound, indirectly, to the SRC-1A:Dam fusion protein 
via the receptor (ERa or PR-B) and hormone (oestrogen or progesterone) and contains a 
promoter element, following HeLa cell transfections with the relevant receptor and 
hormone, the luciferase assay will be able to detect the promoter activity. 
The results from these transactivation assays were unsuccessful as all reporter plasmids 
showed no response. Lack of response could mean a number of things; that the 
sequences that are inserted in the plasmid do not contain a promoter and therefore Luc 
could not be transcribed, that the sequences have some other effect on gene expression 
or that the sites isolated bind to SRC-1A in association with other proteins and not 
specifically the nuclear receptor and hormone that was added (endogenous transcription 
factors). 
In total there were approximately 65 reporter plasmids in each library. Sequencing was 
performed on 5 plasmids from each library to determine which sequence inserts are 
from genomic origin (using NCBI Blast) and which are bacterial or vector sequences. 
lnitial sequencing determined that the library obtained from pCR3.1 SRC- 1 A:Dam 
cotransfection with PR-B followed by treatment with progesterone contained a higher 
percentage of sequences of genomic origin than the library obtained from pCR3.1 SRC- 
1A:Dam cotransfection with ERa followed by treatment with oestrogen. As neither of 
the library sequence inserts appeared to respond to the receptor and hormone (Figure 
4.29.) it was constructed with further analysis was performed on the PR-B library as it 
contained a higher amount of genomic inserts. The first 21 plasmids that contained 
genomic inserts from the SRC-1A:Dam PR-B progesterone library were used for further 
analysis. 
Additionally, NCBI Blast revealed genes located upstream and downstream the isolated 
sequences. Providing information about the genes possibly controlled by the isolated 
sequences provides additional information regarding on the isolated sequences and their 
function in the genome. 
The initial .assays performed on these plasmids involved two transactivation assays. 
The first was a cotransfection of HeLa cells with the said plasmids and expression 
vectors for SRC-IA, ERa, PR-B and GR. The cells were then simultaneously treated 
with oestrogen, progesterone and dexamethasone. The second transactivation was set 
up the same except the SRC-IA expression vector was substituted with pCR3.1, the 
empty expression vector. The theory behind this was to assess if any of these ligand 
bound receptors interacted with the plasmid inserts and if SRC-1A had any affect on 
their action on the sequences. pGRE/El bLuc, a reporter plasmid containing a sequence 
responsive to GR was used as a control to ensure the procedure was working. The 
control responded to the transactivation assay as expected, with the addition of SRC-1A 
to the transfection the gene expression of the control increased by 13 fold. However the 
test plasmids showed no significant response to either transactivation assay. A 
significant response would be that similar to the control, in that there is a response to the 
addition of hormone and not to the addition of EtOH. The test plasmids showed 
approximately equal response to hormone and to EtOH indicating the isolated 
sequences do not interact with ERa, PR-B or GR. 
It was a possibility that during DamID step whereby GATC methylation occurred SRC- 
1A:Dam indirectly bound to the DNA via proteins endogenously present in the HeLa 
cells. A bioinformatical approach was then taken to attempt to identify possible binding 
sites within the isolated sequences. Two programmes were used; MotifViz and The 
MEME Suite. Motifviz (Fu et al, 2004) identifies overrepresented regulatory motifs 
(i.e.: transcription factor binding sites) in a given set of sequences while MEME does 
not locate transcription factor binding sites but merely identifies over-represented 
sequence motifs in a set of given sequences (Bailey and Elkan, 2004). A second part of 
the MEME Suite is a programme, known as TOMTOM, which is used to then identify 
transcription factor binding sites within the overrepresented sequence motifs identified 
by the MEME programme. 
Of the transcription factor binding motifs identified by the above mentioned 
programmes, the transcription factors SNAIL, RORa and COUP TFI & I1 were the ones 
most prevalent and these were focused on for further investigations. 
Transactivation assays with SNAIL and SRC-IA and with RORa revealed no 
significant results. 
Transactivation assays with COUP T F I  (chicken ovalbumin upstream promoter 
transcription factor I) and COUP TFII did find 5 responsive plasmids. However, 
plasmids that responded to COUP TFI and COUP TFII did not, according to 
bioinformatical results, contain COUP binding motifs. 
COUP TFI and COUP TFII belong to the steroid receptor superfamily (Wang et al, 
1989). Currently, no specific ligands for these transcription factors have been identified 
and thus they are classed as orphan nuclear receptors. 
COUP-TF is one of the best characterized orphan nuclear receptors. It was first 
identified as a homodimer, found to bind to a direct repeat regulatory element, 
containing an imperfect direct repeat of AGGTCA, in the chicken ovalbumin promoter 
(Pastorcic et al, 1986; Sagarni et al, 1986; Wang et al, 1989). In mammals two genes 
have now been identified: COUP TFIlEAR3 and COUP TFIIIARP-1 (Miyajima et al, 
1988; Wang et al, 1991; Ladias et al, 1991). COUP TFI and COUP TFII are closely 
related transcription factors however each factor has the ability to generate its own 
distinct expression profile during mammalian development (Qiu et al, 1994). 
Both COUP TF I and I1 are expressed in many human tissues, being involved in many 
biological regulation processes such as neurogenesis, organogenesis, determination of 
cell fate and metabolic homeostasis (Tsai et al, 1994; Ladias and Karathanasis; 1991; 
Wang et al, 1991; Mangeldorf et al, 1995; Ritchie et al, 1990; Qui et al, 1994; Kastner 
et al, 1995; Park et al, 2003) 
COUP TF contains a 66-amino acis region which contains two conserved Zinc finger 
motifs, this is the DBD region; COUP TF I and I1 are identical but for one amino acid 
difference within the DBD which is a conservative change from Ser to Thr (Miyajima et 
al, 1988; Wang et al, 1989). 
COUP-TF has been seen to act as a transcriptional activator and repressor. It was 
initially identified as a transcriptional activator (Sagami et al, 1986) and further to this 
has been seen to demonstrate transrepression capabilities (Cooney et al, 1992; Tran et 
al, 1992; Park et al, 2003; Achatz et al, 1997; Leng et al, 1996), via DNA-independent 
heterodimerization of the ligand binding domain COUP TFs with other nuclear 
receptors, for example thyroid hormone receptors, retinoic acid receptors and retinoid x 
receptors (Leng et al, 1996; Kruse et al, 2008). 
One possible mechanism of action hypothesised by Leng et al, suggests that the 
heterodimerization of the COUP TFs with the nuclear receptor LBD results in either 
suppression of the AF regions in these receptors or reduction of the nuclear receptors 
ligand binding ability (Leng et al, 1996). 
The ability of COUP TF to heterodimerize to other nuclear receptors raised a number of 
questions relating to the results already found. The fact that none of the COUP TF 
responsive plasmids contained a known COUP TF binding sites (results from clover 
bioinformatical approach) lead to the question: perhaps COUP TF is interacting through 
another nuclear receptor and is operating via a novel binding site? 
Initially, transactivation assays were performed to reduce background (non specific 
response from the empty vector) obtained in the plasmids response to COUP TFI and 
COUP TF 11. It was then determined from these titre assays that 2ng was the optimal 
amount of COUP TFI and COUP TFII to use in further investigations. 
As the affects of RORa on the reporter plasmids was studied previous to COUP TF, and 
COUP TF has been demonstrated to have RAR (retinoic acid receptor) interaction 
capabilities (Kliewer et al, 1992), RORa was the first investigated. 
HeLa cell transfections were performed, cotransfecting reporter plasmids with COUP 
TFI or COUP TFII (or empty expression vector, pCR3.1) and then each of these groups 
with either expression vectors for RORa alone or with expression vectors for RORa and 
SRC-1A. pGL3 Basic was used as a control. The results demonstrated that the COUP 
TF responsive plasmids did respond more favorably to COUP TF, RORa and SRC-IA. 
Figure 4.43. demonstrates a summary of these results obtained, this response was seen 
in P27 and P45 in particular. From this figure it can be seen that there is no response 
with the empty vector transfection alone (pGL3 Basic; V). Results from transfections 
with reporter plasmid with either COUP TFI, COUP TFII or RORa showed a slight 
response, but when compared to further responses it was negligible. Cotransfection 
reporter plasmid, RORa and SRC-1A showed a response approximately double to that 
seen in RORa alone. Cotransfection of reporter plasmid, COUP TFI and RORa showed 
a dramatic response, as did COUP TFI and RORa although this was not as significant. 
When SRC-1A was added to these transfections the response increased further. 
It is clear from these results that P27 and P45 contain binding sites that facilitate some 
form of cooperational binding between COUP TFI and RORa, whose relationship with 
DNA is enhanced with the addition of SRC-IA. 
As, in this situation, the association of COUP TFI with RORa results in transcriptional 
acitivaiton it suggests that COUP TF is not associating with the ligand binding domain 
of RORa, as previous studies have found the binding of COUP TF to the ligand binding 
domain of other nuclear receptors (thyroid hormone receptors, retinoic acid receptors 
and retinoid x receptors) (Leng et al, 1996) to result in transcriptional repression. 
Rather than forming a COUP TF1:RORa heterodimer, the two molecules could bind to a 
novel binding motif within these sequences at separate times and cany out separate 
fhctions. The action of each of these molecule alone may not be sufficient to induce 
transcription, however when the actions of each of the molecules are combined 
transcription is activated. The role of SRC-IA may involve mediation of the 
association of these molecules to the DNA, acting perhaps as a 'crane', moving one of 
the receptors in, enabling it to cany out its actions, removing it and bringing in the 
second. 
However, these are only hypothesized models of how these factors are interacting and 
fiuther work would have to be carried out to assess the exact mechanism of how these 
nuclear receptors are functioning to activate transcription and what the role of SRC-IA 
has in this mechanism. 
Additionally, in order for this to have occurred during the construction of the library 
RORa and COUP TF would have to be endogenously present in the HeLa cells used 
during these steps, as the SRC-1A:Darn would have had to preferentially bind to the 
COUP-TFs and RORa than to the ligand bind progesterone receptor. 
RORa, COUP TFI and COUP TFII can be found in cancerous cervical cells, which is 
the origin of HeLa cells (www.genecards.com). This confirms that cancerous cervical 
cells have the ability to produce all three of the orphan nuclear receptors, therefore there 
is the possibility that instead of SRC-IA Dam binding to the respective hormone 
receptor which attached to its ligand (hERa and E2 or hPR-B and Progesterone), it 
therefore seemed that SRC-1A Dam had a higher affinity for COUP TF or RORa in the 
conditions provided than it had for ERa or PR-B. 
The five COUP TF responsive plasmids were bioinformaticaly analyzed using the 
MEME Suite. TOMTOM revealed no COUP-TF or RORa binding sites in the 
sequences. 
5.3. Locating Transcrition Start Sites 
It was attempted to locate the transcription start sites of a selection of reporter plasmids 
from both the ERE reporter library and the SRC-IA reporter library. This was. 
unsuccessful despite optimisation of the techniques used. 
The identification of transcription start sites within the reporter plasmid sequences 
would have enabled further investigation into the effect of the transcription start site to 
transcriptional activation. 
Further optimisation would be required to enable this technique to be used to investigate 
transcription start sites. 
5.4. Future Work 
Further work still needs to be performed on the activity of SRC-3 as a transcriptional 
repressor in the SERM responsive plasmids identified. 
The role of DamID to investigate this further was unsuccessful and once a SRC-3:Dam 
fusion plasmid has been constructed this may be an option to identify where SRC-3 
association sites on the genome. It would prove interesting to identify sites in the 
genome where SRC-3 binds via Tamoxifen bound ERa, and to attempt to locate more 
SERM responsive sequences. 
The DamID technique did not work as expected but with alternative methods the 
problems encountered could be avoided. Primarily the method did not produce a library 
of sequences that bound to either of the ligand bound receptors that were being 
investigated. However it did result in a selection of sequences that were isolated due to 
SRC-1A:Darn binding via endogenous transcription factors in HeLa cells, of which it 
was identified that COUP TF and RORa were just two that a selection of the reporter 
plasmids responded to. Further investigations, and perhaps trial and error, would be 
required to identify the endogenous transcription factors that the remaining sequences 
were isolated by. 
Additionally, an interesting study would involve deducing the mechanism of action of 
the cooperation between COUP TFI, RORa and SRC-IA to activate gene transcription. 
Co-IP (Co Immunoprecipitation) followed by western blots could be used to identify if 
there is and heterodimerization occurring between COUP TFI and RORa or not and the 
results from those investigation would influence further work performed. 
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Machines 
Agitating Incubator 37OC (for LB Broth Cultures) New Brunswick Scientific 
Incubator 37OC with 5% COz (for Cell Line Cultures) Nuaire 
Incubator 37OC (for Agar Plates) Lab-Line 
Water Bath 37OC Fisher Scientific 
AccuBlock Digital Dry Bath (42OC170 OC) Labnet 
Mini Centrifuge 
Centrifuge (Avanti 5-25) 
Microwave 
ThermoIEC 
Beckman Coulter 
GE Appliances 
Spectrophotometer Eppendorf (Biophotometer) 
UV Trans-illuminator (photographic) 
(Image Master VDS-CL) 
Amersham Biosciences 
UV Trans-illuminator (non-photographic) Fisher Scientific 
(Fisher Biotech: 3 12 nm Variable Intensity Trans-illuminator FBTIV-614) 
PCR Engine MJ Research 
Cell Plate Rocker CMS 
Luciferase Microplate Luminometer (Centro LB 960) Berthold Technologies 
Laminar Flow Hood (Biogard Hood) 
Axiavert 25 Inverted Microscope 
Baker Company Inc. 
Zeiss 
Equipment 
Pipetttes 
Pipette Tips 
Ependorf Tubes 
14ml Polypropylene Round-Bottom Tube 
Stripette Pipettes 
Ultra High Performance Centrifuge Tubes 15ml 
Ultra High Performance Centrifuge Tubes 45ml 
Vortex 
Powder Free Latex Examination Gloves 
PCR Tubes 
6 Well Plate Culture Plate 
24 Well Cell Culture Plate 
96 Well Plate 
Eppendorf Research 
Coming Incorporated 
Sarstedt 
Falcon 
Costar 
VWR 
VWR 
Scientific Industries 
VWR 
Discovery Scientific 
Falcon 
Falcon 
Greiner Bio-One 
Reagents 
1 OX Accuprime Buffer I Invitrogen 
200 mM Tris-HC1 (pH 8.4), 500 mM KCI, 15 mM MgC12,2 mM dGTP, 2 mM dATP, 2 
rnM dTTP, 2 mM dCTP, thermostable AccuPrimeTM protein, 10% glycerol 
NEB Buffer 3 New England Biolabs 
100mM NaC1,50mM Tris-HCI, 1OmM MgC12, 1mM Dithiothreitol 
NEB Buffer 4 New England Biolabs 
50mM Potassium acetate; 20mM Tris-acetate, lOmM Magnesium Acetate, 1 
1 mM Dithiothreitol 
Prepared Solutions 
TEN Buffer (pH 8.0) 
20p1 Tris (pH8.0), 500p1 EDTA (pH8.0), 15ml NaCI. 
TAE Buffer 
50X TAE Buffer 
242 g Tris, 57.lml Acetic Acid, 100ml 0.5M EDTA pH8.0 
(Final concentrations of 2M Tris, 2M Acetic Acid, 0.05M EDTA pH8.0 ) 
Dilute 1 5 0  dH20 to get working solution. 
40 mM Tris, 20 mM NaOAc, 1 mM EDTA, pH 8 
HeLa Cell Lysis Buffer 
O.lml lOmM Tris pH 8.0, 0.2ml lOmM EDTA, 0.5ml SDS (0.5%), 9.2ml dH2O 
Prior to use 25 .7~1  Proteinase K (200pgIml) was added to 2.5mls of the stock sol'ution. 
TE Buffer pH 8.0 
1 OX TE Buffer 
5 ml I M Tris-HC1, pH 8.0, 1 ml 0,5 M EDTA, pH 8.0, 494 ml of water 
(Final concentrations of 10 mM Tris-HC1, 1 mM EDTA) 
Luciferase Lysis Buffer 
25 mM TRIS pH 8.0, 150 mM NaC1, 0.5% Triton X-100, 1 mM EDTA, 5% Glycerol 
and 1M DTT (DTT added immediately prior to use) 
Agarose Gel (I %) 
25ml 1% Agarose (Img Ultrapure Agarose powder in 100ml TAE Buffer, dissolved in 
microwave) and 2.5 pg Ethidium Bromide 
MetaPhor Agarose Gel (3%) 
25ml3% MetaPhor Agarose (3mg MetaPhor Agarose powder (Carnbrex) in 100ml TAE 
Buffer, dissolved in microwave) add 2.5 pg Ethidium Bromide 
Ampicillin Agar (50 pg//rl) 
16g LB Agar (Lennox L Agar, Invitrogen) 
500mls dH2O 
250 pl Ampicillin (from 100 mglml Stock Solution) 
Spectinomycin Agar (50 pg/pl) 
16g LB Agar (Lennox L Agar, Invitrogen) 
500mls dHzO 
250 p1 Spectinomycin (from 100 mgtml Stock Solution) 
Ampicillin LB Broth (1 00 pUml) 
12g LB Broth Base ( Lennox L Broth Base, Invitrogen) 
600mls dH20 
600 p1 Ampicillin (from 100 mgtml Stock Solution) 
Spectinomycin LB Broth (100 pL/ml) 
12g LB Broth Base (Lennox L Broth Base, Invitrogen) 
600mls dHzO 
600 p1 Spectinomycin (from 100 mg/ml Stock Solution) 
Double Stranded AdR (drAdR) 5OmM 
Dissolve IOOmM each of AdRt and AdRb in dH20. Combine equal volumes of AdRt 
(100 mM) and AdRb (100 mM). Mix and place in a tightly closed tube in a beaker with 
water of about 90°C. Let the beaker cool to room temperature (20°C), to enable the 
adaptors to anneal slowly. Aliquots were stored at -20°C. 
APPENDIX I1 
Trans-Activation Assays 
8 
9 
10 
P26,27,33,40,45 
P26,27,33,40,45 
P26,27,33,40,45 
long COUP-TF II 
lOng RORa 
2ng pCR3.1 or COUP TFI or COUP TF 11 
And 
SOngpCR3.1 or lOngRORaorSongpCR3.1 SRClA 
~ n g p ~ ~ 3 . 1  ~ ~ C O U P T F ~ ~ C O U P T F ~  
And 
5Ong pCR3.1 or ZSng RORa with 25ng pCR3.1 or 25ng 
RORa with 25ng pCR3.1 SRC lA 
O.lngpCR3.1 COUPTFI 
COUP TF I1 
0.25ng pCR3.1 COUP TF 1 
COUP TF I1 
Ing pCR3.1 COUP TF I 
COUP TF I1 
pG13 basic control 
pGl3 basic control 
pGU Basic 
* Transfection Number 4. 
Plate was divided into 3 groups 
I Reporter 1 Receptors I Additional Hormone Control 
I I I I I 
Group 3 1 Yes 
Group 1 1 Yes 
1 I I I I 
Yes 
Group 2 Yes Yes 
50 ng pCR3.1 
50ng pCR3.1 SRC 1A 
Hormone Premix Substitute Hormone for EtOH IO-'M 
Hormone Premix Substitute Hormone for EtOH 1 0 . ' ~  
Control 
Substitute Ral for lW7M EtOH for each hansfection 
2OOng pGL3-Basic and pERE-E lb-LUC 
Substitute Hormone for 10-'M EtOH for each eansfection 
Substitute Hormone for lW7M EtOH for each transfection 
pERE-El b-LUC as positive conhol. 
1 
2 
3 
4 
5 
6 
7 
Reporter Libruy 
ERa DAM (28) 
ERa - DAM 
20 h m  
EtOH, E2 and 4HT 
SERM induction reporters 
(hm E2 and 4HT Libraries) 
ESP, T4p, El0 
ESP, T4p, El0 
ESP, T4p, El0 
ESP, T4p, El0 
Expression Plasmid 
2.5ng hERa 
5ng hERa 
5ng hERa (in all transfections) 
25ng pCR3.1 
25ng SNAIL 
25ng SRC-3 
5 ng pCR3.1 
5ng pCR3.1 hERa 
5ngpCR3.1 hERa& long SNAIL 
sng p c ~ 3 . 1  ~ E R U  & long P A X ~  
pCR3.1 hERa& SOngpCR3.1 SRC3 
5ngpCR3.1 
5ng pCR3.1 hERa 
5ngpCR3.1 hERa& IOngSNAIL 
5ngpCR3.1 hERa& lOngPAX4 
pCR3.1 hERa & 50ngpCR3.1 SRC3 
5ngpCR3.1 
Sag hERa 
5ng C205H 
5ng L539A 
5ng S118A 
5ngpCR3.1 
5ng hERa 
5ng C205H 
5ng L539A 
5ng S118A 
Hormone 
Treatment 
10-lM Ral 
10% E2 
IO-~M ~ H T  
10-'M ~ a l  
10% E2 
1 0-'M 4HT 
~ o - ~ M  E~OH 
10% E2 
10-M 4HT 
l a - l ~  a l  
1 W7M EtOH 
~ o - ~ M  ~2 
~o-'M 4HT 
IO-~M Ral 
10-lM EtOH 
10% E2 
IO-~M ~ H T  
1 0 . ' ~  ~ a l  
IO-lM EtOH 
10% E2 
1 0 - l ~  ~ H T  
1 0-'M Ral 
P-Library reporter plasmid sequences 
>SP1 
GATCCTTGTTGGCRTATCACTTCCATACCCTCRRRTRTTRTTCRTCCTTGGATTCATTGTTGGCTCTTGTTTCTATGCATACTGTTTGGATTCCTTGGTGRRGT 
TGCTCTGTRTGTGCCTGTTRTTCTTRGTCRTRCCCACRGCCCRGAGCRCTTCCTCGRRCTCTGTCTCATGRRTGTCTCTATTTGGTGTACAGCACGGGCTTGTC 
AGTCTCCRRRRCTGRGTTCTGRTC 
>SP2 
GATCCTCTAGTCAGCCCTRTGTTCRTRRTTCCTRRGGGGAGRRCCC&CCTGCCCTGTGTAGAGGCCCCGACCCACTGTCCCTTTTCCAGGCRGAGCTTGGACCC 
ATCRTRRRTGTCATGACT~GGCGTGGGAGGGTGGGGATCGTGTACTGTRRTATTWGAGRRTTAGGACATCTGTTTRRTTTAGTATTCRRRTGGGGATAC 
TTTGGRTGTTWLTGRTC 
>SP4 
G A T C A T C C R R G T R G G R G G G G G R R G G T G R R T G G G T A G G G T  
I G G C A G C G A G G G T C C A G T T ~ G G C T G G A m C T G T G T A  
TGCTGGCTRTTTGGRRGGGTCCRGRRTCGCCTGGTRRGACRCRRCRGTGGGGCRRGGGATC 
>SF10 
TCTGRRRCTCCTGGCCTCMGCRRCAGCCTCCCRRGTCRCTGGGGTTRCAGGCRTGRGCCRCCGTGCCCRGCTCCTRRTATGATMTTCCRRTTCATATTTGAT 
TGRTGGRRRCCTGCATRTMTCRRGACCRGCRTAGTTTRRRRAGGGTCRRCTGTRTTGTGTTCMGACRTTTTCTGGTGGGTATGACTGGATCCTG 
>sell 
GATCGR%GTTCCRGACCTRRCTTGGCRGTAGCACTGCTTTATTCAGATGGCCCATCCTATTCCGRRTGTTRRTTTGCTCTGTTCTTCRTATTCAtATTTTTAT 
GCCGRRTTTCTAGCTCCTGCGTCTCTATTGCGGGCCCTMGTCGCTGTTTCACTWCTTTGGMCCTGACTCCGGWTCTCATTCTTTCGTCCCRRGAT 
CTCAGCCAGRRRGAGAGTTCCGCGCGGCGGCGTCTTCRRGCGCGCGGGCTGGGAGCGCGGGTTCTGATC 
SSP15 
GRTCCRCRTGTGCRRGCTTGGGRRCGAGTCCARRRTTTATM-TTATTTGWTTGATTTCCTGAGTTTTCCTTTTTCTCCATRRCTTTCATACTTTCTGG 
TTCCTTGGGGTCCTTCTATATCRRGGRRGCCRGGGTTTTAGTTATCCCRCTCTGAGGTGCRCTTCTGGTGTGCCCACRTCCAGGTCWCRRTGMGGAW 
TCCRGRTGGACGACAGTGGTGGTCRGCCTCRCCRTCCRGGTCCRAACRRTGRRRGGACRRTCCRGRTGGRCGACAGTGGTGGTCAGCCTCRCTCTCTTGGRRCC 
RRGGRTCCTC 
.SP19 
~TCCTCTGGTTTGCCTRRGCTTTCCWGRRTCRTCTGRWTTTTTCTCRTTGAGCTGTGCCAGCRTRTRGCRRRGTTTGTATTAGCTTGGTCCRRRTGGA 
CTCRGTTAGRRGATI\GTATATCTGCRGCRGCAGRGCCRCCTCCTRGCCTCCCTCRCTCRCCRTCCTGAGCGRTRCCCTCCCTGTTGATC 
>SPZO 
GATCCAGGAGGCTCTAGGGTCCTGACTCCRGGCCTGRGRTCTTTCCRCMGTCCCTGTTGCCTGGCCTGTGTTTGCCRRTGRRRCCRGCTTGCTRRCCTGG 
TCRCWTTAGRRTAGTGTTGATGTCCTAG~GGCCRCTRTGRRRGGTRGCCAGGAGGGGGCTGCCCGRRRCTGTATGTGGTGAGGRCACTCCACATCG 
GATGGGAGGRRGGCAGCCCRTCAGAGCCTCCTTTTTGGGTRTATTGRGAGTRGATGGTTCRCCTGGCTTGGGGCTRRCCCTGAGTGATCC 
>SP21 
GRTCATGRRGTCGRRRRGAGTRRRGTCCCATTTWCCAGGCAGTCTRRGTCCAGACRCGTGGCATTTGGCCAGTCCTCTCCCTGCATCCRRCCTGCCCTCTCA 
RRTCCTTGTCRCTCGGGCAGATGCCCCTGCTCACTGTGCCCTTCCCTTTGGGGGTTCCTGATAGACCRCAGCTAGCCCAGTGGGTGCCACATTCACTGTGTCRR 
GTRTAGARRGGGCRGCCGAGRTC 
>SP22 
WLTCCRTTTGTGTTCRTGCCGCRGmTCTRCCRGRTCRTGCGCCRGTGCCGATGRCTTCTGRRCCCTTTCTCATGAGCTTCTGCTTTTGGGTCCTGAGcTTGGc 
CTTCRCRRRTGCCCTTCCTGGGRGCRGCRTCTGTGACCRGCTGTRGTAGTCRGGGTTCTCCRGRGRRRRAGRRCCRRTTRTGTGTGTGTGTGTATTTGTATGTA 
TIITTATGRTRRTTRCTRTTATRRRGRRTTGGCTCRTGTGRTTATGGRGGCRGTCRRGTCTCRR~ATC 
>SF23 
GATCCTWCAGGGACCCCCTCRGIUU\CTRRRCARCAGTGTGGTARRGRGGRRRGTCTGRTCGRCTTGRGTTMTCCCTRTTGCACAGCTGGGTGCGTTGG 
CTCACGCCTATRRTCCCRGTAcTTTGGGAGGCCGAGCRRGGTGGRTCRCCTGAGGTCAGGAGTTCGAGACCAGCCTGGCC~GGTGGCMCACTGTCTCTAc 
TRRRRRTRCRRRRATTAGCCRGACGTGGTCACGGACRCCTGTRRCCCCGGCTACTTGGGAGGCTGAGGCACRRGRRTCGCTTGRRCCCAGGAGGCAGAGGTTTC 
AGTGAGCCRRGRTC 
X P 2 4  
GATCTGTGRTGCTCTCTGTCRCCCRTTGGRGRRGCCCRRCGTCWGGGCTCAGCCTCTGCCRRRGGCTGCCCTCTGGTGGCTGCTTGGTTCTTGAGGGTCCAG 
*G*GRRTAGCTTGCTGGTTCCTTCTTTCCRGRGmTCRGCTGGCRTTGCAGAGGGATc 
'np26 
GIITCATGTGTRRCRRTGTRCTGRTGGRRARTGCTTACCTCRRTRRRCTRRTGCTRGTGRCCGRRTTATTCRTTGGTGTGGATTCATAGATACTTRRCCAGTTGA 
TGACRRGRRTGCTGRRGRRRTACCRRGRTCTTCRGCCCTTTT~TTCCGTCTAGRGGCCGGGCACGGTGGCTCRTGCCTGTRRTCCCRGCACTTTGGGAGG 
CTGAGGCGGGCGGATC 
>SP27 
GRTCTACGCRTGCGTCTGTAGACGTGGTGGTACATGTATGCCCACACATTGCACACGCCCRCACGCGC 
>SF32 
G R T C A T C C R R G T A G G A G G G G G R R G G T G A R T G G G T R G G G T T  
TGGCRGCGAGGGTCCRGTTRRGGCTGGRRRCTGARTTTTACRGCAGmGCGTTCTGTCTAGTTGTGGGATTTTCCTCTAGGRRTACGGTTATAGWCWGA 
TGCTGGCTRTTTGGRRGGGTCCAGRRTCGCCTGGTRRGACACRRCAGTGGGGCRRGGGATc 
>SF33 
GRTCTGTGTTTGTRRCCRCACGTGTTGTRGGTTRTRTGGTGTGCARTGGRRCCCRGCCRTGACTCCTRTACGTGGGTGTGRRRCRRCRCCCRTTTTTCTCTGAG 
TACRGRRGGlilUjRRRGCRGRTTCCRCTRGCATCACTGTCACTTCCTGAGATCRTTTGTTWTGCACTATTGRRTTTTAGGATC 
>SF36 
G G A T C A C A G G G T C A G G A G R T C G R G G C C G C A C T G G C T C G  
AGGTGCGAGRRTTGAGRRRGTCCTGRRCRRTRRTTGCCAGA 
>SP37 
GATCCTCTAGTCAGCCCTRTGTTCATRRTTCCTRRGGGGAGRRCCCRCCTGCCCTGTGTAGAGGCCCCaCCCACTGTCCCTTTTCCAGGCRGAGCTTGGACCC 
ATCRTRRRTGTCATGRCTRRRRGGCGTGGGAGGTGGGGGATCGTGTACTGTRRTATTWGAGRRTTAGGACATCTGTTTRRTTTAGTATTCRRRTGGGGATAC 
TTTGGATGTTGATGATC 
>SP38 
GATCRGTGCAWLGRTATGTGRCRRGACCCCATTWCAGAGTCTAGACRRTRGTTACGTRRCCTGRGTGRTCRRTGCRGRGATCTGTCACRRTGCCCTTTRGGC 
AGRCCTTR~C~GAGTGACRRCACCTGGGTGATCRGTGCRGAGRTRTGTCRCRRTGCGCCCATRGGCRRRTCCMGA~GTCCGTCACCTGTGTGATCAG 
TTCRGmTATGTGAGRRTGCCCCCRGTAGGCRGRGCCTRGRGRRCRGTCCCTTCACCTGGGTGRTCRGTGCRGRTRTRTTTCACRRTGCCCCTGCAGGCRGRG 
TGTRRGC19RGAGTTACATCRCCTAGRTGRTC 
>SP40 
AGGRTCGRTGGTTCCRGRCCTRRCTTGGCRGTAGCRCTGCTTTATTCAGATGGCCCATCCTATTCCGRRTGTTRRTTTGCTCTGTTCTTCATATTCRGATTTTT 
ATGCCGRRTTTCTAGCTCCTGCGTCTCTRTTGCGGGCCCTMGTCGCTGTTTCRCTRRGCTTTGGRRCCTGRCTCCGGGmTCTCATTCTTTCGTCCWG 
ATCTCAGCCRGMGAGRGTTCCGCGCGGCGGCGTCTTCRRGCGCGCGGGCTGGGAGCGCGGGTTCTGATCCTCGGCCGC 
>spa5 
GATCCTCCCGCCTCGGCCTCCCRRRTTGCTGGGRTTACAGGCGTGRGCCRCTGCGCCTGGCCTRTTTRRRGTCTTTCRGCAGRRGTAGTRRTACGCRCAGAGAT 
GCATTTTGGGRRGATGMTGTGCCRGTGTTRTGTTCTAGAGCIGRGTTGTCCAGTRTGGTAGCCACTGGCTRCATGTGGCTATTTMCTTMT~T 
TCAGATCCTC 
Gene-Racer sequences 
- 
TSSl 
-
G G A G G C T T A C G A T T C G C C C T T G G A C A C T G A C A T G G A C T G R G G T G G T T T T C  
C C A G G G C G A G G C T T A T C C A T T G C A C T C C G G A T G T G C T G A C A C G  
A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C G C C C T A T A C C  
CTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCWCAGTT 
GCGCAGCCTATACGTACGGCAGTTTAFiGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACG 
CCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATW 
GCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGWGAAGTGGCTGATCTCAGCCACCGC-TGACAT- 
C G C C R T T A A C C T G A T G T T C T G G G G A R T A T A R A T G T C A G G C T C C G  
CAGAEACGGTGCTGACCCCGGATGAATGTCAGCTACTGGCTATCTGGACAAGGWCGWGCGWGA-GCAGGTAGCTTGCAGTGGGCT 
TACATGCGATAGCTAGACTGGGCGGTTTATGGACAGCAGCGACGATGCAGCTGGGGCGCCCTCTGTAGTGGGAGCCTGWGTAACTGATGCTTTCT 
GCGCAGATCTGATGGCGCAGGGATCAGCTCTGATWGAWCGATGAGATCGTCGCATGATGGAACAGATGAATGGCACGCAAGTCCCGACCTTGC 
TGAAGCTATCGATAGACTGCCACAAAGACAAATCGGTCTTGAGCCAGTTCGGTTACCGAAG 
TSS2 
-
GTCGGGTAACGGAATTCGCCCTTCGTATCTCTTCATAGCCTTATGCAGTGTccTTTTCTAcTccTTCAGTCCATGTCAGTGTccTcGTGcTCcAGTc 
T T T C T A C T C C T T C A G T C C A T G T C A G T G T C C A A G G G C C C T G G C C G  
T C G T T T T A C A R C G T C G T G A C T G G G W C C C T G G C G T T A  
GGCCCGCRCCGATCGCCCTTCCWCAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATMGAGAGAGccGTTATcGTcTGTTT 
G T G G A T G T A C A G A G T G A T A T T A T T G A C R C G C C G G G G C C C  
TTTACCCGGTGGTGCATATCGGGGATGAARGCTGGCGCATGATGACCAccGATATGGCCAGTGTGccGGTcTccGTTATcGGGGAAmGTGGcTGA 
T C T C A G C C A C C G C G A A A R T G A C A T C ~ C G C C A T T A C C  
TAGATCCTTTTCACGTAWGCCAGTCCGCAGAAACGGTGCTGACCCCGGATWTGTCAGCTACTGGGCTATCTGGAWGGGMCGWGCG 
C A A R G A G A A A G C A G G T A G C T T G C A G T G G G C T T A C A T G G C G G C T G G G G C  
GCCCTCTGGTAAGGTTGGGAAGCCCTGCAARGTAAACTGTGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGA?CAAGCTCTGATWGAG 
A C A G G A T G A G G A T C G T T T C G C A T G A T T G A A C A A G A T G G A C  
AACAGAACATCGCTGCTCTGATGCGCGTGTCGCTGTCAGCGCAGGGcGcCGTTcTTTTGTcAAGGAcc~ccTGTcGTGccTAGAATGAAcTGm 
GAACGGAAGGWl 
TSS3 
GCAGGCTTAACGW\TTCGCCCTTCGTATCTCTTCATAGCCTTATGCAGTGTCCTTTTCTACTCCTTCAGTCCATGTCAGTGTCCTCGTGCTCCAGTC 
T T T C T A C T C C T T C A G T C C A T G T C A G T G T C C A A G G G C G A A T T G G C C G  
TCGTTTTAWCGTCGTGACTGG~CCCTGGCGTTACcmcTTAATCGccTTGCAGCACATcCcccTTTcGccAGcTGGCGTAATAGcGAAGA 
GGCCCGCACCGATCGCCCTTCCWCAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATMGAGAGAGCCGTTATcGTcTGTTT 
G T G G A T G T A C A G A G T G A T A T T A T T G A C A C G C C G G G G C G 4 C  
TTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATaTGAcCACcGATATGGcCAGTGTGccffiTcTccGTTATcGGGmGAAGTGGcTGA 
T C T C A G C C A C C G C G A A A A T G A C A T C A L V A C G C C A T T A R C C C  
TAGATCCTTTTCACGTAGAEAGCCAGTCCGCAGRRACGGTGCTaCCCCGGATaTGTCAGCTACTGGGCTATCTGGACAGGWCGCAGCGmG 
AGRARGCAGTAGCTTGCAGTGGGCTTAACATGCGATAGCTAacTGGGCGTTTATGACAGcAGcGATcGATGCAGcTGGGGcGcccTcTGTTAGGTG 
G A G C C T G C A G T A C T G G A T G C T T T C T G G C G C C A G G A T C T T G  
TGGATGGCCRGGTTCCCGCGC?AGTGP.GGCATCCTAACTGCWGAATCGGGTCCTCTAGGCCGGTTCCGTTACCAGG 
TSS4 
C T C C A G A T T A C G A T T C G C C C T T G G A C A C T G A C A T G G A C T  
TTTTCGTGAAAACCCTTACGGGOWGACCATCACCCTCGAGGTTGAACCCTCGWlTACGATAMTGCATAAGGCTATGAAGAGATACGAAGGGc 
GAATTCGCGGCCGCTAAATTCAATTCGCCCTATAGTGAGTCGTATTAWTTCACTGGCCGTCGTTTTACAACGTCGTGACTGGWCCCTGGCG 
TTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCaGCTGGCGTAATAGCmGAGGCCCGaCCGATCGCCCTTCCWCAGTTGCGWG 
CCTATACGTACGGCAGTTTRAGGTTTACACCTATAAAAGAGRGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCGGGG 
C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G C T G G C  
GCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATcGGGGAAGAAGTGGcTGATCTCAGcCAcCGcWTaCAT~cGccAT 
TAACCTGATGTTCTGGGGAATATARATGTCAGGCATGAGATTAT~GGATCTTCACCTAGATCCTTTTCACGTAGAAAGCCAGTCCGCA~ 
CGGTGCTGACCCCGGATmTGTCAGCTACTGGGCTATCTGGAcmGGWcGCAAGCGCAARGA~GCAGGTAGcTTGCAGTGGGcTTAmT 
GGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGGGAGCCCTGCAAAGTARA 
C T G G A T G G C T T T T C T T G C C G C A A G A T C T G A T G G C G C A G G G T G  
ATGGCACGCAGTTTCTCGCCGCTGGGTGGAGAGGCCTATTCGCTATGACTTGGCACAACAWCATCGGCTGCCTmTGCGCGGTTCCGACTGTTC 
AAGCCGAARGGAGCT 
ACTaGATTACGAATTCGCCCTTGGAaCTGACATGGACTmGGAGTAGAAARTAcTTAcCTGGCAGGGGAGATACCATGATcAcGAAGGTGGTTT 
T C C C A G G G C G A G G C T T A T C C A T T G C A C T C C G G A T G T G C T G T A  
CGAAGGGCGAATTCGCGGCCGCTARATTCAATTCGCCCTATAGTGAGTCGTATTAWTTCACTGGCCGTCGTTTTAWCGTCGTGACTGGW 
CCCTGGCGTTACCWCTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGRGGCCCGCACCaTCGCCCTTCCWCAG 
TTGCGCAGCCTATACGTACGGCAGTTTRAGGTTTACACCTATMGAaGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTaCA 
C G C C G G G G C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G  
AAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTccGTTATCGGGGAAGAAGTGGcTW\TcTCAGcCACcGcWTGACATm 
A A C G C C A T T A A C C T G A T G T T C T G G G G R A T A T A A A T G T C A G T C  
CGCAGRAACGGTGCTGACCCCGGATGI\ATGTCAGCTACTGGGCTATCTGGAWGGGAAARCGWGCGCAAAGAGRARGCAGGTAGCTTGCAGTGG 
G C T T A C A T G G C G A T A G C T A G A C T G G G C G G G T T T A T G C  
A G T A A A C T G G A T G G C T T T C T T G C G C A G G A T C T G A T G C G C G G  
ATGCACGCAAGTCTCGACGCTGGGTGGAAGCTATCGGCTATGACTGGGCACGACATCGCTGCCTGATGCGCGGTTTCCCG 
TSS6 
-
CTTPATCTTACGRT?CGCCCTTCGTATCTCTTCATAGCCTTATGCAGTCGAGTTTCCCACATTTGGGWTCGCAGGGGTCAGCACATCCGGAGTG 
W T G G A T A A G C C T C G C C C T G G ~ C C A C C T T C G T G A T C  
CAAGGGCGAATTCGCGGCCGCTAAATTWTTCGCCCTATAGTGAGTcGTATTA~TTacTGGccGTcGTTTTAWcGTcGTGACTGGMc 
CCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCcTTTcGCcAGcTGGCGTmTAGCmGAGGcccGCAccGATcGcccTTccCAACAGT 
TGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATMGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACAC 
GCCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAaTARAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATW 
AGCTGGCGCATGATGACCACCGRTRTGGCCAGTGTGCCGGTcTcCGTTATcGGG~GAAGTGGcTaTcTCAGcCACCGC~TGACAT~ 
ACGCCATTAACCTGRTGTTCTGGGGAATATAAATGTCAGGcAT~ATTAT~GaTcTTcAccTAGATCC??TTCAcGTAGAEAGcCAGTcc 
GCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGAWGGWCGWGCGCaGAWGCAGGTAGCTTGCAGTGGG 
C T T A C A T G G C G A T A G C T A G A C T G G G G C G G T T T T A T G C G C C C T G C A  
A A G T R A A C T G G A T G G C T T T C T T G C G C A G R T C T G A T G C G C T G G  
CAACGCAGTTCTCGGCCGCTGGTGGAGRGCCTATTCGCTTGRCTGGCAACAAMaTTCGTTGCCTTGATGCGCGGTTCGACGTTCAGGCAGGGAGT 
G 
TSS7 
CGCAAGGTTACGATTCGCCCTTGGACACTGACATGGACTGAAGGAGTAGAAAGACTGGAGCACGAGGACACTGCATGGACTGAAGGRGTAGAAA 
G A C T G G A G C A C G A G G A C A C T G C A T G G A C T G A A G G A G T A G A  
CGAGGACACTGCATMGGCTATGAAGAGATACGAAGGGcGAATTcGcGGccGcTAAATTCAATTcGcccTATAGTGAGTcGTATTACAATTCAc 
TGGCCGTCGTTTTACAACGTCGTGACTGG-CCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA 
TAGCWGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGcGCAGccTATAcGTAcGGCAGTTTAAGGTTTACAccTAT~GAGAGAGccGT 
TATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATA 
A A G T C T C C C G T W L A C T T T A C C C G G T G G T G C A T A T C G G G G A T  
CGGGWGRRGTGGCTGATCTCAGCCACCGC~TGXCATmCGCCATTAACCTGATGTTCTGGGGAATATAARTGTCAGGCATGAGA 
T T A T C M G G A T C T T C A C C T A G A T C C T T T T C A C G T A G G C T A C T G G G C T A  
TCTGGACAAGGGAAARCGCAAGCGmGAGARAGCAGGTAGCTTGCAGTGGGcTTACATGGcGATAGcTAGAcTGGGcGGTTTTATmCAGc 
AAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGGRAGCCCT~GTRRRCTGGATGGCTTTCTTKCGCCAAGGATCTGA 
TGCGCAAGGGATCAAGCTCTGATCAAGAGACAGATGRGATCGTTCGCATGATGWCAGGATGATGCACGCAGTTTCTCCGCGCTGGGTGGAGA 
GCCTATTCCGGCTATGAACTTGGWCAGACCAATCGGCCTGTCTCTGTGAATTGC 
TSSB 
CGTAGGGCTTAACGAAATTCGCCCTTGGACACTGACRTGGACTGAAGGAGTAwTACTTACCTGGCAGGGGAGATACCATGATCACGAAGG 
TGGTTTTCCCAGGGCGAGGCTTATCULTTGCACTCCGGATGTGCTGACCCCTGCGATTTCCC~TGTGGGAAACTCGACTGCRTMGGCTAT 
G A A G A G A T A C ~ G G G C W T T C G C G G C C G C T A A A T T C A A G T C G  
TGACTGGG~CCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTRATAGCGAAGAGGCCCGCACCGAT 
CGCCCTTCCmCAGTTGCGCAGCCTATACGTACGGCAGTTTMGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTAc 
AGAGTGATATTATTGACACGCCffiGGCGACGGATGGTGATCCCCCTffiCCAGTGCACGTCTKTGTCAGATAARGTCTCCCGTWCTTTACCC 
GGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAWGTGGCTGATcTc 
AGCCACCGCGAAARTGACATWCGCCATTAACCTGATGTTCTGGGGAATATAARTGTCAGGCATGAGXTTATWGGATCTTCACCT 
AGXTCCTTTTCACGTAGAAAGCCAGTCCGCAGAARCGGTGCTGAccccG~TWTGTCAGcTAcTGGGcTATCTGGACAAGGGAAARcGcAAG 
CGmGAGAAAGCAGGTAGcTTGCAGTGGGCTTACATGGcGATAGcTAGAcTGGGcGGTTTTATGGACAGCAAGcGAAccGGAATTGcCAGcT 
GGGGCGCCCTCTGGTAAGGTTGGGAAGCCCTG~GTAARCTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGATCARGCTCTG 
A T C A A G A G A C A G G A T G A G G R T C G T T T C G C A T G A T T G A A G G C T A T T C G G G C C T  
ATGACTGGGCACRAACAWCATCGCTGCTCTGAATGGCGTCGTGTTCAGGCATGTTCCAGCGCGCACAATGAGCT 
TSS9 
C T C A G C T T A A C G G A T T C G C C C T T G R C T G C A T G A A G  
G G C G A A T T C G C G G C C G C T R R R T T C A A T T C G C C C T A T A G T G C  
CTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACA 
G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T  
GACACGCCGGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAARGTCTCCCGTWCTTTACCCGGTGGTGCATATCG 
GGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGWLAWLAGTGGCTGATCTCAGCCACCGC~ 
TGACATmCGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCATGAGATTAT~GGATcTTCAccTAGATccTTTTCAcG 
TAGAAAGCCAGTCCGCAGRRACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTmCAAGGGAAARCGCAAGCGCAARGAGRAAGc 
AGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGT 
AAGGTTGGGAAGCCCTGmGTAAACTGGRTGGCTTTCTTGccGcCAAGGATcTGXTGGcGCAGGGGATCAAGcTcTGATCAAGAGACAGGAT 
G A G G A T C G T T T C G C R T G A T T G A A C A G R T G G A T T G C  
T C G G C T G C T C T G A T G C G C G T G T C G C T G T C A G C G C A G G G C  
GCAGCCGTCTATGCCGTGACCTGCCACCGTGCCTGAGC 
TSSlO 
CTTAAGCTTACGATTCGCCCTTCGTATCTCTTCATAGCCTTATGCATCACCATCATAACTCTGAAGGTCCAGCAACACCAATCCATGTGGGTAA 
ATTCTCAARTTGGCAARGCTGCCGTTCTTGTTTGTGTAGGTTGCTAAATAGCCATGGTCCTGCCAffiTGTGCACCGACTCCGCCATCCCCTGCT 
C C T G G A A A R T G G A C T G G A G G C C T T T T A G A A T G G T C T C A C G C G T G C T G T G C C G T G C T G C T G C C A T  
AGTGAGGCGAGGCCCTGTGCCATGCCTGGGGGXGCAGCCGCGGGAGACTGGGGGGCCGCGCGGCGTGTCAGGCTGCGGCCGGCTGGGXGTTTTc 
TACTCCTTCAGTCCATGT~TGTCmGGGCWTTCGCGGccGCTAARTTCAATTcGcccTATAGTGAGTcGTATTACAATTCAcTGGccGTc 
GTTTTACAACGTCGTGACTGGWCCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGKGTMTAGCWG 
AGGCCCGCACCGATCGCCCTTCCCAACRGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCT 
GTTTGTGGATGTACAGAGT~TATTATTGACACGCCGGGGcGAcGGXTGGTGATcccccTGGccAGTGCAcGTcTGcTGTCAGXTAARGTcTcc 
CGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAG 
AAGTGGCTGATCTCAGCCACCGC~TGACATWCGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCATGAGATTATm 
AAGGATCTTCACCTAGATCCTTTTCACGTAGAAAGCCAGTCCGCRGAACGGTGCTGACCCCGGGATGRRTGTCAGCTACTGGGCTATCTGGACA 
G G G A A A A A C G C A A G C G C A A A G A A G A A A G C A G T A G C T T G C G  
GCAAGCTGGGGCGCTCTGGT~GGTTGGTAGTCCTGCCARAGATARRACT 
TSSll 
C T C C A G C T T A A C G G A l i T T C G C C C T T C G T A T C T C T T C T C C  
GGAGTGCAATGGATAAGCCTCGCCCT~CCACCTTCGTGATCATGGTATCTCCCCTGCCAGGTAAGTATTTTCTACTCCTTCAGTCCAT 
G T C A G T G T C C A A G G G C G A A T T C G C G G C C G C T R R R T T C C C G T C G T  
GXCTGG~CCCTGGCGTTACCCAACTTAATCGCCTTGCAGCAcATcccccTTTcGCCAGcTGGcGTAATAGcWGAGGcccGCAccGATc 
GCCCTTCCCAACAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTTTACACCTATWGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACR 
GAGTGATATTATTGRCACGCCGGGGCGACGGATGGTGATCCCCCTffiCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACccG 
GTGGTGCATATCGGGGATGRRAGCTGGCGCATGATGACCACCGRTATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCA 
GCCACCGCGAAARTGACATWCGCmTTAACCTGATGTTCTGGGGAATATRRRTGTCAGGCATGAGATTAT~GGATCTTCACcTA 
GATCCTTTTCACGTAGRRAGCCAGTCCGCAGAAACGGTGCTGRCCCCGGATWTGTCAGCTACTGGGCTATCTGGACAAGG-CGCAAGC 
GmGAGARAGCAGGTAGCTTGCAGTGGGCTTAmTGGcGATAGcTAGAcTGGGcGGTTTTATGGACA~GcGAAccGGAATTGcCAGcTG 
G G G C G C C C T C T G G T M G G T T G G G A A G C C C T G m G T A  
TCAGAGACAGGATGAGGGATCGTTTCGCATGXTTGACAGATGGATTGCACGCAGGTCCTCCGCGCTGGGTGGAGXGGCTATCGGCTATGACTGA 
CACACAGACATCGGCTGCTCTGATGCGCGATATTCGGCCGGATCAGCGCGCACAAGXGC 
TSS12 
CGTCAGGCTTMCGAATTCGCCCTTCGTATCTCTTCATAGCCTTATGCAGTGTCCTCGTGTTTCTACTCCTTCAGTCCATGTCAGTGTCCTCGT 
GTTTCTACTCCTTCAGTCCATGTCAGTGGTCCTCGTGCTTTTcTAcTCcTTCAGTcCATGTCRGTGTcmGGGcGAATTcKGGccGcTRRRT 
TCAATTCGCCCTATAGTGAGTCGTATTACAATTCAcTGGCcGTcGTTTTAcAAcGTcGTGAcTGGwcccTGGcGTTACcCAAcTTRATcG 
CCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTATACGTACGG 
CAGTTTI\RGGTTTACRCCTATAAAAGAGAGAGCCGTTATcGTcTGTTTGTGGATGTACAGAGTGATATTATTGACAcKcGffiGcGAcGGATGG 
TGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAARGTCTCCCGTWCTTTACCCGGTGGTGCATATCffiGGATWGCTGGCGCATGAT 
GACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGWWGTGGCTGATCTCAGCCRCCGC-TGACATWCGCCATTAAC 
CTGATGTTCTGGGGAATATAAATGTCAGGCATGAGATTATc~GGXTcTTCACcTAGATccTTTTCAcGTAGAAAGcCAGTccGCAGAARc 
GGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATcTGGAmGG~cGCAAGcG~GAGAAAGCRGGTAGcTTGCAGTGGGcTTAc 
ATGGCGATAGCTAGACTGGGCGGTTTTATGGACAG~GCGRRCCGGRRTTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGWGCCCTG~ 
GTAAACTGGRTGGCTTCTTGCCGCCAAGGATCTGATGGCGCAGGGRTCAAGCTCTGATCAGAGACAGGATGAGGATCGTTTCGCATGATTGAAC 
A A G A T G G A T T G C A C G C A G G T T C T C G G C C G C T G G G G T G C T G  
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